Ionizable lipid molecule as well as preparation method and application thereof
Patent Information
- Application Number
- CN202480001065.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-09
- Filing Date
- 2024-03-08
- Publication Date
- 2024-11-12
AI Technical Summary
Due to their large molecular weight and strong negative charge, nucleic acid drugs are difficult to penetrate cell membranes and are easily degraded by nucleases, which limits their application in treatment.
An ionizable lipid molecule was developed to prepare lipid nanoparticles by binding nucleic acid drugs to achieve their efficient delivery into cells and protect them from enzymatic degradation in vivo.
It achieves the effective delivery of various forms of nucleic acid drugs (such as ASO, siRNA, miRNA, mRNA, etc.), improves the therapeutic effect, reduces sensitivity to nucleases, and enhances the stability of the drug.
Smart Images

Figure CN118946544A_ABST
Abstract
Description
Ionizable lipid molecules and their preparation method and application Technical Field
[0001] The present invention relates to ionizable lipid molecules and a preparation method and application thereof. Background Art
[0002] Nucleic acid drugs primarily include antisense nucleic acids, small interfering nucleic acids, micronucleic acids, messenger nucleic acids, and the CRISPR system. These nucleic acid drugs can effectively regulate and control human gene function in a variety of ways, thereby achieving therapeutic effects. However, compared with traditional small molecules, nucleic acid drugs generally have a large molecular weight and carry a strong negative charge, making them nearly impossible to penetrate cell membranes and enter cells to exert their effects. Furthermore, nucleic acids are highly susceptible to degradation by various nucleases, leading to loss of function.
[0003] The successful application of ionizable lipid molecules has rapidly advanced the clinical application of nucleic acid drugs. Onpattro, the first siRNA drug, uses DLin-MC3-DMA as an ionizable liposome for delivery into liver cells for the treatment of neurological damage caused by transthyretin amyloidosis (hATTR, familial amyloid polyneuropathy). Moderna and BioNTech / Pfizer developed two COVID-19 vaccines using SM-102 and ALC-0315, respectively, which effectively responded to the COVID-19 pandemic in early 2019. Generally speaking, nucleic acid drugs require four components: ionizable lipids, phospholipids, cholesterol, and PEG. Ionizable lipids play a crucial role in delivering nucleic acids into cells and releasing them into the cytoplasm to function. To date, a variety of ionizable lipid molecules have been developed, and through structural modification and formulation optimization, a variety of delivery functions have been achieved. However, there is still a need for improved ionizable lipid molecules for nucleic acid delivery.
[0004] Summary of the Invention
[0005] In view of the deficiencies of the prior art, the present invention provides a delivery vector that can be used to deliver genes into cells, as well as a preparation method and use thereof.
[0006] The first aspect of the present invention provides an ionizable lipid molecule, wherein the ionizable lipid molecule is a compound represented by Chemical Formula I, or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof:
[0007] Where:
[0008] L1, L2, L3 are each independently selected from optionally substituted alkylene, optionally substituted alkenylene, and optionally substituted alkynylene;
[0009] M1, M2, and M3 are each independently selected from -C(O)O-, -OC(O)-;
[0010] R1, R2, R3 are each independently selected from optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl;
[0011] L4 is selected from optionally substituted alkylene, optionally substituted alkenylene, and optionally substituted alkynylene;
[0012] R4 is -OR5, R5 is selected from H, optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl;
[0013] m is an integer from 3 to 6.
[0014] In a second aspect, the present invention provides a lipid nanoparticle comprising an ionizable lipid compound represented by Formula I.
[0015] The third aspect of the present invention provides a composition comprising the ionizable lipid compound represented by Formula I, or the lipid nanoparticles.
[0016] In a fourth aspect, the present invention provides a method for treating or preventing a disease or condition in a subject, the method comprising administering a lipid nanoparticle containing a therapeutic agent or active agent as described in any embodiment of the present invention or a pharmaceutical composition as described in any embodiment herein.
[0017] The fifth aspect of the present invention provides use of the compound of formula I according to any embodiment of the present invention in the preparation of lipid nanoparticles or pharmaceutical compositions.
[0018] The ionizable lipid molecules of the present invention can achieve the effective delivery of various forms of nucleic acid drugs such as ASO, siRNA, miRNA, mRNA, saRNA, sgRNA, etc., allowing different nucleic acid molecules to enter the cell to function and achieve therapeutic effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 is the molecular structure of Yangshen 1.
[0020] Figure 2 is a photograph of the fluorescence intensity of mice 6 hours after intramuscular injection.
[0021] FIG3 is a photograph of the fluorescence intensity of mice after intravenous injection for 6 hours.
[0022] FIG4 is a photograph of fluorescence intensity 24 hours after intramuscular injection in mice.
[0023] FIG5 is a photograph of the fluorescence intensity of mice after intravenous injection for 24 hours.
[0024] FIG6 shows the whole-body fluorescence intensity values of mice after intravenous injection for 6 hours and 24 hours.
[0025] FIG7 shows the whole-body fluorescence intensity values of mice 6 hours and 24 hours after intramuscular injection.
[0026] FIG8 shows the fluorescence intensity values at the injection site of mice after intramuscular injection at 6 hours and 24 hours.
[0027] FIG9 shows the fluorescence intensity values of the abdominal liver of mice 6 hours and 24 hours after intramuscular injection.
[0028] FIG10 is a photograph of fluorescence intensity 6 hours after intramuscular injection in mice.
[0029] FIG11 is a photograph of fluorescence intensity 24 hours after intramuscular injection in mice.
[0030] FIG12 shows the whole-body fluorescence intensity values of mice 6 hours and 24 hours after intramuscular injection.
[0031] FIG13 shows the fluorescence intensity values at the injection site of mice 6 hours and 24 hours after intramuscular injection.
[0032] FIG14 is a photograph of fluorescence intensity 6 hours after intramuscular injection in mice.
[0033] FIG15 is a photograph of fluorescence intensity 24 hours after intramuscular injection in mice.
[0034] FIG16 shows the whole-body fluorescence intensity values of mice 6 hours and 24 hours after intramuscular injection.
[0035] FIG17 shows the fluorescence intensity values at the injection site of mice 6 hours and 24 hours after intramuscular injection. DETAILED DESCRIPTION
[0036] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a preferred technical solution.
[0037] I. Terminology
[0038] Unless otherwise indicated, the following terms used herein have the following meanings:
[0039] As used herein, "including," "comprising," and the like are to be interpreted in an open and inclusive sense and, unless the context requires otherwise, mean "including but not limited to" throughout the specification and claims.
[0040] Throughout the present invention, reference to "one embodiment" means that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrase "in one or more embodiments" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.
[0041] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used in the specification and claims, the singular forms "a / an", "the", and "said" include plural referents unless the context clearly dictates otherwise.
[0042] An "effective amount" or "therapeutically effective amount" of an active or therapeutic agent, such as a therapeutic nucleic acid, is an amount sufficient to produce the desired effect, such as an increase or inhibition of target sequence expression compared to normal expression levels detected in the absence of the nucleic acid.
[0043] As used herein, "nucleic acid" refers to a polymer containing at least two deoxyribonucleotides or ribonucleotides in single-stranded or double-stranded form, including DNA, RNA, and hybrids thereof. DNA can be in the form of an antisense molecule, plasmid DNA, cDNA, PCR product, or vector. RNA can be in the form of small hairpin RNA (shRNA), messenger RNA (mRNA), antisense RNA, small interfering RNA (siRNA), microRNA (miRNA), self-replicating RNA (saRNA), small guide RNA (sgRNA), multivalent RNA, Dicer substrate RNA, or viral RNA (vRNA), and combinations thereof.
[0044] As used herein, "gene" refers to a nucleic acid (eg, DNA or RNA) sequence that contains a partial or full-length coding sequence necessary to produce a polypeptide or precursor polypeptide.
[0045] As used herein, "lipids" refer to a group of organic compounds that include, but are not limited to, esters of fatty acids and are generally characterized by being poorly soluble in water but soluble in many organic solvents. They are generally divided into at least three categories: (1) "simple lipids," which include fats and oils as well as waxes; (2) "complex lipids," which include phospholipids and glycolipids; and (3) "derivative lipids," such as steroids.
[0046] "Steroids" are compounds containing the following carbon skeleton:
[0047] Non-limiting examples of steroids include cholesterol and the like.
[0048] The “cholesterol derivative” may be a cholesterol derivative known in the art for preparing lipid nanoparticles. Exemplary cholesterol derivatives include commonly used cholesterol, CAS: 57-88-5.
[0049] " polymer-conjugated lipid " as described herein refers to the molecule comprising lipid moiety and polymer moiety.The example of the polymer-conjugated lipid is polyethylene glycol (PEG) lipid.Term " PEGylated lipid " refers to the molecule comprising lipid moiety and polyethylene glycol moiety.PEGylated lipid is known in the art, comprises 1- (monomethoxy-polyethylene glycol) -2,3- dimyristoyl glycerol (PEG-DMG), PEG-DAG (diacylglycerol), PEG-PE (phosphatidylethanolamine), PEG-S-DAG, PEG-DSPE (- distearoylphosphatidylethanolamine), PEG-cer (ceramide) and PEG dialkoxypropyl carbamate etc.In a preferred embodiment of the present invention, the polymer-conjugated lipid is PEG2000-DMG.
[0050] " neutral lipid " as described herein refers to the lipid material existing in the form of uncharged or neutral zwitterionic under selected pH.At physiological pH, such lipids include but are not limited to: phosphatidylcholine such as 1,2-distearoyl-sn-glyceryl-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glyceryl-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glyceryl-3-phosphocholine (DMPC), 1-palmitoyl-2-oleoyl-sn-glyceryl-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glyceryl-3-phosphocholine (DOPC), phosphatidylethanolamine such as 1,2-dioleoyl-sn-glyceryl-3-phosphoethanolamine (DOPE), sphingomyelin (SM) and ceramide.Neutral lipid can be synthetic or natural origin.
[0051] "Lipid nanoparticles" as described herein refer to particles with at least one nanometer size (e.g., 1-1000 nm). Lipid nanoparticles can be included in formulations for delivering active agents or therapeutic agents (e.g., nucleic acids) to target sites (e.g., cells, tissues (e.g., diseased tissues such as tumor tissue), organs). In some embodiments, the lipid nanoparticles of the present invention comprise nucleic acids. Such lipid nanoparticles typically comprise one or more compounds of Formula I of the present invention, one or more auxiliary lipid molecules, one or more cholesterol or cholesterol derivatives, and / or one or more polymer-conjugated lipid molecules. The auxiliary lipid molecule can be one or more neutral lipid molecules. Active agents or therapeutic agents can be encapsulated in the lipid portion of the lipid nanoparticle or in the aqueous space encapsulated by some or all of the lipid portions of the lipid nanoparticle to protect them from enzymatic degradation, or to avoid other undesirable effects induced by the mechanisms of the host organism or cell, such as adverse immune responses.
[0052] As is known in the art, the average diameter of lipid nanoparticles can be about 30 nm to about 200 nm, 30 nm to about 150 nm, about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, about 70 nm to about 100 nm, about 80 nm to about 100 nm, about 90 nm to about 100 nm, about 70 nm to about 90 nm, about 80 nm to about 90 nm, about 70 nm to about 80 nm, or about 30 nm to about 100 nm. In some embodiments, the lipid nanoparticles have a length of about 0 nm, about 35 nm, about 40 nm, about 45 nm, about 50 nm, about 55 nm, about 60 nm, about 65 nm, about 70 nm, about 75 nm, about 80 nm, about 85 nm, about 90 nm, about 95 nm, about 100 nm, about 105 nm, about 110 nm, about 115 nm, about 120 nm, about 125 nm, about 130 nm, about 135 nm, about 140 nm, about 145 nm or about 150 nm, and the lipid nanoparticles are substantially non-toxic. In certain embodiments, when present in lipid nanoparticles, nucleic acids are resistant to degradation by nucleases in aqueous solutions. Lipid nanoparticles comprising nucleic acids and methods for preparing the same are known in the prior art, for example, can be found in CN102712935A or related patents, etc., the entire disclosure of which is incorporated herein by reference in its entirety for all purposes.
[0053] The form of the lipid nanoparticles of the present invention is not particularly limited. Examples of the form in which the ionizable lipid of the present invention is dispersed in an aqueous solvent include unilamellar vesicles, multilamellar vesicles, and unspecified lamellar structures.
[0054] As used herein, "halogen" refers to fluorine, chlorine, bromine or iodine.
[0055] "Hydroxy" refers to an -OH group.
[0056] "Carbonyl" refers to a -C(=O)- group.
[0057] "Carboxyl" refers to -COOH.
[0058] "Nitro" refers to -NO2.
[0059] "Cyano" refers to -CN.
[0060] "Amino" refers to -NH2.
[0061] "Alkyl" refers to a straight or branched chain saturated aliphatic hydrocarbon group containing, for example, 1-24, 1-18, 1-15, 1-12, 3-10, or 1-8 carbon atoms, such as methyl, ethyl, propyl, butyl, pentyl, heptyl, undecyl, tridecyl, pentadecyl, heptadecyl, heneicosyl, tricosyl, methylpentadecyl, hexylnonyl, and the like, and the alkyl group is attached to the rest of the molecule by a single bond.
[0062] "Alkylene" is a saturated, branched or straight chain hydrocarbon radical having, for example, 1-24, 1-18, 1-15, 1-12, 3-10 or 1-8 carbon atoms and having two monovalent radical centers derived by removing two hydrogen atoms from the same or two different carbon atoms of a parent alkane, such as -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and -CH2CH(CH3)CH2-.
[0063] "Alkoxy" refers to an alkyl-O- group, where alkyl is as defined herein. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, and the like. Alkyleneoxy refers to an alkylene group with an O attached to one end. Alkylene is as defined herein. An exemplary alkyleneoxy group is -CH2CH2-O-.
[0064] "Alkoxycarbonyl" refers to a group in which a carbonyl group is attached to the oxygen of an alkoxy group, such as CH3OC(=O)-, CH3CH2OC(=O)-, etc.
[0065] "Alkylsulfinyl" refers to an alkyl-S(=O)- group.
[0066] "Alkenyl" refers to a straight or branched aliphatic hydrocarbon group containing, for example, 2-24, 2-18, 2-15, 2-12, 3-10, or 2-8 carbon atoms, which contains one or more unsaturated carbon-carbon double bonds, such as ethenyl, propenyl, tridecenyl, tetradecadienyl, octadecatrienyl, etc., and is attached to the rest of the molecule by a single bond.
[0067] "Alkenylene" refers to a divalent straight or branched chain alkenyl group, typically having 2-24, 2-18, 2-15, 2-12, 3-10, or 2-8 carbon atoms, containing one or more unsaturated carbon-carbon double bonds and connected to the rest of the molecule by two single bonds. An exemplary alkenylene group can be -CHCH=CHCH-.
[0068] "Cycloalkenyl" refers to an unsaturated cyclic alkenyl group containing three to ten ring carbon atoms.
[0069] "Alkynyl" refers to a straight or branched chain aliphatic hydrocarbon group containing 2-24, 2-18, 2-15, 2-12, 3-10 or 2-8 carbon atoms, which contains one or more unsaturated carbon-carbon triple bonds, such as ethynyl, propynyl, etc., and is attached to the rest of the molecule by a single bond.
[0070] "Cycloalkynyl" refers to an unsaturated cyclic alkynyl group containing three to ten ring carbon atoms.
[0071] "Alkynylene" refers to a divalent straight or branched chain alkynyl group, typically having 3-24, 3-18, 3-15, 3-12, 3-10, or 3-8 carbon atoms, containing one or more unsaturated carbon-carbon triple bonds and connected to the rest of the molecule by two single bonds. An exemplary alkenylene group can be -CHC≡CCH-.
[0072] "Acyl" refers to an alkyl-C(O)- group, such as acetyl, propionyl, and the like.
[0073] "Aryl" refers to a carbocyclic ring system radical comprising hydrogen, 6 to 18 carbon atoms (preferably 6-14 carbon atoms) and at least one aromatic ring. Aryl groups can be monocyclic, bicyclic, tricyclic, or tetracyclic ring systems, which can include fused or bridged ring systems. Aryl groups include, but are not limited to, aryl groups derived from aceanthrene, acenaphthene, acephenanthren, anthracene, acenaphthene, anthracene, fluoranthene, fluorene, asymmetric indacene, symmetric indacene, indane, indene, naphthalene, phenanthren, phenanthren, pyrene, and triphenylene.
[0074] "Aryloxy" refers to -OR, where R is aryl.
[0075] "Carbocyclyl" refers to a stable, saturated or unsaturated, non-aromatic monocyclic or polycyclic hydrocarbon radical consisting only of carbon and hydrogen atoms, with a ring carbon number of 3-18. A carbocyclyl may include a fused or bridged ring system having 3 to 18 carbon atoms, which is saturated and connected to the rest of the molecule by a single bond. In some embodiments, a carbocyclyl is a cycloalkyl, representative of which include but are not limited to cycloalkyls having three to fifteen carbon atoms (C3-C 15 cycloalkyl), three to ten carbon atoms (C3-C 10The cycloalkyl groups of the present invention include cycloalkyl, cycloalkyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The cycloalkyl groups of the present invention include cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The cycloalkyl groups of the present invention include ... cycloheptyl, cyclooctyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclopropyl, cyclo In a preferred embodiment, the cycloalkyl group is a 3-8 membered cycloalkyl group, such as cyclopropyl, cyclopentyl and cyclohexyl.
[0076] "Heterocyclic radical" refers to a stable 3- to 20-membered non-aromatic cyclic group consisting of 2 to 14 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, phosphorus, oxygen, and sulfur. A heterocyclic radical can be a monocyclic, bicyclic, tricyclic, or more polycyclic ring system, and can include a fused ring system, a bridged ring system, or a spirocyclic system. A heterocyclic radical can be partially or completely saturated. A heterocyclic radical can be connected to the rest of the compound via a carbon atom or a heteroatom by a single bond. A heterocyclic radical is preferably a stable 4- to 11-membered non-aromatic monocyclic, bicyclic, bridged, or spirocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur, and more preferably a stable 4- to 8-membered non-aromatic monocyclic, bicyclic, bridged, or spirocyclic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur. Examples of heterocyclic groups include, but are not limited to, pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, thiomorpholinyl, 2,7-diaza-spiro[3.5]nonan-7-yl, 2-oxa-6-aza-spiro[3.3]heptan-6-yl, 2,5-diaza-bicyclo[2.2.1]heptan-2-yl, azetidinyl, pyranyl, tetrahydropyranyl, thiopyranyl, tetrahydrofuranyl, oxazinyl, dioxolane, tetrahydroisoquinolinyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, quinolizinyl, thiazolidinyl, isothiazolidinyl, isoxazolidinyl, indolinyl, octahydroindolyl, octahydroisoindolyl, pyrrolidinyl, pyrazolidinyl, phthalimido, and the like.
[0077] "Heteroaryl" refers to a 5- to 16-membered conjugated ring system having 1 to 15 carbon atoms (preferably 1 to 10 carbon atoms) and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur. Heteroaryl groups can be monocyclic, bicyclic, tricyclic, or higher ring systems. Heteroaryl groups are preferably stable 5- to 12-membered aromatic groups containing 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur, more preferably stable 5- to 10-membered aromatic groups containing 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur, or 5- to 6-membered aromatic groups containing 1 to 3 heteroatoms selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include, but are not limited to, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, benzopyrazolyl, indolyl, furanyl, pyrrolyl, triazolyl, tetrazolyl, triazinyl, indolizinyl, isoindolyl, indazolyl, isoindazolyl, purinyl, quinolyl, isoquinolyl, naphthazinyl, naphthyridinyl, quinoxalinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, phenanthrolinyl, acridinyl, phenazinyl, isothiazolyl, benzothiazolyl, benzothiophenyl, oxatriol, oxazolyl, cinnolinyl, quinazolinyl, phenylthio, indolizinyl, o-phenanthroline, isoxazolyl, phenoxazinyl, phenothiazinyl, 4,5,6,7-tetrahydrobenzo[b]thienyl, naphthopyridinyl, [1,2,4]triazolo[4,3-b]pyridazine, [1,2,4]triazolo[4,3-a]pyrazine, [1,2,4]triazolo[4,3-c]pyrimidine, [1,2,4]triazolo[4,3-a]pyridine, imidazo[1,2-a]pyridine, imidazo[1,2-b]pyridazine, imidazo[1,2-a]pyrazine, and the like.
[0078] Herein, when a group is "optionally substituted", it may be optionally substituted with 1-5 substituents, and the substituents may be selected from: alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, cyano, nitro, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted heterocyclyl. Each of these aryl, heteroaryl, cycloalkyl and heterocyclyl substituents may be optionally substituted with groups such as alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, cyano, nitro, aryl, heteroaryl, cycloalkyl and heterocyclyl. It should be understood that the number of substituents is affected by the molecular structure of the compound. For example, when the substituent is aryl, heteroaryl, cycloalkyl or heterocyclyl, the number of substituents is generally 1; when the substituent is halogen, the number of halogen atoms may be 2-5 depending on the chain length of the substituted group or the number of ring carbon atoms.
[0079] As used herein, "ionizable lipid compound" refers to a lipid compound that exists in a charged form at a specific pH value or pH range, including positively or negatively charged, preferably positively charged lipid compounds (i.e., cationic lipid compounds). The specific pH value or pH range refers to the pH value or pH range of the environment in which the lipid compound is stored or intended for use, including but not limited to physiological pH.
[0080] Herein, "pharmaceutically acceptable salts" include acid addition salts and base addition salts.
[0081] "Pharmaceutically acceptable acid addition salts" refer to salts that retain the biological effectiveness and properties of the free base and are formed with inorganic or organic acids. The inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. The organic acids include acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, hexanoic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo- Glutaric acid, glycerophosphate, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid and undecylenic acid, etc.
[0082] "Pharmaceutically acceptable base addition salts" refer to those salts that retain the biological effectiveness and properties of the free acids. These salts are prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Preferred inorganic salts are ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, diarnol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrazine, choline, betaine, pheniramine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
[0083] As used herein, a "pharmaceutical composition" refers to a formulation containing a pharmaceutically active ingredient and a compound of Formula I of the present invention. A pharmaceutical composition typically contains a therapeutically effective amount of a therapeutic agent or agent, i.e., the therapeutic agent or agent. A "therapeutically effective amount" refers to an amount sufficient to achieve treatment in a mammal, preferably a human, when administered to the mammal. The amount of the therapeutic agent or agent that constitutes a "therapeutically effective amount" will vary depending on the therapeutic agent or agent used, the condition and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by one of ordinary skill in the art based on their knowledge and this disclosure.
[0084] As used herein, "pharmaceutically acceptable carriers or excipients" include, but are not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier approved by the FDA or NMPA as acceptable for use in humans or domestic animals.
[0085] "Treatment" as used herein encompasses treatment of a target disease or condition in a mammal, preferably a human, suffering from the target disease or condition, and includes:
[0086] (1) preventing the disease or condition from occurring in a mammal, particularly when such mammal is susceptible to the condition but has not yet been diagnosed as having the condition;
[0087] (2) inhibit the disease or condition, i.e., prevent its development;
[0088] (3) alleviate the disease or condition, i.e., cause the disease or condition to regress; or
[0089] (4) Relieve symptoms caused by the disease or condition, i.e., relieve pain without addressing the underlying disease or condition.
[0090] Herein, "disease" and "condition" may be used interchangeably, or may be different in that a particular disease or condition may have no known etiology (so that the cause has not yet been identified) and therefore is not yet recognized as a disease but is considered merely an undesirable condition or syndrome in which clinicians have identified a more or less specific set of symptoms.
[0091] As used herein, "mammal" includes humans as well as domestic animals such as laboratory animals and household pets (e.g., cats, dogs, pigs, cows, sheep, goats, horses, rabbits) and non-domestic animals (e.g., wild animals, etc.).
[0092] The compounds of Formula I or their pharmaceutically acceptable salts may contain one or more asymmetric centers and thus may produce enantiomers, diastereomers and other stereoisomeric forms that may be defined in terms of absolute stereochemistry as (R)- or (S)- or (D)- or (L)- (for amino acids). The present invention includes all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques such as chromatography and fractional crystallization. Conventional techniques for preparing / isolating individual enantiomers include chiral synthesis from suitable optically pure precursors or resolving the racemate (or racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise indicated, the compounds are intended to include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
[0093] "Stereoisomers" refer to compounds composed of the same atoms bonded by the same bonds but with different three-dimensional structures that are not interconvertible. The present invention encompasses various stereoisomers and mixtures thereof, and includes "enantiomers," which refer to two stereoisomers whose molecules are nonsuperimposeable mirror images of each other.
[0094] "Tautomer" refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present invention includes tautomers of any of the described compounds.
[0095] II. Ionizable lipid molecules
[0096] The ionizable lipid molecules described herein have the structural formula shown below in Formula I:
[0097] In the formula, L1, L2, L3 are each independently selected from optionally substituted alkylene, optionally substituted alkenylene and optionally substituted alkynylene; M1, M2, M3 are each independently selected from -C(O)O-, -OC(O)-; R1, R2, R3 are each independently selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl; L4 is selected from optionally substituted alkylene, optionally substituted alkenylene and optionally substituted alkynylene; R4 is -OR5; R5 is selected from H, optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl; m is an integer from 3 to 6.
[0098] Also included herein are stereoisomers, tautomers, pharmaceutically acceptable salts, prodrugs, and solvates of the compound of Formula I.
[0099] In Formula I, when a group is "optionally substituted", the substituents may be selected from hydroxy, alkoxy, halogen, alkyl, haloalkyl, alkyl substituted with hydroxy, alkenyl, haloalkenyl, alkenyl substituted with hydroxy, -NR'R", optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or optionally substituted heterocyclic. The number of substituents may be 1-6. The R' and R" are each independently selected from H and C 1-4 Alkyl. The alkyl, alkoxy, haloalkyl and hydroxy substituted alkyl groups may be C 1-6 Alkyl or C 1-4 Alkyl; the alkenyl, haloalkenyl and hydroxyl substituted alkenyl groups may be C 2-6 Alkenyl or C 2-4 Alkenyl; the cycloalkyl group may be C 3-8 Cycloalkyl, optionally substituted by 1-4 groups selected from halogen, C 1-4 Alkyl, hydroxyl and -NR'R" substituents; the aryl group can be a 6-14 membered aryl group, such as phenyl and naphthyl, and the aryl group can be optionally substituted by 1-4 halogen, C 1-4 The heteroaryl group may be a 5-10 membered heteroaryl group, such as a 5-10 membered nitrogen and / or oxygen-containing heteroaryl group, such as a pyridyl group, a pyrazolyl group and an imidazolyl group, and the heteroaryl group may be optionally substituted by 1-4 groups selected from halogen, C 1-4 The heterocyclic group may be a 4-10 membered heterocyclic group, preferably a 4-10 membered nitrogen and / or oxygen-containing heterocyclic group, such as morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, etc., and the heterocyclic group may be optionally substituted by 1-4 groups selected from halogen, C 1-4 The alkyl, hydroxy and -NR'R" substituents are substituted.
[0100] In a preferred embodiment, in Formula I, L1, L2, and L3 are each independently selected from optionally substituted C 1-24 Alkylene, optionally substituted C 2-24 Alkenylene and optionally substituted C 2-24 Preferably, L1, L2, L3 are each independently selected from -(CH2) n -, n is an integer of 1-24, preferably an integer of 2-24, more preferably an integer of 3-15, and further preferably an integer of 3-11. In some embodiments, L1, L2, L3 n Each is independently an integer from 3 to 8. In some embodiments, L1, L2, and L3 are the same group.
[0101] In a preferred embodiment, in Formula I, R1, R2, and R3 are each independently selected from optionally substituted C 1-24 Alkyl, optionally substituted C 2-24Alkenyl and optionally substituted C 2-24 Preferably, R1, R2, R3 are each independently selected from: optionally substituted by one or more C 1-24 Alkyl substituted C 1-24 Alkyl, optionally substituted by one or more C 1-24 Alkyl substituted C 2-24 In one or more embodiments, the C 2-24 The alkenyl group contains 1 to 4 carbon-carbon double bonds, which may be in Z and / or E configuration, preferably in Z configuration.
[0102] In a preferred embodiment, in Formula I, R1, R2, and R3 are each independently selected from:
[0103] wherein a is an integer of 1-24, preferably an integer of 2-20, more preferably an integer of 3-15; R 1a and R 2a H or C independently at each occurrence 1-24 Alkyl; or each R 1a Independently H or C 1-24 alkyl, and at least one R 2a Together with the carbon atom to which it is connected and the adjacent R 2a and the carbon atom to which it is connected together to form a carbon-carbon double bond; R 3a is H or methyl.
[0104] In some embodiments, a, R 1a 、R 2a 、R 3a Each is selected such that R1, R2, and R3 each independently contain 1 to 40, preferably 1-30, more preferably 1-24, and even more preferably 3-24 carbon atoms.
[0105] In some embodiments, at least one R 1a For H, for example, all R 1a All are H; at least one R 2a For H, for example, all R 2a are all H. In other embodiments, at least one R 1a For H, for example, all R 1a All are H, and at least one R 2a C 1-24 Alkyl, preferably C 3-20 Alkyl, more preferably C 3-15 alkyl.
[0106] In some embodiments, R1, R2, and R3 are each independently selected from:
[0107] wherein p is an integer from 0 to 2, p' is an integer from 1 to 24, and p" is an integer from 0 to 24; b, c, d, and e are each independently an integer from 1 to 22; R 1b and R 2b H or C independently at each occurrence 1-12 Alkyl, or each R 1b Independently H or C 1-12 alkyl, and at least one R 2b Together with the carbon atom to which it is connected and the adjacent R 2b and the carbon atom to which it is connected together to form a carbon-carbon double bond; R 1c and R 2c H or C independently at each occurrence 1-12 Alkyl, or each R 1c Independently H or C 1-12 alkyl, and at least one R 2c Together with the carbon atom to which it is connected and the adjacent R 2c and the carbon atom to which it is connected together to form a carbon-carbon double bond; R 1d and R 2d H or C independently at each occurrence 1-12 Alkyl, or each R 1d Independently H or C 1-12 alkyl, and at least one R 2d Together with the carbon atom to which it is connected and the adjacent R 2d and the carbon atom to which it is connected together to form a carbon-carbon double bond; R 1e and R 2e H or C independently at each occurrence 1-12 Alkyl, or each R 1e Independently H or C 1-12 alkyl, and at least one R 2e Together with the carbon atom to which it is connected and the adjacent R2 e and the carbon atom to which it is connected together to form a carbon-carbon double bond; R 3a is H or methyl.
[0108] In some embodiments, p' and p" are each selected such that R1, R2, and R3 each independently contain 1 to 40, preferably 1-30, more preferably 1-24, and even more preferably 3-24 carbon atoms.
[0109] In some embodiments, p' and p" are the same integer.
[0110] In some embodiments, b, c, d, e, R 1b 、R 2b 、R 1c 、R 2c 、R 1d 、R2d 、R 1e 、R 2e Each is selected such that R1, R2, and R3 each independently contain 1 to 40, preferably 1-30, more preferably 1-24, and even more preferably 3-24 carbon atoms.
[0111] In some embodiments, at least one R 1b For H, for example, all R 1b All are H; at least one R 2b For H, for example, all R 2b All are H; at least one R 1c For H, for example, all R 1c All are H; at least one R 2c For H, for example R 2c All are H; at least one R 1d For H, for example, all R 1d All are H; at least one R 2d For H, for example, all R 2d All are H; at least one R 1e For H, for example, all R 1e All are H; at least one R 2e For H, for example, all R 2e Both are H.
[0112] In some embodiments, b, c, d, and e are each independently an integer from 1 to 10.
[0113] In some embodiments,
[0114] Examples include, but are not limited to:
[0115] -(CH2) p *CH3, p* is an integer from 1 to 23, preferably an integer from 3 to 14,
[0116] In some embodiments,
[0117] Examples include, but are not limited to:
[0118] In some embodiments,
[0119] Examples include, but are not limited to:
[0120] In some embodiments, R1, R2, and R3 are each independently selected from C 2-24 Alkenyl, which may be 1-4 C 1-The alkyl group is substituted with 6 alkyl groups, preferably methyl groups, and the number of carbon-carbon double bonds may be 1-4, preferably 1-2, and the carbon-carbon double bonds may be in E configuration. Examples of the alkenyl group include, but are not limited to:
[0121] In one or more embodiments, R1, R2, and R3 are the same group.
[0122] In a preferred embodiment, in Formula I, L4 is selected from optionally substituted C 1-8 Alkylene, optionally substituted C 2- 6 alkenylene and optionally substituted C 2-6 Alkyne, preferably, L4 is selected from -(CH2) o -, wherein o is an integer from 1 to 8. In some embodiments, L4 is selected from optionally substituted C 1-6 Alkylene, optionally substituted C 2-6 Alkenylene and optionally substituted C 2-6 Alkyne, preferably, L4 is selected from -(CH2) o -, wherein o is an integer of 1-6, preferably an integer of 2-5, more preferably 2, 3 or 4.
[0123] In a preferred embodiment, in Formula I, R5 is selected from H, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2-6 Alkynyl, preferably, R5 is selected from H, C 1-6 alkyl.
[0124] In a preferred embodiment, the compound of formula I has the following structure:
[0125] Among them, f, g, h, i, j, k, g1, g2, i1, i2, k1, k2, r, s, t, u, v, w, x, y, and z are each independently an integer from 1 to 24.
[0126] In some embodiments, f, h, and j are each independently an integer of 2-24, preferably an integer of 3-15, and more preferably an integer of 3-11.
[0127] In some embodiments, g, g1, g2, i, i1, i2, k, k1, and k2 are each independently an integer from 1 to 15, preferably an integer from 3 to 15.
[0128] In some embodiments, r, s, t, u, v, w, x, y, and z are each independently an integer from 1 to 15, preferably an integer from 1 to 10.
[0129] In some embodiments, q is an integer of 1-6, preferably an integer of 2-5, and more preferably an integer of 2-4.
[0130] In some embodiments, f, h, and j are the same integer, g, i, and k are the same integer, g1, g2, i1, i2, k1, and k2 are the same integer, r, t, and v are the same integer, s, u, and w are the same integer, and x, y, and z are the same integer.
[0131] In Formulas I, Ia, Ib, Ic, and Id, m is an integer of 3-6, for example, 3, 4, 5, or 6.
[0132] In some embodiments, the compound of formula I described in the present invention is a compound represented by formula Ia, wherein i and k are each independently an integer of 1-15, preferably each independently an integer of 3-15, preferably, i and k are the same integer; h and j are each independently an integer of 2-11, preferably each independently an integer of 3-7, preferably, h and j are the same integer; m is 3, 4, 5 or 6, preferably 3 or 4; f is an integer of 3-11, preferably an integer of 3-6; g is an integer of 3-15, preferably an integer of 6-12; q is an integer of 2-5.
[0133] In some embodiments, the compound of formula I described in the present invention is a compound represented by formula Ia, wherein i, k, and g are each independently an integer of 1-15, preferably each independently an integer of 3-15, more preferably each independently an integer of 8-12, preferably, i, k and g are the same integer; f, h and j are each independently an integer of 2-11, preferably each independently an integer of 3-7, preferably, f, h and j are the same integer; m is 3, 4, 5 or 6, preferably 3 or 4; q is an integer of 2-5, preferably 2 or 3.
[0134] In some embodiments, the compound of formula I described in the present invention is a compound represented by formula Id, wherein h and j are each independently an integer of 2-11, preferably each independently an integer of 3-8, preferably, h and j are the same integer; m is 3, 4, 5 or 6, preferably 3 or 4; t and v are each independently an integer of 1-10, preferably each independently an integer of 5-10, preferably, t and v are the same integer; y and z are each independently an integer of 1-10, preferably each independently an integer of 3-8, preferably, y and z are the same integer; f is an integer of 3-11, preferably an integer of 3-8; r is an integer of 1-10, preferably an integer of 5-10; x is an integer of 1-10, preferably an integer of 3-8; q is an integer of 2-5.
[0135] In some embodiments, the compound of formula I described in the present invention is a compound represented by formula Id, wherein f, h and j are each independently an integer of 2-11, preferably each independently an integer of 3-7, preferably, f, h and j are the same integer; m is 3, 4, 5 or 6, preferably 3 or 4; t, r and v are each independently an integer of 1-10, preferably each independently an integer of 6-10, preferably, t, r and v are the same integer; x, y and z are each independently an integer of 1-10, preferably each independently an integer of 3-7, preferably, x, y and z are the same integer; q is an integer of 2-5.
[0136] III. Lipid Nanoparticles
[0137] The compounds of formula I of the present invention can be used to prepare lipid nanoparticles for delivering nucleic acid therapeutic agents or active agents in vivo and in vitro.
[0138] In addition to the compound of formula I of the present invention, the lipid nanoparticles of the present invention may further contain one or more helper lipid molecules, one or more cholesterol or cholesterol derivatives and / or one or more polymer-conjugated lipid molecules.
[0139] Preferably, the helper lipid molecule is a neutral lipid molecule, preferably selected from the group consisting of: DSPC, DPPC, DMPC, DOPC, POPC, DOPE and SM. In a preferred embodiment, the lipid nanoparticles contain DOPE.
[0140] Preferably, the cholesterol derivative is cholesterol (abbreviated as chol, CAS: 57-88-5).
[0141] Preferably, the polymer-conjugated lipid molecule is polyethylene glycol. In a preferred embodiment, the polymer-conjugated lipid molecule is selected from PEG-DAG, PEG-PE, PEG-S-DAG, PEG-DSPE, PEG-cer and PEG dialkoxypropyl carbamate. Preferably, the lipid nanoparticle contains PEG2000-DSPE.
[0142] In a preferred embodiment, the lipid nanoparticles, when contained, have a molar ratio of the compound of formula I, its stereoisomer, racemate or pharmaceutically acceptable salt to the auxiliary lipid molecule, cholesterol or cholesterol derivative, polymer-conjugated lipid molecule of 60-5:60-5:50-5:10-1, preferably 60-30:30-10:50-30:5-1.
[0143] The estimated particle size of the lipid nanoparticles of the present invention can generally be 50 nm to 200 nm, preferably 80 nm to 120 nm.
[0144] The lipid nanoparticles of the present invention can be used to express proteins encoded by mRNA, wherein the proteins are proteins that have therapeutic, preventive or improvement effects on the physiological functions of an organism, including antigens, antibodies and proteins with biological functions known in the art; or for upregulating endogenous protein expression by delivering miRNA inhibitors targeting specific miRNAs or a group of miRNAs that regulate one target mRNA or several mRNAs; or for downregulating (such as silencing) the protein level and / or mRNA level of a target gene; or for delivering mRNA and plasmids to express transgenes; or for inducing pharmacological effects produced by protein expression, such as increasing the production of red blood cells by delivering a suitable erythropoietin mRNA, or protecting from infection by delivering mRNA encoding an antigen or antibody of interest.
[0145] Therefore, in a preferred embodiment, the lipid nanoparticles of the present invention contain a therapeutic agent or active agent, preferably, the therapeutic agent or active agent is a nucleic acid therapeutic agent or active agent. More preferably, the nucleic acid therapeutic agent or active agent is selected from the group consisting of messenger RNA (mRNA), antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA (miRNA), self-replicating RNA (saRNA), small guide RNA (sgRNA), ribozymes, and aptamers.
[0146] The lipid nanoparticles of the present invention can be prepared using conventional preparation methods in the art. For example, Compound I is mixed with a helper lipid molecule, cholesterol, and a polymer-conjugated lipid molecule in a certain molar ratio and dissolved in ethanol to obtain an ethanol lipid solution. mRNA is dissolved in a citric acid buffer to obtain an mRNA aqueous solution. The ethanol lipid solution and the mRNA aqueous solution are mixed in a certain volume ratio using a microfluidic device. The solution is replaced by ultrafiltration, the ethanol is removed, and the volume is fixed with DPBS. Finally, the lipid nanoparticles are filtered through a 0.2 μm sterile filter to obtain an LNP formulation using an ionizable lipid.
[0147] IV. Composition
[0148] The present invention also provides a composition comprising a compound of Formula I of the present invention. In some embodiments, the composition is a pharmaceutical composition comprising a compound of Formula I of the present invention, a therapeutic agent or active agent, and one or more auxiliary lipid molecules, one or more cholesterol or cholesterol derivatives and / or one or more polymer-conjugated lipid molecules.
[0149] Preferably, the helper lipid molecule is a neutral lipid molecule, preferably selected from the group consisting of: DSPC, DPPC, DMPC, DOPC, POPC, DOPE and SM. In a preferred embodiment, the lipid nanoparticles contain DOPE or DSPC.
[0150] Preferably, the cholesterol derivative is cholesterol.
[0151] Preferably, the polymer-conjugated lipid molecule is polyethylene glycol. In a preferred embodiment, the polymer-conjugated lipid molecule is selected from PEG-DMG, PEG-DAG, PEG-PE, PEG-S-DAG, PEG-DSPE, PEG-cer and PEG dialkoxypropyl carbamate. Preferably, the lipid nanoparticle contains PEG2000-DMG.
[0152] Preferably, the therapeutic agent or active agent is a nucleic acid therapeutic agent or active agent. More preferably, the nucleic acid therapeutic agent or active agent is selected from the group consisting of messenger RNA (mRNA), antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA (miRNA), self-replicating RNA (saRNA), small guide RNA (sgRNA), ribozymes, and aptamers.
[0153] Preferably, the pharmaceutical composition contains a therapeutically or prophylactically effective amount of the lipid nanoparticles of any embodiment of the present invention and a pharmaceutically acceptable carrier or excipient. Specifically, the compound of Formula I of the present invention is present in the composition in an amount effective to form lipid nanoparticles and deliver a therapeutically or prophylactically effective amount of a therapeutic agent or active agent, such as for treating a specific target disease or condition. Appropriate concentrations and dosages can be readily determined by those skilled in the art.
[0154] The pharmaceutical compositions of the present invention can be formulated into formulations in solid, semisolid, liquid or gaseous form, such as tablets, capsules, powders, granules, ointments, solutions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols. Routes of administration of such pharmaceutical compositions include, but are not limited to, oral, topical, transdermal, inhalation, intraperitoneal, sublingual, buccal, rectal, vaginal and intranasal. As used herein, the term "intraperitoneal" includes subcutaneous, intravenous, intramuscular, intradermal, intrasternal injection or infusion techniques.
[0155] Suitable pharmaceutically acceptable carriers and excipients can be selected according to the specific dosage form and route of administration. For example, as a solid composition for oral administration, the pharmaceutical composition can be formulated into a powder, granules, compressed tablets, pills, capsules, chewing gum, thin slices, etc. Such solid compositions generally contain one or more inert diluents or edible carriers. In addition, one or more of the following may be present: a binder such as carboxymethyl cellulose, ethyl cellulose, microcrystalline cellulose, tragacanth gum, or gelatin; an excipient such as starch, lactose, or dextrin; a disintegrant such as alginic acid, sodium alginate, Primogel, corn starch, etc.; a lubricant such as magnesium stearate or Sterotex; a glidant such as colloidal silicon dioxide; a sweetener such as sucrose or saccharin; a flavoring such as peppermint, methyl salicylate, or orange flavor; and a colorant.
[0156] When the pharmaceutical composition is in the form of a capsule, eg, a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil.
[0157] The pharmaceutical composition of the present invention can be prepared by methods well known in the pharmaceutical field. For example, a pharmaceutical composition intended for administration by injection can be prepared by combining the lipid nanoparticles of the present invention with sterile distilled water or other carriers to form a solution.
[0158] The pharmaceutical compositions of the present invention are administered in a therapeutically effective amount, which will vary depending on a variety of factors, including the activity of the specific therapeutic agent employed; the metabolic stability and duration of action of the therapeutic agent; the age, weight, general health, sex, and diet of the patient; the route and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject being treated.
[0159] V. Treatment Methods and Uses
[0160] The lipid nanoparticles and pharmaceutical compositions of the present invention can be used to deliver therapeutic or active agents, such as nucleic acids, in vivo and in vitro for treating or preventing a disease or condition in a subject.
[0161] Therefore, the present invention provides the use of a compound of formula I according to any embodiment of the present invention in the preparation of a lipid nanoparticle or pharmaceutical composition for treating or preventing a disease or condition in a subject, the use of a lipid nanoparticle or pharmaceutical composition according to any embodiment of the present invention in the preparation of a medicament for treating or preventing a disease or condition in a subject, and the compound of formula I, lipid nanoparticle or pharmaceutical composition according to any embodiment of the present invention for treating or preventing a disease or condition in a subject.
[0162] The present invention also provides a method for treating or preventing a disease or condition in a subject, comprising administering to a subject in need thereof a therapeutically effective amount or a prophylactically effective amount of a therapeutic agent or active agent, such as a nucleic acid, wherein the therapeutic agent or active agent is encapsulated within a lipid nanoparticle containing a compound of Formula I as described in any embodiment herein; or the method comprises administering to a subject in need thereof a therapeutically effective amount or a prophylactically effective amount of a pharmaceutical composition as described in any embodiment herein.
[0163] The diseases and conditions described herein can be various diseases and conditions known in the art that are suitable for treatment and prevention of the therapeutic agents or active agents (such as nucleic acids) described herein, and depend on the specific biological function of the therapeutic agent or active agent (such as nucleic acid) delivered by the lipid nanoparticles. In some embodiments, the pharmaceutical composition is a vaccine, and the method includes immunizing an individual so that the individual is immune to the corresponding disease or condition. In some embodiments, the disease or condition includes but is not limited to infectious diseases, such as infectious diseases caused by viruses and / or bacteria. Exemplary diseases or conditions include influenza, hepatitis B, hepatitis C, infections caused by the new coronavirus, etc. In some embodiments, the disease or condition also includes, for example, tumors, including solid tumors and blood tumors, and various inflammations, etc.
[0164] In this article, suitable routes and methods of administration are well known in the art and as described above, such as, but not limited to, oral, topical, transdermal, inhalation, intraperitoneal, sublingual, buccal, rectal, vaginal and intranasal. In some embodiments, the intraperitoneal administration route includes: subcutaneous injection, intravenous, intramuscular, intradermal, intrasternal injection or infusion technology.
[0165] The present invention also includes the application of the compound of formula I of the present invention in delivering therapeutic agents or active agents such as nucleic acids, or in preparing the application of the reagent for delivering therapeutic agents or active agents such as nucleic acids. The present invention also provides a method for delivering therapeutic agents or active agents such as nucleic acids in vivo or in vitro, the method including encapsulating the therapeutic agent or active agent in lipid nanoparticles made using the compound of formula I, and delivering the therapeutic agent or active agent via the lipid nanoparticles or the composition containing the lipid nanoparticles. The nucleic acid may be as described in any embodiment herein. In some embodiments, the therapeutic agent or active agent (such as nucleic acid) is delivered to a target target site (such as a cell, tissue (such as diseased tissues such as tumor tissue), organ) via the lipid nanoparticles or the composition containing the lipid nanoparticles. In some embodiments, the cell is an immune cell, including but not limited to T cells, dendritic cells (DC cells) or tumor infiltrating lymphocytes (TIL) etc.
[0166] VI. Preparation of Compounds of Formula I
[0167] The compound of formula I of the present invention can be prepared by the following general synthetic route 1 or 2:
[0168] Route 1:
[0169] Route 2:
[0170] Wherein R1, R2, R3, R4, L1, L2, L3, L4, M1, M2, M3, m are as defined in any embodiment herein; X may be a halogen such as Br, Cl, etc. First, compound 1 and compound 2 react to form compound 3a, and the reaction may be carried out under conditions suitable for condensation. Suitable conditions for condensation are, for example, selected from one of the following conditions: ① H2SO4; ② EDC·HCl and DMAP; ③ oxalyl chloride. 3b and 3c may be synthesized using the same method as 3a. Then, 3a, 3b, 3c and 4 react under conditions suitable for nucleophilic substitution reaction (e.g., alkaline) to form a compound of formula I. Alternatively, 3a, 3b, 3c and 5 react under conditions suitable for nucleophilic substitution reaction (e.g., alkaline) to form compound 6, and then compound 6 reacts with compound 7 under conditions suitable for nucleophilic substitution reaction (e.g., alkaline) to form a compound of formula I.
[0171] The present invention will be further described below by way of specific examples. It should be understood that these examples are merely illustrative and are not intended to limit the scope of the present invention. The methods and reagents used in the examples are, unless otherwise stated, conventional methods and reagents in the art.
[0172] Example
[0173] Example 1: Synthesis of ionizable lipid molecules
[0174] Example 1
[0175] Heneicosyl 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(undecanyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0176] Step 1: Synthesis of 8-bromooctanoate
[0177] Undecanol (1.0 g, 5.8 mmol) and 8-bromooctanoic acid (1.6 g, 7.5 mmol) were mixed, the temperature was raised to 60°C, concentrated sulfuric acid (0.1 mL) was added, and the mixture was stirred at this temperature for 3 hours. TLC showed that the starting material was completely consumed. The sample was directly mixed and eluted by column chromatography with PE:EA=15:1 to obtain 1.8 g of colorless oily product, with a yield of 82.2%.
[0178] 1H-NMR (400MHz, CDCl3) δ4.06 (t, J=6.7Hz, 2H), 3.40 (t, J=6.8Hz, 2H), 2.29 (t, J=7.5Hz, 2H), 1.90-1.80 (m, 2H), 1.67-1.58(m, 4H), 1.48-1.39(m, 2H), 1.37-1.31(m, 7H), 1.30-1.27(m, 4H), 1.26(s, 9H), 0.88(t, J=6.7Hz, 3H).
[0179] Step 2: Synthesis of Heneicosyl 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(undecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0180] 2-((3-Aminopropyl)amino)ethan-1-ol (135 mg, 1.1 mmol) was dissolved in acetonitrile (16 mL), and 8-bromooctanoate (1.4 g, 3.8 mmol), K2CO3 (0.7 g, 5.1 mmol), and KI (13 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with EA (50 mL*3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 50:1 as the eluent to give 0.5 g of the product as a colorless oil, in a yield of 43.5%.
[0181] ESI-MS m / z:cald for C 62 H 123 N2O7[M+H] + :1007.9, found 1007.9.
[0182] 1 H-NMR (400MHz, CDCl3) δ4.05 (t, J=6.7Hz, 6H), 3.57-3.50 (m, 2H), 2.58-2.42 (m, 5H), 2.42-2.35 (m, 6H), 2.28 (t, J =7.5Hz, 6H), 1.65-1.52(m, 13H), 1.49-1.41(m, 5H), 1.40-1.33(m, 5H), 1.33-1.23(m, 64H), 0.88(t, J=6.8Hz, 9H).
[0183] Example 2
[0184] diheptadecan-9-yl) 8,8′-((3-((8-(heptadecan-9-oxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl) dioctanoate
[0185] Step 1: Synthesis of 8-bromooctanoic acid heptane-9-yl ester
[0186] Heptadecane-9-ol (9.0 g, 35.1 mmol) and 8-bromooctanoic acid (8.6 g, 38.6 mmol) were dissolved in DCM (100 mL). EDC·HCl (13.5 g, 70.2 mmol), DMAP (8.6 g, 70.2 mmol) and triethylamine (14.2 g, 140.4 mmol) were added, and the mixture was stirred at room temperature for 16 hours. TLC showed that the starting material was completely consumed. An appropriate amount of water was added, and the mixture was extracted with DCM (100 mL x 3). The organic phase was dried and then spin-dried. The crude product was eluted by column chromatography with PE:EA=20:1 to obtain 5.6 g of a light yellow oily product in a yield of 34.3%.
[0187] 1 H-NMR (400MHz, CDCl3) δ4.92-4.80 (m, 1H), 3.40 (t, J=6.8Hz, 2H), 2.28 (t, J=7.4Hz, 2H), 1.91-1.72 (m, 2H), 1.6 8-1.59 (m, 2H), 1.54-1.47 (m, 4H), 1.46-1.42 (m, 1H), 1.42-1.27 (m, 12H), 1.26 (s, 17H), 0.88 (t, J=6.7Hz, 6H).
[0188] Step 2: Di(heptadecan-9-yl) 8,8′-((3-((8-(heptadecan-9-oxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl) dioctanoate
[0189] 2-((3-Aminopropyl)amino)ethan-1-ol (60 mg, 0.5 mmol) was dissolved in acetonitrile (6 mL), and 8-bromooctanoic acid heptane-9-yl ester (1.4 g, 3.0 mmol), K2CO3 (0.4 g, 3.0 mmol), and KI (10 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with EA (50 mL*3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 40:1 as the eluent to give 73 mg of the product as a colorless oil, with a yield of 11.6%.
[0190] ESI-MS m / z:cald for C 80 H 159 N2O7[M+H] + :1260.1, found 1260.1.
[0191] 1 H-NMR (400MHz, CDCl3) δ4.91-4.80 (m, 3H), 3.54 (t, J=5.2Hz, 2H), 2.57-2.35 (m, 14H), 2.27 (t, J=7.5Hz, 8H), 1.67-1.55 (m, 10H), 1.50 (d, J=6.1Hz, 14H), 1.45-1.36 (m, 11H), 1.31-1.25 (m, 78H), 0.87 (t, J=6.7Hz, 18H).
[0192] Example 3
[0193] Di((E)-3,7-dimethylocta-2,6-dien-1-yl) 8,8′-((3-((8-(((E)-3,7-dimethylocta-2,6-dien-1-yl)oxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl) dioctanoate
[0194] Step 1: Synthesis of (E)-3,7-dimethylocta-2,6-dien-1-yl 8-bromooctanoate
[0195] Under nitrogen, 8-bromooctanoic acid (5 g, 22.41 mmol) was dissolved in 100 mL of anhydrous DCM, and oxalyl chloride (3.41 g, 28.89 mmol, 1.2 eq) was added under ice. The mixture was then allowed to react at 40°C for one hour, dried by spin-drying, and redissolved in 100 mL of anhydrous DCM. (E)-3,7-Dimethylocta-2,6-diene-1-ol (2.77 g, 7.93 mmol, 0.8 eq) was dissolved in 20 mL of Et3N and added dropwise to the reaction mixture, stirring at room temperature for one hour. After the reaction, the mixture was separated, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and then dried by spin-drying and column chromatography to obtain 2.3 g of the desired product in a 28.6% yield.
[0196] Step 2: Synthesis of bis((E)-3,7-dimethylocta-2,6-dien-1-yl)8,8′-((3-((8-(((E)-3,7-dimethylocta-2,6-dien-1-yl)oxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl)dioctanoate
[0197] 2-((3-Aminopropyl)amino)ethane-1-ol (0.1 g, 0.846 mmol) was dissolved in 20 mL of anhydrous acetonitrile, and (E)-3,7-dimethylocta-2,6-dien-1-yl 8-bromooctanoate (1.06 g, 2.96 mmol), K2CO3 (0.584 g, 4.23 mmol, 5 eq), and KI (14 mg, 0.084 mmol, 0.1 eq) were added and heated to 85°C overnight. After the reaction, 20 mL of DCM was added and filtered to remove insoluble matter. The product was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, and then dried by column drying. 0.54 g of the desired product was obtained with a yield of 67%.
[0198] ESI-MS m / z:cald for C 59 H 105 N2O7[M+H] + :953.8,found 953.8.
[0199] 1 H NMR (400MHz, CDCl3) δ5.40-5.32 (m, 3H), 5.15-5.07 (m, 3H), 4.61 (d, J=7.1Hz, 6H), 3.7 7-3.64(m, 4H), 2.91-2.87(m, 1H), 2.83-2.75(m, 4H), 2.73-2.64(m, 4H), 2.59-2.53(m, 2H), 2.37-2.28(m, 7H), 2.17-2.03(m, 12H), 1.92-1.85(m, 2H), 1.72(d, J=8.0Hz, 17H) , 1.68-1.61 (m, 17H), 1.51 (d, J=8.5Hz, 2H), 1.35 (d, J=8.5Hz, 16H), 1.31-1.24 (m, 4H).
[0200] Example 4
[0201] Diheptyl 8,8f-((3-((8-(heptyloxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl)dioctanoate
[0202] Step 1: Synthesis of Heptyl 8-Bromooctanoate
[0203] Under nitrogen, 8-bromooctanoic acid (5 g, 22.41 mmol) was dissolved in anhydrous DCM (100 mL). Oxalyl chloride (3.41 g, 28.89 mmol, 1.2 eq) was added under ice. The mixture was reacted at 40°C for one hour, then dried by vortexing and redissolved in 100 mL of anhydrous DCM. n-Heptanol (2.08 g, 17.93 mmol, 0.8 eq) was dissolved in 20 mL of Et3N and added dropwise to the reaction mixture, stirring at room temperature for one hour. After the reaction, the organic phase was separated and washed with saturated brine, dried over anhydrous sodium sulfate, and then dried by vortexing and column chromatography. 1.39 g of the desired product was obtained, with a yield of 19.3%.
[0204] Step 2: Synthesis of diheptyl 8,8′-((3-((8-(heptyloxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl)dioctanoate:
[0205] 2-((3-Aminopropyl)amino)ethan-1-ol (0.1 g, 0.846 mmol) was dissolved in 20 mL of anhydrous acetonitrile. Heptyl 8-bromooctanoate (0.95 g, 2.96 mmol, 3.5 eq), K2CO3 (0.584 g, 4.23 mmol, 5 eq), and KI (14 mg, 0.084 mmol, 0.1 eq) were added and heated to 85°C overnight. After the reaction, 20 mL of DCM was added and filtered to remove insoluble matter. The product was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, and then dried by column drying. 0.21 g of the desired product was obtained with a yield of 29.6%.
[0206] ESI-MS m / z:cald for C 50 H 99 N2O7[M+H] + :839.7,found 839.7.
[0207] 1 H NMR (400MHz, CDCl3) δ4.08 (t, J=6.8Hz, 6H), 3.80-3.69 (m, 4H), 2.93 (t, J=7.3Hz, 2H), 2.83 (t, J=8.2Hz, 4H), 2.75- 2.65(m, 4H), 2.61-2.53(m, 2H), 2.37-2.30(m, 5H), 1.64(t, J=6.9Hz, 16H), 1.40-1.25(m, 42H), 0.95-0.87(m, 9H).
[0208] Example 5
[0209] Dipentyl 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(pentyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0210] Step 1: Synthesis of Pentyl 8-Bromooctanoate
[0211] Under nitrogen, bromooctanoic acid (5g, 22.41mmol) was dissolved in 100mL of anhydrous DCM. Oxalyl chloride (3.41g, 28.89mmol, 1.2eq) was added under ice. The mixture was reacted at 40°C for one hour, then dried by vortexing and redissolved in 100mL of anhydrous DCM. Pentanol (1.58g, 17.93mmol, 0.8eq) was dissolved in 20mL of Et3N and added dropwise to the reaction mixture, stirring at room temperature for one hour. After the reaction, the organic phase was separated and washed with saturated brine, dried over anhydrous sodium sulfate, and then dried by vortexing and column chromatography. 1.39g of the desired product was obtained, with a yield of 19.3%.
[0212] Step 2: Synthesis of dipentyl 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(pentyloxy)octyl)amino)propyl)azanediyl)dioctanoate:
[0213] 2-((3-Aminopropyl)amino)ethane-1-ol (0.1 g, 0.846 mmol) was dissolved in 20 mL of anhydrous acetonitrile. Amyl 8-bromooctanoate (0.95 g, 2.96 mmol, 3.5 eq), K2CO3 (0.584 g, 4.23 mmol, 5 eq), and KI (14 mg, 0.084 mmol, 0.1 eq) were added and heated to 85°C overnight. After the reaction was completed, 20 mL of DCM was added and filtered to remove insoluble matter. The product was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, and then spin-dried through a column. 0.21 g of the desired product was obtained with a yield of 29.6%.
[0214] ESI-MS m / z:cald for C 44 H 87 N2O7[M+H] + :755.6, found 755.6.
[0215] 1H NMR (400MHz, CDCl3) δ4.12-4.02(m, 6H), 3.64-3.57(m, 2H), 2.70(s, 1H), 2.66-2.52(m, 8H), 2.52-2.45(m, 2H), 2.33-2.25( m, 6H), 1.82-1.72 (m, 2H), 1.67-1.50 (m, 16H), 1.50-1.40 (m, 2H), 1.39-1.30 (m, 27H), 1.30-1.22 (m, 4H), 0.96-0.87 (m, 9H).
[0216] Example 6
[0217] Di((Z)-non-2-en-1-yl) 8,8′-((3-((2-hydroxyethyl)(8-(((Z)-non-2-en-1-yl)oxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate
[0218] Step 1: Synthesis of (Z)-non-2-en-1-yl 8-bromooctanoate
[0219] Mix cis-2-nonen-1-ol (1.0 g, 7.0 mmol) and 8-bromooctanoic acid (1.9 g, 8.4 mmol), heat the temperature to 60°C, add concentrated sulfuric acid (0.1 mL), and stir at this temperature for 5 hours. TLC shows that the starting material is completely consumed. The sample is directly mixed and eluted by column chromatography with PE:EA=50:1 to obtain 2.2 g of colorless oily product, with a yield of 91.7%.
[0220] 1 H-NMR (400MHz, CDCl3) δ5.70-5.59 (m, 1H), 5.58-5.46 (m, 1H), 3.43-3.36 (m, 2H), 3.40 (t, J=6.8Hz, 2H), 2.31 (t, J=7.5Hz , 2H), 2.15-2.05(m, 2H), 1.90-1.80(m, 2H), 1.68-1.59(m, 2H), 1.47-1.39(m, 2H), 1.38-1.25(m, 12H), 0.92-0.84(m, 3H).
[0221] Step 2: Synthesis of di((Z)-non-2-en-1-yl) 8,8′-((3-((2-hydroxyethyl)(8-(((Z)-non-2-en-1-yl)oxy)-8-carbonyloctyl)amino)propyl)azanediyl) dioctanoate
[0222] N-(2-Hydroxyethyl)-1,3-propanediamine (60 mg, 0.5 mmol) was dissolved in acetonitrile (6 mL), and (Z)-non-2-en-1-yl 8-bromooctanoate (0.6 g, 1.7 mmol), K2CO3 (0.3 g, 2.3 mmol), and KI (10 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with EA (50 mL x 3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 40:1 as the eluent to afford 180 mg of the product as a colorless oil, yield: 38.5%.
[0223] ESI-MS m / z:cald for C 56 H 105 N2O7[M+H] + :917.5, found 917.5.
[0224] 1 H-NMR (400MHz, CDCl3) δ5.68-5.58 (m, 3H), 5.56-5.46 (m, 3H), 4.61 (d, J=6.8Hz, 6H), 3.53 (t, J=5.2Hz, 2H), 2.57-2.36 (m, 10H ), 2.35 (d, J=5.1Hz, 2H), 2.29 (t, J=7.5Hz, 6H), 2.14-2.04 (m, 6H), 1.66-1.50 (m, 8H), 1.44-1.24 (m, 48H), 0.91-0.83 (m, 9H).
[0225] Example 7
[0226] Di((4Z,7Z)-dec-4,7-dien-1-yl) 8,8′-((3-((8-(((4Z,7Z)-dec-4,7-dien-1-yl)oxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl) dioctanoate
[0227] Step 1: Synthesis of (4Z,7Z)-dec-4,7-dien-1-yl 8-bromooctanoate
[0228] Mix (4Z,7Z)-decadienol (0.9 g, 5.8 mmol) and 8-bromooctanoic acid (1.6 g, 7.0 mmol), heat the temperature to 60°C, add concentrated sulfuric acid (0.1 mL), and stir at this temperature for 4 hours. TLC shows that the starting material is completely consumed. The sample is directly mixed and eluted by column chromatography with PE:EA=30:1 to obtain 1.3 g of colorless oily product, with a yield of 61.9%.
[0229] 1H-NMR (400MHz, CDCl3) δ5.47-5.23 (m, 4H), 4.07 (t, J=6.6Hz, 2H), 3.40 (t, J=6.8Hz, 2H), 2.77 (t, J=6.6Hz, 2H), 2.30 (t, J=7.5 Hz, 2H), 2.19-2.01 (m, 4H), 1.90-1.80 (m, 2H), 1.74-1.58 (m, 4H), 1.48-1.39 (m, 2H), 1.39-1.23 (m, 4H), 0.97 (t, J=7.5Hz, 3H).
[0230] Step 2: Synthesis of di((4Z,7Z)-dec-4,7-dien-1-yl)8,8′-((3-((8-(((4Z,7Z)-dec-4,7-dien-1-yl)oxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl)dioctanoate
[0231] N-(2-Hydroxyethyl)-1,3-propanediamine (120 mg, 1.0 mmol) was dissolved in acetonitrile (8 mL), and (4Z,7Z)-deca-4,7-dien-1-yl 8-bromooctanoate (1.3 g, 3.6 mmol), K2CO3 (0.6 g, 4.6 mmol), and KI (10 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with DCM (50 mL*3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 30:1 as the eluent to give 340 mg of the product as a colorless oil, with a yield of 35.0%.
[0232] ESI-MS m / z: cald for C59H105N2O7[M+H] + :953.5,found 953.5.
[0233] 1 H-NMR (400MHz, CDCl3) δ5.48-5.18 (m, 12H), 4.07 (t, J=6.6Hz, 6H), 3.57-3.50 (m, 2H), 2.77 (t, J=6.6Hz, 6H), 2.57-2.25 (m , 19H), 2.17-1.97(m, 13H), 1.73-1.65(m, 7H), 1.63-1.53(m, 4H), 1.41(s, 5H), 1.35-1.23(m, 21H), 0.97(t, J=7.5Hz, 9H).
[0234] Example 8
[0235] Di((Z)-non-6-en-1-yl) 8,8′-((3-((2-hydroxyethyl)(8-(((Z)-non-6-en-1-yl)oxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate
[0236] Step 1: Synthesis of (Z)-non-6-en-1-yl 8-bromooctanoate
[0237] Under nitrogen, bromooctanoic acid (5 g, 22.41 mmol) was dissolved in 100 mL of anhydrous DCM. Oxalyl chloride (3.41 g, 28.89 mmol, 1.2 eq) was added under ice. The mixture was reacted at 40°C for one hour, then dried by vortexing and redissolved in 100 mL of anhydrous DCM. (Z)-non-6-en-1-ol (2.55 g, 17.93 mmol, 0.8 eq) was dissolved in 20 mL of Et3N and added dropwise to the reaction mixture, stirring at room temperature for one hour. After the reaction, the organic phase was separated and washed with saturated brine, dried over anhydrous sodium sulfate, and then dried by column chromatography to yield 2.78 g of the desired product in a 35.7% yield.
[0238] Step 2: Synthesis of di((Z)-non-6-en-1-yl)8,8′-((3-((2-hydroxyethyl)(8-(((Z)-non-6-en-1-yl)oxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate:
[0239] 2-((3-Aminopropyl)amino)ethan-1-ol (0.15 g, 1.27 mmol) was dissolved in 20 mL of anhydrous acetonitrile. (Z)-non-6-en-1-yl 8-bromooctanoate (1.54 g, 4.44 mmol, 3.5 eq), K2CO3 (0.877 g, 6.35 mmol, 5 eq), and KI (0.21 g, 0.127 mmol, 0.1 eq) were added and heated to 85°C overnight. After the reaction, 20 mL of DCM was added and filtered to remove insoluble matter. The product was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, and then filtered through a column. 0.32 g of the desired product was obtained with a yield of 27.6%.
[0240] ESI-MS m / z:cald for C 56 H 105 N2O7[M+H] + :917.8,found 917.8.
[0241] 1H NMR (400MHz, CDCl3) δ5.46-5.29 (m, 6H), 4.09 (t, J=6.7Hz, 6H), 3.81-3.71 (m, 1H), 3.59 (t, J=5.2Hz, 2H), 2.64-2.54 (m, 4H), 2.54-2.43 (m, 8H), 2 .32(t, J=7.5Hz, 6H), 2.13-1.99(m, 13H), 1.69-1.59(m, 13H), 1.50-1.4 7(m, 3H), 1.45-1.38(m, 12H), 1.36-1.25(m, 21H), 0.99(t, J=7.5Hz, 9H).
[0242] Example 9
[0243] Dinonyl 8,8′-((3-((2-hydroxyethyl)(8-(nonyloxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate
[0244] Step 1: Synthesis of 8-nonylbromooctanoate
[0245] 8-Bromooctanoic acid (7.23 g, 32.4 mmol) was dissolved in 100 mL of DCM, and oxalyl chloride (4.94 g, 38.89 mmol) was slowly added. The resulting mixture was refluxed for 4 hours and then dried to give 8 g of crude product. Half of the mixture was added to DCM (150 mL), dissolved in TEA (3.28 g, 32.4 mmol), and then 1-nonanol (2.34 g, 16.2 mmol) was added. The mixture was stirred at 40° C. for 4 hours. TLC showed that the starting material was completely consumed. The sample was directly mixed and eluted by column chromatography with PE:EA=15:1 to give 4.5 g of the product as a colorless oil, with a yield of 79.5%.
[0246] Step 2: Synthesis of dinonyl 8,8′-((3-((2-hydroxyethyl)(8-(nonyloxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate
[0247] 2-((3-Aminopropyl)amino)ethan-1-ol (59.1 mg, 0.5 mmol) was dissolved in DMF (5 mL), and 8-bromooctanoic acid nonyl ester (611.36 mg, 1.75 mmol), K2CO3 (345.53 mg, 2.5 mmol), and KI (13 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and EA (50 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 0.3 g of the product as a colorless oil, in a yield of 65%.
[0248] ESI-MS m / z:cald for C 56 H 111 N2O7[M+H] + :923.7, found 923.7.
[0249] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 3.67 (t, J=5.1Hz, 2H), 3.00-2.84 (m, 3H), 2.84-2.74 (m, 4H), 2.73-2.63 (m, 4H), 2.56 (t, J= 7.8Hz, 2H), 2.29 (t, J=7.5Hz, 6H), 2.02-1.88 (m, 2H), 1.71-1.56 (m, 16H), 1.54-1.45 (m, 2H), 1.42-1.13 (m, 54H), 0.88 (t, J=6.7Hz, 9H).
[0250] Example 10
[0251] Di((Z)-pent-2-en-1-yl) 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(((Z)-pent-2-en-1-yl)oxy)octyl)amino)propyl)azanediyl)dioctanoate
[0252] Step 1: Synthesis of (Z)-pent-2-en-1-yl 8-bromooctanoate
[0253] 8-Bromooctanoic acid (7.23 g, 32.4 mmol) was dissolved in 100 mL of DCM, and oxalyl chloride (4.94 g, 38.89 mmol) was slowly added. The resulting mixture was refluxed for 4 hours and then dried to give 8 g of crude product. Half of the mixture was added to DCM (150 mL), dissolved in TEA (3.28 g, 32.4 mmol), and then (Z)-pent-2-en-1-ol (1.395 g, 16.2 mmol) was added. The mixture was stirred at 40° C. for 4 hours. TLC showed that the starting material was completely consumed. The sample was directly mixed and eluted by column chromatography with PE:EA = 15:1 to give 4.0 g of the product as a colorless oil, with a yield of 84.78%.
[0254] Step 2: Synthesis of di((Z)-pent-2-en-1-yl) 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(((Z)-pent-2-en-1-yl)oxy)octyl)amino)propyl)azanediyl) dioctanoate
[0255] 2-((3-Aminopropyl)amino)ethan-1-ol (59.1 mg, 0.5 mmol) was dissolved in DMF (5 mL), and (Z)-8-bromooctanoic acid pent-2-en-1-yl ester (509.65 mg, 1.75 mmol), K2CO3 (345.53 mg, 2.5 mmol), and KI (13 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and EA (50 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 0.1 g of the product as a colorless oil, in a yield of 26.7%.
[0256] ESI-MS m / z:cald for C 44 H 81 N2O7[M+H] + :949.4,found 949.4.
[0257] 1 H NMR (400MHz, CDCl3) δ5.71-5.59 (m, 3H), 5.55-5.43 (m, 3H), 4.62 (dd, J=6.9, 1.3Hz , 6H), 3.67 (t, J=5.0Hz, 2H), 2.99-2.90 (m, 1H), 2.87-2.78 (m, 4H), 2.74-2.65 (m, 4 H), 2.61-2.51 (m, 2H), 2.31 (t, J=7.5Hz, 6H), 2.17-2.07 (m, 6H), 2.02-1.88 (m, 2H) , 1.70-1.56 (m, 10H), 1.54-1.44 (m, 2H), 1.39-1.24 (m, 20H), 1.00 (t, J=7.5Hz, 9H).
[0258] Example 11
[0259] Heneicosyl 6,6′-((3-((2-hydroxyethyl)(6-carbonyl-6-(undecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate
[0260] Step 1: Synthesis of Undecyl 6-bromohexanoate
[0261] Undecanol (2.0 g, 11.6 mmol) and 6-bromohexanoic acid (2.7 g, 13.9 mmol) were mixed, the temperature was raised to 60°C, concentrated sulfuric acid (0.1 mL) was added, and the mixture was stirred at this temperature for 6 hours. TLC showed that the starting material was completely consumed. The sample was directly mixed and eluted by column chromatography with PE:EA=20:1 to obtain 3.5 g of colorless oily product, with a yield of 86.4%.
[0262] 1H-NMR (400MHz, CDCl3) δ4.06 (t, J=6.7Hz, 2H), 3.40 (t, J=6.8Hz, 2H), 2.31 (t, J=7.4Hz, 2H), 1.95 -1.80 (m, 2H), 1.70-1.59 (m, 4H), 1.54-1.40 (m, 2H), 1.27 (d, J=7.7Hz, 16H), 0.88 (t, J=6.7Hz, 3H).
[0263] Step 2: Synthesis of heneicosyl 6,6′-((3-((2-hydroxyethyl)(6-carbonyl-6-(undecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate
[0264] 2-((3-Aminopropyl)amino)ethan-1-ol (60 mg, 0.5 mmol) was dissolved in acetonitrile (6 mL), and undecyl 6-bromohexanoate (0.6 g, 1.8 mmol), K2CO3 (0.3 g, 2.3 mmol), and KI (10 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with DCM (30 mL x 3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 40:1 as the eluent to afford 160 mg of the product as a colorless oil (yield: 34.0%).
[0265] ESI-MS m / z:cald for C 56 H 111 N2O7[M+H] + :923.5, found 923.5.
[0266] 1H-NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 3.53 (t, J=5.2Hz, 2H), 2.56-2.34 (m, 12H), 2.29 (t, J =7.5Hz, 6H), 1.68-1.57 (m, 12H), 1.49-1.39 (m, 6H), 1.28 (d, J = 17.3Hz, 57H), 0.88 (t, J = 6.8Hz, 9H).
[0267] Example 12
[0268] Heneicosyl 4,4′-((3-((2-hydroxyethyl)(4-carbonyl-4-(undecanyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0269] Step 1: Synthesis of 4-bromobutyrate undecyl ester
[0270] Undecanol (2.0 g, 11.6 mmol) and 4-bromobutyric acid (2.3 g, 13.9 mmol) were mixed, the temperature was raised to 60°C, concentrated sulfuric acid (0.1 mL) was added, and the mixture was stirred at this temperature for 6 hours. TLC showed that the starting material was completely consumed. The sample was directly mixed and eluted by column chromatography with PE:EA=20:1 to obtain 3.3 g of colorless oily product, with a yield of 88.5%.
[0271] 1 H-NMR (400MHz, CDCl3) δ4.07 (t, J=6.7Hz, 2H), 3.46 (t, J=6.4Hz, 2H), 2.49 (t, J=7.2Hz , 2H), 2.22-2.11(m, 2H), 1.66-1.60(m, 2H), 1.35-1.23(m, 16H), 0.88(t, J=6.7Hz, 3H).
[0272] Step 2: Synthesis of heneicosyl 4,4′-((3-((2-hydroxyethyl)(4-carbonyl-4-(undecanyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0273] 2-((3-Aminopropyl)amino)ethan-1-ol (60 mg, 0.5 mmol) was dissolved in acetonitrile (8 mL), and 4-bromobutyric acid undecyl ester (0.6 g, 1.8 mmol), K2CO3 (0.3 g, 2.3 mmol), and KI (10 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with DCM (30 mL*3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 30:1 as the eluent to afford 180 mg of the product as a colorless oil, yield: 42.0%.
[0274] ESI-MS m / z:cald for C 50 H 99 N2O7[M+H] + :839.3, found 839.3.
[0275] 1H-NMR (400MHz, CDCl3) δ4.09-4.01 (m, 6H), 3.54 (t, J=5.2Hz, 2H), 2.57 (t, J=5.2Hz, 2H), 2.48 (t, J=7.2Hz, 4H), 2.41 (t, J=7. 2Hz, 6H), 2.35-2.26 (m, 6H), 2.02 (s, 1H), 1.82-1.68 (m, 6H), 1.66-1.49 (m, 8H), 1.27 (d, J=8.8Hz, 48H), 0.88 (t, J=6.7Hz, 9H).
[0276] Example 13
[0277] Tricosyl 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(tridecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0278] Step 1: Synthesis of tridecyl 8-bromooctanoate
[0279] Under nitrogen, bromooctanoic acid (5g, 22.41mmol) was dissolved in 100mL of anhydrous DCM. Oxalyl chloride (3.41g, 28.89mmol, 1.2eq) was added under ice. The mixture was reacted at 40°C for one hour, then dried by vortexing and redissolved in 100mL of anhydrous DCM. Tridecanol (2.55g, 17.93mmol, 0.8eq) was dissolved in 20mL of Et3N and added dropwise to the reaction mixture, stirring at room temperature for one hour. After the reaction, the organic phase was separated and washed with saturated brine, dried over anhydrous sodium sulfate, and then dried by vortexing and column chromatography. 2.44g of the desired product was obtained, with a yield of 26.8%.
[0280] Step 2: Synthesis of tricosyl 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(tridecyloxy)octyl)amino)propyl)azanediyl)dioctanoate:
[0281] 2-((3-Aminopropyl)amino)ethane-1-ol (0.1 g, 0.846 mmol) was dissolved in 20 mL of anhydrous acetonitrile. Tridecyl 8-bromooctanoate (1.2 g, 2.96 mmol, 3.5 eq), K2CO3 (0.584 g, 6.35 mmol, 5 eq), and KI (0.21 g, 0.127 mmol, 0.1 eq) were added and heated to 85°C overnight. After the reaction was completed, 20 mL of DCM was added and filtered to remove insoluble matter. The product was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, and then spin-dried through a column. 0.34 g of the desired product was obtained with a yield of 36.8%.
[0282] ESI-MS m / z:cald for C 68 H 135 N2O7[M+H] + :1092.0,found 1092.0.
[0283] 1 H NMR (400MHz, CDCl3) δ4.09 (t, J=6.8Hz, 6H), 3.79-3.72 (m, 1H), 2.76-2.57 (m, 8H), 2.52 (t, J=7. 6Hz, 2H), 2.32 (t, J=7.5Hz, 6H), 1.71-1.55 (m, 16H), 1.45-1.20 (m, 85H), 0.92 (t, J=6.8Hz, 9H).
[0284] Example 14
[0285] Heneicosyl 10,10′-((3-((2-hydroxyethyl)(10-carbonyl-10-(undecanyloxy)decyl)amino)propyl)azanediyl)di(decanoate)
[0286] Step 1: Synthesis of Undecyl 10-Bromodecanoate
[0287] Under nitrogen, bromodecanoic acid (5 g, 19.9 mmol) was dissolved in 100 mL of anhydrous DCM. Oxalyl chloride (3.03 g, 23.89 mmol, 1.2 eq) was added under ice. The mixture was reacted at 40°C for one hour, then dried by vortexing and redissolved in 100 mL of anhydrous DCM. Undecanol (2.74 g, 15.93 mmol, 0.8 eq) was dissolved in 20 mL of Et3N and added dropwise to the reaction mixture, stirring at room temperature for one hour. After the reaction, the organic phase was separated and washed with saturated brine, dried over anhydrous sodium sulfate, and then dried by vortexing and column chromatography. 1.96 g of the desired product was obtained, with a yield of 24.3%.
[0288] Step 2: Synthesis of Heneicosyl 10,10′-((3-((2-hydroxyethyl)(10-carbonyl-10-(undecanyloxy)decyl)amino)propyl)azanediyl)di(decanoate):
[0289] 2-((3-Aminopropyl)amino)ethan-1-ol (0.1 g, 0.846 mmol) was dissolved in 20 mL of anhydrous acetonitrile. Undecyl 10-bromodecaneate (1.2 g, 2.96 mmol, 3.5 eq), K2CO3 (0.584 g, 6.35 mmol, 5 eq), and KI (0.21 g, 0.127 mmol, 0.1 eq) were added and heated to 85°C overnight. After the reaction, 20 mL of DCM was added and filtered to remove insoluble matter. The product was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, and then filtered through a column. 0.34 g of the desired product was obtained with a yield of 36.8%.
[0290] ESI-MS m / z:cald for C 68 H 135 N2O7[M+H] + :1092.0,found 1092.0.
[0291] 1 H NMR (400MHz, CDCl3) δ4.09 (t, J=6.8Hz, 6H), 3.83-3.76 (m, 1H), 3.24-3.17 (m, 1H), 3.09 (t, J=8.5Hz, 3H), 2.88-2.77 (m, 2H), 2.65 (d, J=9.1Hz, 1H), 2.33 (t, J=7.5Hz, 7H), 2.12-1.98 (m, 2H), 1.80-1.54 (m, 16H), 1.46-1.16 (m, 85H), 1.01-0.83 (m, 10H).
[0292] Example 15
[0293] Di((Z)-non-2-en-1-yl) 10,10′-((3-((2-hydroxyethyl)(10-(((Z)-non-2-en-1-yl)oxy)-10-carbonyldecyl)amino)propyl)azanediyl)di(decanoate)
[0294] Step 1: Synthesis of (Z)-non-2-en-1-yl 10-bromodecaneate
[0295] Under nitrogen, 10-bromodecanoic acid (5 g, 19.9 mmol) was dissolved in 100 mL of anhydrous DCM. Oxalyl chloride (3.03 g, 23.89 mmol, 1.2 eq) was added under ice. The mixture was then reacted at 40°C for one hour, dried by vortexing, and redissolved in 100 mL of anhydrous DCM. (Z)-non-2-en-1-ol (2.74 g, 15.93 mmol, 0.8 eq) was dissolved in 20 mL of Et3N and added dropwise to the reaction mixture, stirring at room temperature for one hour. After the reaction, the organic phase was separated and washed with saturated brine, dried over anhydrous sodium sulfate, and then dried by vortexing. 3.93 g of the desired product was obtained with a yield of 52.6%.
[0296] Step 2: Synthesis of bis((Z)-non-2-en-1-yl)10,10′-((3-((2-hydroxyethyl)(10-(((Z)-non-2-en-1-yl)oxy)-10-carbonyldecyl)amino)propyl)azanediyl)bis(decanoate):
[0297] 2-((3-Aminopropyl)amino)ethan-1-ol (0.1 g, 0.846 mmol) was dissolved in 20 mL of anhydrous acetonitrile. (Z)-non-2-en-1-yl 10-bromodecaneate (1.11 g, 2.96 mmol, 3.5 eq), K2CO3 (0.584 g, 4.23 mmol, 5 eq), and KI (0.014 g, 0.084 mmol, 0.1 eq) were added and heated to 85°C overnight. After the reaction, 20 mL of DCM was added and filtered to remove insoluble matter. The product was washed with 20 mL of saturated brine, dried over anhydrous sodium sulfate, and then spin-dried through a column. 0.319 g of the desired product was obtained with a yield of 22.4%.
[0298] ESI-MS m / z:cald for C 62 H 117 N2O7[M+H] + :1001.9,found 1001.9.
[0299] 1 H NMR (400MHz, CDCl3) δ5.73-5.62(m, 2H), 5.61-5.50(m, 2H), 4.73-4.62(m, 6H), 4.21-4.12(m, 1H), 3.69-3.61(m, 1H), 2.83-2.63(m, 6H), 2 .53-2.48(m, 2H), 2.34(t, J=7.6Hz, 6H), 2.18-2.06(m, 8H), 1.88-1.75(m, 2H), 1.69-1.62(m, 6H), 1.45-1.21(m, 64H), 0.97-0.88(m, 9H).
[0300] Example 16
[0301] di((Z)-non-2-en-1-yl) 4,4′-((3-((2-hydroxyethyl)(4-(((Z)-non-2-en-1-yl)oxy)-4-carbonylbutyl)amino)propyl)azanediyl)dibutyrate
[0302] Step 1: Synthesis of (Z)-non-2-en-1-yl 4-bromobutyrate
[0303] Mix (Z)-non-2-en-1-ol (1.0 g, 7.0 mmol) and 4-bromobutyric acid (1.4 g, 8.4 mmol), heat the temperature to 60°C, add concentrated sulfuric acid (0.1 mL), and stir at this temperature for 6 hours. TLC shows that the starting material is completely consumed. The sample is directly mixed and eluted by column chromatography with PE:EA=20:1 to obtain 1.9 g of colorless oily product, with a yield of 95.0%.
[0304] 1 H-NMR (400MHz, CDCl3) δ5.70-5.60 (m, 1H), 5.57-5.46 (m, 1H), 4.67-4.60 (m, 2H), 3.46 (t, J= 6.5Hz, 2H), 2.51 (t, J=7.2Hz, 2H), 2.23-2.04 (m, 4H), 1.38-1.22 (m, 8H), 0.92-0.84 (m, 3H).
[0305] Step 2: Synthesis of di((Z)-non-2-en-1-yl) 4,4′-((3-((2-hydroxyethyl)(4-(((Z)-non-2-en-1-yl)oxy)-4-carbonylbutyl)amino)propyl)azanediyl)dibutyrate
[0306] 2-((3-Aminopropyl)amino)ethan-1-ol (60 mg, 0.5 mmol) was dissolved in acetonitrile (8 mL), and (Z)-non-2-en-1-yl 4-bromobutyrate (0.6 g, 2.0 mmol), K2CO3 (0.4 g, 2.6 mmol), and KI (10 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and DCM (30 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 30:1 as the eluent to give 58 mg of the product as a colorless oil, with a yield of 15.2%.
[0307] ESI-MS m / z:cald for C 44 H 81N2O7[M+H] + :749.1, found 749.1.
[0308] 1H-NMR (400MHz, CDCl3) δ5.69-5.57 (m, 3H), 5.56-5.46 (m, 3H), 4.65-4.58 (m, 6H), 3.54 (t, J=5.2Hz, 2H), 2.56 (t, J=5.2Hz, 2H), 2.48 (t, J=7.2Hz , 4H), 2.41 (t, J=7.2Hz, 6H), 2.36-2.27 (m, 6H), 2.14-2.04 (m, 6H), 1.82 -1.68(m, 6H), 1.61-1.49(m, 2H), 1.38-1.25(m, 25H), 0.92-0.84(m, 9H).
[0309] Example 17
[0310] di((Z)-hex-2-en-1-yl) 8,8′-((3-((8-(((Z)-hex-2-en-1-yl)oxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl) dioctanoate
[0311] Step 1: Synthesis of (Z)-hex-2-en-1-yl 8-bromooctanoate
[0312] 8-Bromooctanoic acid (10.1 g, 45.27 mmol) was dissolved in 150 mL of DCM, and oxalyl chloride (6.9 g, 54.33 mmol) was slowly added. The resulting mixture was refluxed for 4 hours and then dried to give 10 g of crude product. 5 g of the product was dissolved in DCM (200 mL) and TEA (4.09 g, 40.4 mmol) and then cis-(Z)-hex-2-en-1-ol (2.02 g, 20.19 mmol) was added. The mixture was stirred at 40° C. for 4 hours. TLC showed that the starting material was completely consumed. The sample was directly mixed and eluted by column chromatography using PE:EA=15:1 to give 4.0 g of the product as a colorless oil, in a yield of 64.9%.
[0313] Step 2: Di((Z)-hexyl-2-en-1-yl)8,8′-((3-((8-(((Z)-hexane-2-en-2-yl)oxy)-8-oxooctyl)(2-hydroxyethyl)amino)propyl)azadiyl)dioctanoic acid
[0314] N-(2-Hydroxyethyl)-1,3-propylenediamine (108.6 mg, 0.92 mmol) was dissolved in DMF (5 mL), and (Z)-8-bromooctanoic acid hex-2-en-1-yl ester (981.8 mg, 3.22 mmol), K2CO3 (762.8 mg, 5.52 mmol) and KI (30 mg) were added respectively, and the mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with EA (80 mL×3). The organic phase was dried and spin-dried, and the crude product was eluted by column chromatography with DCM (containing 5% EA):MeOH=50:1 to 5:1 to give 0.1 g of the product as a colorless oil in a yield of 13.74%.
[0315] ESI-MS m / z:cald for C 47 H 87 N2O7[M+H] + :791.7, found 791.7.
[0316] 1 H NMR (400MHz, CDCl3) δ5.74-5.62 (m, 3H), 5.62-5.52 (m, 3H), 4.66 (d, J=6.8Hz, 6H), 3.59 (t, J=5.2Hz, 2H), 2.60 (t, J=5.2Hz, 2H), 2.56-2 .42 (m, 9H), 2.34 (t, J=7.5Hz, 6H), 2.17-2.07 (m, 6H), 1.71-1.58 (m, 8H), 1.54-1.37 (m, 13H), 1.37-1.24 (m, 19H), 0.94 (t, J=7.4Hz, 9H).
[0317] Example 18
[0318] Heneicosyl 8,8′-((3-((3-hydroxypropyl)(8-carbonyl-8-(undecanyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0319] Step 1: Synthesis of 8-bromooctanoate
[0320] 8-Bromooctanoic acid (9 g, 40.34 mmol) and undecanol (5 g, 29 mmol) were stirred at 60°C for 0.5 hour, then dissolved. 3 drops of concentrated sulfuric acid were added. The mixture was reacted at 60°C for 6 hours. TLC indicated complete consumption of the starting material. The sample was directly mixed and column chromatography was performed using PE:EA = 15:1 as the eluent to afford 8.2 g of the product as a colorless oil, yield: 74.9%.
[0321] Step 2: Synthesis of Heneicosyl 8,8′-((3-((8-carbonyl-8-(undecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0322] Propane-1,3-diamine (80 mg, 1.08 mmol) was dissolved in DMF (5 mL), and 8-bromooctanoic acid undecyl ester (1.22 g, 3.24 mmol), K2CO3 (895.54 mg, 6.48 mmol), and KI (30 mg) were added, respectively. The mixture was stirred at 60°C for 6 hours. An appropriate amount of water was added, and EA (80 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 0.32 g of the product as a colorless oil, with a yield of 30.75%.
[0323] Step 3: Synthesis of Heneicosyl 8,8′-((3-((3-hydroxypropyl)(8-carbonyl-8-(undecanyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0324] Heneicosyl 8,8′-((3-((8-carbonyl-8-(undecyloxy)octyl)amino)propyl)azanediyl) dioctanoate (320 mg, 0.332 mmol) was dissolved in DMF (5 mL). 3-Chloro-1-propanol (62.77 mg, 0.664 mmol), KCO (138.2 mg, 1 mmol), and KI (30 mg) were added, respectively, and the mixture was stirred at 90°C for 16 hours. EA (80 mL*3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 to afford 0.13 g of the product as a colorless oil (yield: 38.33%).
[0325] ESI-MS m / z:cald for C 63 H 125 N2O7[M+H] + :1021.9, found 1021.9.
[0326] 1H NMR (400MHz, CDCl3) δ4.09 (t, J=6.8Hz, 6H), 3.81 (t, J=5.2Hz, 2H), 3.02-2.94 (m, 2H), 2.93-2.81 (m, 5H), 2.79-2.58 (m, 4H), 2.33 (t, J=7.5Hz, 6 H), 2.13-2.01(m, 2H), 1.85-1.77(m, 2H), 1.77-1.68(m, 4H), 1.68-1.60 (m, 12H), 1.59-1.51 (m, 2H), 1.43-1.23 (m, 68H), 0.92 (t, J=6.7Hz, 9H).
[0327] Example 19
[0328] Di((Z)-non-2-en-1-yl) 8,8′-((3-((3-hydroxypropyl)(8-(((Z)-non-2-en-1-yl)oxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate
[0329] Step 1: Synthesis of (Z)-non-2-en-1-yl 8-bromooctanoate
[0330] 8-Bromooctanoic acid (5 g, 22.41 mmol) and (Z)-non-2-en-1-ol (3.188 g, 22.41 mmol) were stirred at 60°C for 0.5 hour, then dissolved. Three drops of concentrated sulfuric acid were added and the mixture was allowed to react at 60°C for 6 hours. TLC indicated complete consumption of the starting material. The sample was directly stirred and column chromatography eluted with PE:EA = 15:1 to afford 6 g of the product as a colorless oil, yield: 77%.
[0331] Step 2: Synthesis of di((Z)-non-2-en-1-yl)8,8′-((3-((8-(((Z)-non-2-en-1-yl)oxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate
[0332] Propane-1,3-diamine (128 mg, 1.73 mmol) was dissolved in DMF (5 mL), and (Z)-non-2-en-1-yl 8-bromooctanoate (1.8 g, 5.18 mmol), K2CO3 (956.34 mg, 6.92 mmol), and KI (30 mg) were added, respectively. The mixture was stirred at 60°C for 6 hours. An appropriate amount of water was added, and EA (80 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 0.67 g of the product as a colorless oil, with a yield of 44.34%.
[0333] Step 3: Synthesis of di((Z)-non-2-en-1-yl)8,8′-((3-((3-hydroxypropyl)(8-(((Z)-non-2-en-1-yl)oxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate
[0334] Di((Z)-non-2-en-1-yl) 8,8′-((3-((8-(((Z)-non-2-en-1-yl)oxy)-8-carbonyloctyl)amino)propyl)azanediyl) dioctanoate (420 mg, 0.48 mmol) was dissolved in DMF (5 mL), and 3-chloro-1-propanol (90.76 mg, 0.96 mmol), K2CO3 (276.4 mg, 2 mmol), and KI (30 mg) were added, respectively. The mixture was stirred at 90°C for 16 hours. EA (80 mL*3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 0.1 g of the product as a colorless oil, in a yield of 22.36%.
[0335] ESI-MS m / z:cald for C 57 H 107 N2O7[M+H] + :931.6,found 931.6.
[0336] 1 H NMR (400MHz, CDCl3) δ5.75-5.64 (m, 3H), 5.61-5.48 (m, 3H), 4.66 (dd, J=6.8, 1.3Hz, 6H), 3.81 (t, J=5.2Hz, 2H), 3.07-2.71 (m, 9H), 2.68-2.48 (m, 5H), 2.34 (t, J=7.5Hz, 6H), 2.19-2.10 (m, 6H), 2.05-1.91 (m, 2H), 1.84- 1.60(m, 12H), 1.58-1.48(m, 2H), 1.48-1.27(m, 42H), 0.96-0.88(m, 9H).
[0337] Example 20
[0338] Heneicosyl 8,8′-((3-((4-hydroxybutyl)(8-carbonyl-8-(undecanyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0339] Step 1: Synthesis of Heneicosyl 8,8′-((3-((4-hydroxybutyl)(8-carbonyl-8-(undecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0340] Di((Z)-non-2-en-1-yl) 8,8′-((3-((8-(((Z)-non-2-en-1-yl)oxy)-8-carbonyloctyl)amino)propyl)azanediyl) dioctanoate (660 mg, 0.685 mmol) was dissolved in DMF (5 mL), and 4-chloro-1-butanol (148.74 mg, 1.37 mmol), K2CO3 (207.3 mg, 1.5 mmol), and KI (30 mg) were added, respectively. The mixture was stirred at 90°C for 16 hours. EA (80 mL*3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 0.07 g of the product as a colorless oil, in a yield of 9.87%.
[0341] ESI-MS m / z:cald for C 64 H 127 N2O7[M+H] + :1036.0, found 1036.0.
[0342] 1 H NMR (400MHz, CDCl3) δ4.08 (t, J=6.8Hz, 6H), 3.65 (t, J=5.3Hz, 2H), 3.52-3.46 (m, 1H), 3.01-2.62 (m, 13H) , 2.32 (t, J=7.5Hz, 6H), 2.2-2.05 (m, 2H), 1.82-1.54 (m, 21H), 1.44-1.18 (m, 66H), 0.91 (t, J=6.7Hz, 9H).
[0343] Example 21
[0344] Tetrakis((Z)-non-2-en-1-yl) 8,8′,8″,8″′-(propane-1,3-diylbis(azanetriyl))tetraoctanoate
[0345] Step 1: Synthesis of Tetrakis((Z)-non-2-en-1-yl) 8,8′,8″,8″′-(propane-1,3-diyldi(azanetriyl))tetraoctanoate
[0346] Propane-1,3-diamine (154 mg, 2.077 mmol) was dissolved in DMF (5 mL), and (Z)-non-2-en-1-yl 8-bromooctanoate (2.17 g, 6.25 mmol), K2CO3 (1 g, 7.25 mmol), and KI (30 mg) were added, respectively. The mixture was stirred at 60°C for 6 hours. An appropriate amount of water was added, and EA (80 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 0.6 g of the product as a colorless oil, with a yield of 25.34%.
[0347] ESI-MS m / z:cald for C 71 H 131 N2O8[M+H] + :1140.0, found 1140.0.
[0348] 1 H NMR (400MHz, CDCl3) δ5.80-5.62(m, 4H), 5.61-5.49(m, 4H), 4.66(dd, J=6.8, 1.3Hz, 8H), 2.72-2.40(m, 10H), 2.34( t, J=7.5Hz, 8H), 2.21-2.03 (m, 8H), 1.70-1.59 (m, 10H), 1.59-1.45 (m, 7H), 1.44-1.24 (m, 59H), 0.96-0.81 (m, 12H).
[0349] Example 22
[0350] Pentacosyl 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(pentadecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0351] Step 1: Synthesis of Pentadecyl 8-bromooctanoate
[0352] 1-Pentadecanol (1.0 g, 4.4 mmol) and 8-bromooctanoic acid (1.2 g, 5.3 mmol) were mixed, the temperature was raised to 60°C, concentrated sulfuric acid (0.1 mL) was added, and the mixture was stirred at this temperature for 5 hours. TLC showed that the starting material was completely consumed. The sample was directly mixed and eluted by column chromatography with PE:EA=10:1 to obtain 1.8 g of colorless oily product, with a yield of 94.7%.
[0353] 1H-NMR (400MHz, CDCl3) δ4.05 (t, J=6.7Hz, 2H), 3.40 (t, J=6.8Hz, 2H), 2.29 (t, J=7.5Hz, 2H), 1.90- 1.79 (m, 2H), 1.66-1.58 (m, 4H), 1.43 (t, J=6.8Hz, 2H), 1.36-1.24 (m, 28H), 0.88 (t, J=6.8Hz, 3H).
[0354] Step 2: Synthesis of Pentacosyl 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(pentadecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0355] 2-((3-Aminopropyl)amino)ethan-1-ol (60 mg, 0.5 mmol) was dissolved in acetonitrile (8 mL), and pentadecyl 8-bromooctanoate (0.9 g, 2.0 mmol), K2CO3 (0.4 g, 2.6 mmol), and KI (10 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with DCM (30 mL x 3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 30:1 as the eluent to give 120 mg of the product as a colorless oil, with a yield of 20.0%.
[0356] ESI-MS m / z:cald for C 74 H 147 N2O7[M+H] + :1176.0, found 1176.0.
[0357] 1 H-NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 3.54 (t, J=5.2Hz, 2H), 2.57-2.33 (m, 11H), 2.28 (t , J=7.5Hz, 6H), 1.66-1.58 (m, 12H), 1.46-1.38 (m, 6H), 1.33-1.23 (m, 94H), 0.88 (t, J=6.8Hz, 9H).
[0358] Example 23
[0359] Heneicosyl 12,12′-((3-((2-hydroxyethyl)(12-carbonyl-12-(undecanyloxy)dodecyl)amino)propyl)azanediyl)behenate
[0360] Step 1: Synthesis of Undecyl 12-Bromododecanoate
[0361] Undecanol (1.0 g, 5.8 mmol) and 12-bromododecanoic acid (1.9 g, 7.0 mmol) were mixed, the temperature was raised to 60°C, concentrated sulfuric acid (0.1 mL) was added, and the mixture was stirred at this temperature for 5 hours. TLC showed that the starting material was completely consumed. The sample was directly mixed and eluted by column chromatography with PE:EA = 30:1 to obtain 2.2 g of colorless oily product, with a yield of 88.0%.
[0362] 1 H-NMR (400MHz, CDCl3) δ4.05 (t, J=6.7Hz, 2H), 3.40 (t, J=6.9Hz, 2H), 2.29 (t, J=7.5Hz, 2H), 1.9 0-1.79 (m, 2H), 1.66-1.57 (m, 4H), 1.46-1.38 (m, 2H), 1.34-1.24 (m, 28H), 0.88 (t, J=6.8Hz, 3H).
[0363] Step 2: Synthesis of heneicosyl 12,12′-((3-((2-hydroxyethyl)(12-carbonyl-12-(undecanyloxy)dodecyl)amino)propyl)azanediyl)behenate
[0364] 2-((3-Aminopropyl)amino)ethan-1-ol (60 mg, 0.5 mmol) was dissolved in acetonitrile (10 mL), and undecyl 12-bromododecanoate (0.9 g, 2.0 mmol), K2CO3 (0.4 g, 2.6 mmol), and KI (10 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with DCM (30 mL x 3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 25:1 as the eluent to afford 220 mg of the product as a colorless oil, yield: 36.7%.
[0365] ESI-MS m / z:cald for C 74 H 147 N2O7[M+H] + :1176.0, found 1176.0.
[0366] 1H-NMR (400MHz, CDCl3) δ4.05 (t, J=6.7Hz, 6H), 3.54 (t, J=5.2Hz, 2H), 2.59-2.34 (m, 12H), 2.28 (t, J= 7.5Hz, 6H), 1.61 (t, J=7.2Hz, 12H), 1.45-1.39 (m, 6H), 1.27 (d, J=9.1Hz, 92H), 0.88 (t, J=6.8Hz, 9H).
[0367] Example 24
[0368] Di((9Z,12Z)-octadeca-9,12-dien-1-yl) 8,8′-((3-((2-hydroxyethyl)(8-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate
[0369] Step 1: Synthesis of (9Z, 12Z)-octadeca-9,12-dien-1-yl 8-bromooctanoate
[0370] Mix (9Z,12Z)-octadeca-9,12-dien-1-ol (1.0 g, 3.6 mmol) and 8-bromooctanoic acid (1.0 g, 4.5 mmol), heat the temperature to 60°C, add concentrated sulfuric acid (0.1 mL), and stir at this temperature for 6 hours. TLC shows that the starting material is completely consumed. The sample is directly mixed and eluted by column chromatography with PE:EA=30:1 to obtain 1.6 g of colorless oily product, with a yield of 92.1%.
[0371] 1 H-NMR (400MHz, CDCl3) δ5.43-5.27 (m, 4H), 4.05 (t, J=6.7Hz, 2H), 3.40 (t, J=6.8Hz, 2H), 2.77 (t, J=6.4Hz, 2H), 2.29 (t, J=7.5H z, 2H), 2.09-1.99 (m, 4H), 1.90-1.79 (m, 2H), 1.67-1.58 (m, 4H), 1.48-1.39 (m, 2H), 1.37-1.26 (m, 20H), 0.89 (t, J=6.8Hz, 3H).
[0372] Step 2: Synthesis of bis((9Z,12Z)-octadec-9,12-dien-1-yl)8,8′-((3-((2-hydroxyethyl)(8-(((9Z,12Z)-octadec-9,12-dien-1-yl)oxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate
[0373] 2-((3-Aminopropyl)amino)ethan-1-ol (60 mg, 0.5 mmol) was dissolved in acetonitrile (10 mL), and (9Z,12Z)-octadec-9,12-dien-1-yl 8-bromooctanoic acid (1.0 g, 2.0 mmol), K2CO3 (0.4 g, 2.6 mmol), and KI (10 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and DCM (30 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 30:1 as the eluent to give 220 mg of the product as a colorless oil, with a yield of 33.5%.
[0374] ESI-MS m / z:cald for C 83 H 153 N2O7[M+H] + :1290.1, found 1290.1.
[0375] 1 H-NMR (400MHz, CDCl3) δ5.43-5.27 (m, 12H), 4.05 (t, J=6.8Hz, 6H), 3.54 (t, J=5.2Hz, 2H), 2.77 (t, J=6.4Hz, 6H), 2.57-2 .34 (m, 11H), 2.28 (t, J=7.6Hz, 6H), 2.08-2.01 (m, 12H), 1.61 (t, J=7.1Hz, 12H), 1.47-1.39 (m, 6H), 1.36-1.24 (m, 70H), 0.89 (t, J=6.8Hz, 9H).
[0376] Example 25
[0377] Di((Z)-non-2-en-1-yl) 6,6′-((3-((2-hydroxyethyl)(6-(((Z)-non-2-en-1-yl)oxy)-6-carbonylhexyl)amino)propyl)azanediyl)dihexanoate
[0378] Step 1: Synthesis of (Z)-non-2-en-1-yl 6-bromohexanoate
[0379] Mix cis-2-nonen-1-ol (1.0 g, 7.0 mmol) and 6-bromohexanoic acid (1.6 g, 8.4 mmol), heat the temperature to 60°C, add concentrated sulfuric acid (0.1 mL), and stir at this temperature for 5 hours. TLC shows that the starting material is completely consumed. The sample is directly mixed and eluted by column chromatography with PE:EA=15:1 to obtain 2.1 g of colorless oily product, with a yield of 95.5%.
[0380] 1 H-NMR (400MHz, CDCl3) δ5.70-5.59 (m, 1H), 5.57-5.46 (m, 1H), 4.66-4.59 (m, 2H), 3.40 (t, J=6.8Hz, 2H), 2.33 (t, J=7.4Hz , 2H), 2.14-2.04(m, 2H), 1.93-1.81(m, 2H), 1.71-1.61(m, 2H), 1.53-1.41(m, 2H), 1.39-1.22(m, 8H), 0.92-0.84(m, 3H).
[0381] Step 2: Synthesis of di((Z)-non-2-en-1-yl) 6,6′-((3-((2-hydroxyethyl)(6-(((Z)-non-2-en-1-yl)oxy)-6-carbonylhexyl)amino)propyl)azanediyl)dihexanoate
[0382] 2-((3-Aminopropyl)amino)ethan-1-ol (60 mg, 0.5 mmol) was dissolved in acetonitrile (8 mL), and (Z)-non-2-en-1-yl 6-bromohexanoate (0.6 g, 2.0 mmol), K2CO3 (0.4 g, 2.6 mmol), and KI (10 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and DCM (30 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 30:1 as the eluent to afford 150 mg of the product as a colorless oil, yield: 35.5%.
[0383] ESI-MS m / z:cald for C 50 H 93 N2O7[M+H] + :833.3, found 833.3.
[0384] 1H-NMR (400MHz, CDCl3) δ5.69-5.58(m, 3H), 5.57-5.46(m, 3H), 4.65-4.58(m, 6H), 3.53(t, J=5.2Hz, 2H), 2.58-2.34(m, 11H), 2.31(t, J=7.5Hz, 6H), 2.15-2.04(m, 6H), 1.69-1.59(m, 7H), 1.50-1.40(m, 6H), 1.39-1.23(m, 32H), 0.92-0.84(m, 9H).
[0385] Example 26
[0386] Tricosyl 6,6′-((3-((2-hydroxyethyl)(6-carbonyl-6-(tridecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate
[0387] Step 1: Synthesis of tridecyl 6-bromohexanoate
[0388] Tridecane-1-ol and 6-bromohexanoic acid were used as raw materials, and tridecyl 6-bromohexanoate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain 16.5 g of the target molecule, with a yield of 94.8%.
[0389] 1 H NMR (400MHz, CDCl3) δ4.06 (t, J=6.8Hz, 2H), 3.40 (t, J=6.8Hz, 2H), 2.31 (t, J=7.4Hz, 2H), 1.92-1 .83 (m, 2H), 1.70-1.59 (m, 4H), 1.53-1.42 (m, 2H), 1.26 (d, J = 4.3Hz, 20H), 0.88 (t, J = 6.8Hz, 3H).
[0390] Step 2: Synthesis of tricosyl 6,6′-((3-((2-hydroxyethyl)(6-carbonyl-6-(tridecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate
[0391] Using tridecyl 6-bromohexanoate and 2-((3-aminopropyl)amino)ethan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain tricosyl 6,6′-((3-((2-hydroxyethyl)(6-carbonyl-6-(tridecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate. The crude product was purified by column chromatography to obtain 252 mg of the target molecule, in a yield of 49.0%.
[0392] ESI-MS m / z:cald for C 62 H 123 N2O7[M+H] + :1008.0, found 1008.0.
[0393] 1H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 3.53 (t, J=5.2Hz, 2H), 2.54 (t, J=5.2Hz, 2H), 2.50-2.34 (m, 10H ), 2.29 (t, J=7.5Hz, 6H), 1.67-1.56 (m, 13H), 1.47-1.39 (m, 6H), 1.34-1.24 (m, 68H), 0.87 (t, J=6.8Hz, 9H).
[0394] Example 27
[0395] Diundecyl 6,6′-((3-((3-hydroxypropyl)(6-oxo-6-(undecyloxy)hexyl)amino)propyl)nitrogendiyl)dihexanoate
[0396] Step 1: Synthesis of Undecyl 6-bromohexanoate
[0397] Undecane-1-ol and 6-bromohexanoic acid were used as raw materials, and undecyl 6-bromohexanoate was obtained by referring to the first step of Example 19. The crude product was purified by column chromatography to obtain 11.6 g of the target molecule, with a yield of 86.6%.
[0398] 1 H NMR (400MHz, CDCl3) δ4.06 (t, J=6.7Hz, 2H), 3.40 (t, J=6.8Hz, 2H), 2.31 (t, J=7.4Hz, 2H), 1.93 -1.81 (m, 2H), 1.69-1.59 (m, 4H), 1.55-1.40 (m, 2H), 1.33-1.22 (m, 16H), 0.88 (t, J=6.7Hz, 3H).
[0399] Step 2: Synthesis of 6,6′-(3-((6-oxo-6-(undecyloxy)hexyl)amino)propyl)azahexyl)diundecyl dihexanoate
[0400] Using undecyl 6-bromohexanoate and 1,3-propylenediamine as starting materials, the reaction was carried out according to the second step of Example 19 to obtain diundecyl 6,6′-(3-((6-oxo-6-(undecyloxy)hexyl)amino)propyl)azahexyl)dihexanoate. The crude product was purified by column chromatography to obtain 1.1 g of the target molecule in a yield of 26.2%.
[0401] ESI-MS m / z:cald for C 54 H 107 N2O6[M+H] +:880.0, found 880.0.
[0402] 1 H NMR (400MHz, CDCl3) δ4.04 (t, J=6.8Hz, 6H), 2.66-2.55 (m, 4H), 2.44 (t, J=7.1Hz, 2H), 2.40-2.34 (m, 4 H), 2.32-2.25(m, 6H), 1.68-1.58(m, 14H), 1.54-1.39(m, 6H), 1.35-1.23(m, 55H), 0.90-0.85(m, 9H).
[0403] Step 3: Synthesis of diundecyl 6,6′-((3-((3-hydroxypropyl)(6-oxo-6-(undecyloxy)hexyl)amino)propyl)nitrogendiyl)dihexanoate
[0404] Using diundecyl 6,6′-(3-((6-oxo-6-(undecyloxy)hexyl)amino)propyl)azahexyl)dihexanoate and 3-chloro-1-propanol as raw materials, the method was followed by reference to Step 3 of Example 19 to obtain diundecyl 6,6′-((3-((3-hydroxypropyl)(6-oxo-6-(undecyloxy)hexyl)amino)propyl)azahexyl)dihexanoate. The crude product was purified by column chromatography to obtain 320 mg of the target molecule in a yield of 27.4%.
[0405] ESI-MS m / z:cald for C 57 H 113 N2O7[M+H] + :938.0, found 938.0.
[0406] 1 H NMR (400MHz, CDCl3) δ4.04 (t, J=6.8Hz, 6H), 3.77 (t, J=5.1Hz, 2H), 2.62 (t, J=5.6Hz, 2H), 2.52-2.34 (m, 10H), 2.32-2.25(m, 6H), 1.66-1.57(m, 13H), 1.52-1.39(m, 6H), 1.36-1.20(m, 58H), 1.00-0.78(m, 9H).
[0407] Example 28
[0408] Diundecyl 6,6′-((3-((4-hydroxybutyl)(6-oxo-6-(undecyloxy)hexyl)amino)propyl)nitrogendiyl)dihexanoate
[0409] Step 1: Synthesis of diundecyl 6,6′-((3-((4-hydroxybutyl)(6-oxo-6-(undecyloxy)hexyl)amino)propyl)nitrogendiyl)dihexanoate
[0410] Using diundecyl 6,6′-(3-((6-oxo-6-(undecyloxy)hexyl)amino)propyl)azahexyl)dihexanoate and 4-chloro-1-butanol as starting materials, the reaction was carried out according to the third step of Example 19 to obtain diundecyl 6,6′-((3-((4-hydroxybutyl)(6-oxo-6-(undecyloxy)hexyl)amino)propyl)azahexyl)dihexanoate. The crude product was purified by column chromatography to obtain 104 mg of the target molecule in a yield of 12.4%.
[0411] ESI-MS m / z:cald for C 58 H 115 N2O7[M+H] + :952.0, found 952.0.
[0412] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 3.54 (t, J=4.6Hz, 2H), 2.48-2.34 (m, 11H), 2.33-2 .25(m, 6H), 1.66-1.55(m, 17H), 1.51-1.39(m, 6H), 1.35-1.24(m, 57H), 0.88(t, J=6.7Hz, 9H).
[0413] Example 29
[0414] 8,8′-((3-((3-hydroxypropyl)(8-oxo-8-(tridecyloxy)octyl)amino)propyl)azetidinyl) distearate
[0415] Step 1: Synthesis of tridecyl 8-bromooctanoate
[0416] Using tridecane-1-ol and 8-bromooctanoic acid as raw materials, the method of step 1 of Example 19 was followed to obtain tridecyl 8-bromohexanoate. The crude product was purified by column chromatography to obtain 7.2 g of the target molecule in a yield of 79.23%.
[0417] Step 2: Synthesis of 8,8′-((3-((8-oxo-8-(tridecyloxy)octyl)amino)propyl)azepine hexyl)distearate
[0418] Using tridecyl 8-bromooctanoate and 1,3-propylenediamine as starting materials, the same procedure as in Example 19, Step 2, was followed to obtain 8,8′-((3-((8-oxo-8-(tridecyloxy)octyl)amino)propyl)azahexyl)distearate. The crude product was purified by column chromatography to obtain 1.2 g of the target molecule in a yield of 46.65%.
[0419] ESI-MS m / z:cald for C 66 H 131 N2O6[M+H] + :1048.0, found 1048.0.
[0420] Step 3: Synthesis of 8,8′-((3-((3-hydroxypropyl)(8-oxo-8-(tridecyloxy)octyl)amino)propyl)azepinehexyl)distearate
[0421] Using 8,8′-((3-((8-oxo-8-(tridecyloxy)octyl)amino)propyl)azetyl)distearate and 3-chloro-1-propanol as raw materials, the reaction was carried out according to the third step of Example 19 to obtain 8,8′-((3-((3-hydroxypropyl)(8-oxo-8-(tridecyloxy)octyl)amino)propyl)azetyl)distearate. The crude product was purified by column chromatography to obtain 0.15 g of the target molecule in a yield of 23.67%.
[0422] ESI-MS m / z:cald for C 69 H 137 N2O7[M+H] + :1106.0, found 1106.0.
[0423] 1 H NMR (400MHz, CDCl3) δ4.04 (t, J=6.8Hz, 6H), 3.72-3.81 (m, 2H), 2.97-2.68 (m, 8H), 2.67-2.47 (m, 5H), 2.28 (t, J=7.5Hz, 6H), 2.07-1.90 (m, 2H), 1.84-1.71 (m, 2 H), 1.70-1.55 (m, 16H), 1.53-1.43 (m, 2H), 1.46-1.09 (m, 78H), 0.87 (t, J=6.9Hz, 9H).
[0424] Example 30
[0425] 6,6′-((3-((3-hydroxypropyl)(6-oxo-6-(tridecyloxy)hexyl)amino)propyl)azadiyl)dihexanoic acid ditridecyl
[0426] Step 1: Synthesis of tridecyl 6-bromohexanoate
[0427] Tridecane-1-ol and 6-bromohexanoic acid were used as raw materials, and tridecyl 6-bromohexanoate was obtained by referring to the first step of Example 19. The crude product was purified by column chromatography to obtain 7 g of the target molecule in a yield of 72.37%.
[0428] Step 2: Synthesis of 6,6′-((3-((6-oxo-6-(tridecyloxy)hexyl)amino)propyl)azahexyl)dihexanoic acid ditridecyl
[0429] Using tridecyl 6-bromohexanoate and 1,3-propylenediamine as starting materials, the same procedure as in Step 2 of Example 19 was followed to obtain ditridecyl 6,6′-((3-((6-oxo-6-(tridecyloxy)hexyl)amino)propyl)azahexyl)dihexanoate. The crude product was purified by column chromatography to obtain 1.5 g of the target molecule in a yield of 35.38%.
[0430] ESI-MS m / z:cald for C 60 H 119 N2O6[M+H] + :964.0, found 964.0.
[0431] Step 3: Synthesis of 6,6′-((3-((3-hydroxypropyl)(6-oxo-6-(tridecyloxy)hexyl)amino)propyl)azadiyl)dihexanoic acid ditridecyl
[0432] Using ditridecyl-6,6′-((3-((6-oxo-6-(tridecyloxy)hexyl)amino)propyl)azahexyl)dihexanoate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 19 to obtain ditridecyl-6,6′-((3-((3-hydroxypropyl)(6-oxo-6-(tridecyloxy)hexyl)amino)propyl)azadiyl)dihexanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0433] ESI-MS m / z:cald for C 63 H 125 N2O7[M+H] + :1022.0, found 1022.0.
[0434] 1H NMR (400MHz, CDCl3) δ4.04 (t, J=6.8Hz, 6H), 3.76 (t, J=5.3Hz, 2H), 2.94-2.76 (m, 8H), 2.75-2.55 (m, 5H), 2.36-2 .24(m, 6H), 2.09-1.95(m, 2H), 1.88-1.74(m, 2H), 1.74-1.51(m, 18H), 1.44-1.12(m, 66H), 0.87(t, J=6.7Hz, 9H).
[0435] Example 31
[0436] 6,6′-((3-((4-hydroxybutyl)(6-oxo-6-(tridecyloxy)hexyl)amino)propyl)azadiyl)dihexanoic acid ditridecyl
[0437] Step 1: Synthesis of 6,6′-((3-((4-hydroxybutyl)(6-oxo-6-(tridecyloxy)hexyl)amino)propyl)azadiyl)dihexanoic acid ditridecyl
[0438] Using ditridecyl 6,6′-((3-((6-oxo-6-(tridecyloxy)hexyl)amino)propyl)azahexyl)dihexanoate and 4-chloro-1-butanol as raw materials, the method was followed by reference to Step 3 of Example 19 to obtain ditridecyl 6,6′-((3-((4-hydroxybutyl)(6-oxo-6-(tridecyloxy)hexyl)amino)propyl)azadiyl)dihexanoate. The crude product was purified by column chromatography to obtain 0.09 g of the target molecule in a yield of 9.3%.
[0439] ESI-MS m / z:cald for C 64 H 127 N2O7[M+H] + :1036.0, found 1036.0.
[0440] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 3.64 (t, J=5.4Hz, 2H), 3.02-2.59 (m, 12H), 2.3 1(m, 6H), 2.15-1.96(m, 2H), 1.86-1.50(m, 22H), 1.45-1.16(m, 66H), 0.88(t, J=6.8Hz, 9H).
[0441] Example 32
[0442] 7,7′-(3-((2-hydroxyethyl)(7-oxo-7-(undecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate
[0443] Step 1: Synthesis of Undecyl 7-bromoheptanoate
[0444] Undecane-1-ol and 7-bromoheptanoic acid were used as raw materials, and undecyl 7-bromoheptanoate was obtained by referring to the first step of Example 19. The crude product was purified by column chromatography to obtain the target molecule.
[0445] Step 2: Synthesis of 7,7′-(3-((2-hydroxyethyl)(7-oxo-7-(undecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate
[0446] Using undecyl 7-bromoheptanoate and 2-((3-aminopropyl)amino)ethan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain 7,7′-(3-((2-hydroxyethyl)(7-oxo-7-(undecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0447] ESI-MS m / z:cald for C 59 H 117 N2O7[M+H] + :966.0, found 966.0.
[0448] Example 33
[0449] 7,7′-(3-((2-hydroxyethyl)(7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate
[0450] Step 1: Synthesis of tridecyl 7-bromoheptanoate
[0451] Using tridecane-1-ol and 7-bromoheptanoic acid as raw materials, the first step of Example 19 was followed to obtain tridecyl 7-bromoheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0452] Second step: 7,7′-(3-((2-hydroxyethyl)(7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate
[0453] Using tridecyl 7-bromoheptanoate and 2-((3-aminopropyl)amino)ethan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain 7,7′-(3-((2-hydroxyethyl)(7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0454] ESI-MS m / z:cald for C 65 H 129 N2O7[M+H] + :1050.0, found 1050.0.
[0455] Example 34
[0456] 7,7′-(3-((3-hydroxypropyl)(7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate
[0457] Step 1: Synthesis of 7,7′-((3-((7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azahexyl)diheptanoate
[0458] Using tridecyl 7-bromoheptanoate and 1,3-propylenediamine as starting materials, the synthesis of 7,7′-((3-((7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azahexyl)diheptanoate was achieved by referring to the second step of Example 19. The crude product was purified by column chromatography to obtain the target molecule.
[0459] ESI-MS m / z:cald for C 63 H 125 N2O6[M+H] + :1006.0, found 1006.0.
[0460] Step 2: Synthesis of 7,7′-(3-((3-hydroxypropyl)(7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate
[0461] Using 7,7′-((3-((7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azepinehexyl)diheptanoate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 19 to obtain 7,7′-(3-((3-hydroxypropyl)(7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0462] ESI-MS m / z:cald for C66 H 131 N2O7[M+H] + :1064.0, found 1064.0.
[0463] Example 35
[0464] 7,7′-(3-((4-hydroxybutyl)(7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate
[0465] Step 1: Synthesis of 7,7′-(3-((4-hydroxybutyl)(7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate
[0466] Using 7,7′-((3-((7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azepinehexyl)diheptanoate and 4-chloro-1-butanol as starting materials, the reaction was carried out by referring to the third step of Example 19 to obtain 7,7′-(3-((4-hydroxybutyl)(7-oxo-7-(tridecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0467] ESI-MS m / z:cald for C 67 H 133 N2O7[M+H] + :1078.0, found 1078.0.
[0468] Example 36
[0469] 7,7′-(3-((3-hydroxypropyl)(7-oxo-7-(undecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate
[0470] Step 1: Synthesis of 7,7′-(3-((7-oxo-7-(undecyloxy)heptyl)amino)propyl)azahexyl)diheptanoate
[0471] Using undecyl 7-bromoheptanoate and 1,3-propylenediamine as starting materials, the reaction was carried out in accordance with the second step of Example 3 to obtain 7,7′-(3-((7-oxo-7-(undecyloxy)heptyl)amino)propyl)azahexyl)diheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0472] ESI-MS m / z:cald for C 57 H 113 N2O6[M+H] +:922.0, found 922..0
[0473] Step 2: Synthesis of 7,7′-(3-((3-hydroxypropyl)(7-oxo-7-(undecyloxy)heptyl)amino)propyl)azadiyl)diheptanoate
[0474] Using 7,7′-(3-((7-oxo-7-(undecyloxy)heptyl)amino)propyl)azepinehexyl)diheptanoate and 3-chloro-1-propanol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain 7,7′-(3-((3-hydroxypropyl)(7-oxo-7-(undecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0475] ESI-MS m / z:cald for C 60 H 119 N2O7[M+H] + :980.0, found 980..0
[0476] Example 37
[0477] 7,7′-(3-((4-hydroxybutyl)(7-oxo-7-(undecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate
[0478] Step 1: Synthesis of 7,7′-(3-((4-hydroxybutyl)(7-oxo-7-(undecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate
[0479] Using 7,7′-(3-((7-oxo-7-(undecyloxy)heptyl)amino)propyl)azepinehexyl)diheptanoate and 4-chloro-1-butanol as starting materials, the reaction was carried out by referring to the third step of Example 19 to obtain 7,7′-(3-((4-hydroxybutyl)(7-oxo-7-(undecyloxy)heptyl)amino)propyl)azepinediyl)diheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0480] ESI-MS m / z:cald for C 61 H 121 N2O7[M+H] + :994.0, found 994..0
[0481] Example 38
[0482] 5,5′-((3-((2-hydroxyethyl)(5-oxo-5-(undecanyloxy)pentyl)amino)propyl)azepinediyl)dipentanoate
[0483] Step 1: Synthesis of Undecyl 5-bromovalerate
[0484] Undecane-1-ol and 5-bromovaleric acid were used as raw materials, and undecyl 5-bromovaleric acid was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0485] Step 2: Synthesis of 5,5′-((3-((2-hydroxyethyl)(5-oxo-5-(undecanyloxy)pentyl)amino)propyl)azepinediyl)dipentanoate
[0486] Using undecyl 5-bromovalerate and 2-((3-aminopropyl)amino)ethane-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain 5,5′-((3-((2-hydroxyethyl)(5-oxo-5-(undecanyloxy)pentyl)amino)propyl)azepinediyl)bis(pentanoate). The crude product was purified by column chromatography to obtain the target molecule.
[0487] ESI-MS m / z:cald for C 53 H 105 N2O7[M+H] + :882.0, found 882.0.
[0488] Example 39
[0489] 5,5′-((3-((2-hydroxyethyl)(5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azepinediyl)dipentanoate ditridecyl
[0490] Step 1: Synthesis of tridecyl 5-bromovalerate
[0491] Using tridecan-1-ol and 5-bromovaleric acid as raw materials, the first step of Example 3 was followed to obtain tridecyl 5-bromovalerate. The crude product was purified by column chromatography to obtain the target molecule.
[0492] Step 2: Synthesis of ditridecyl 5,5′-((3-((2-hydroxyethyl)(5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azadiyl)dipentanoate
[0493] Using tridecyl 5-bromovalerate and 2-((3-aminopropyl)amino)ethane-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain ditridecyl 5,5′-((3-((2-hydroxyethyl)(5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azepinediyl)bisvalerate. The crude product was purified by column chromatography to obtain the target molecule.
[0494] ESI-MS m / z:cald for C 59 H 117 N2O7[M+H] + :966.0, found 966.0.
[0495] Example 40
[0496] 5,5′-((3-((2-hydroxyethyl)(5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azepinediyl)dipentanoate ditridecyl
[0497] Step 1: Synthesis of ditridecyl 5,5′-((3-((5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azadiyl)bispentanoate
[0498] Using tridecyl 5-bromovalerate and 1,3-propylenediamine as starting materials, the reaction was carried out in accordance with the second step of Example 19 to obtain ditridecyl 5,5′-((3-((5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azadiyl)bisvalerate. The crude product was purified by column chromatography to obtain the target molecule.
[0499] ESI-MS m / z:cald for C 57 H 113 N2O6[M+H] + :922.0, found 922.0.
[0500] Step 2: Synthesis of ditridecyl 5,5′-((3-((2-hydroxyethyl)(5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azadiyl)dipentanoate
[0501] Using ditridecyl 5,5′-((3-((5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azepinediyl)bispentanoate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 19 to obtain ditridecyl 5,5′-((3-((2-hydroxyethyl)(5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azepinediyl)bispentanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0502] ESI-MS m / z:cald for C 60 H 119 N2O7[M+H] + :980.0, found 980.0.
[0503] Example 41
[0504] Ditridecyl 5,5′-((3-((4-hydroxybutyl)(5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azepinediyl)bis(pentanoate)
[0505] Step 1: Synthesis of ditridecyl 5,5′-((3-((4-hydroxybutyl)(5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azepinediyl)bispentanoate
[0506] Using ditridecyl 5,5′-((3-((5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azepinediyl)bispentanoate and 4-chloro-1-butanol as starting materials, the reaction was carried out by referring to the third step of Example 19 to obtain ditridecyl 5,5′-((3-((4-hydroxybutyl)(5-oxo-5-(tridecyloxy)pentyl)amino)propyl)azepinediyl)bispentanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0507] ESI-MS m / z:cald for C 61 H 121 N2O7[M+H] + :994.0, found 994.0.
[0508] Example 42
[0509] 5,5′-((3-((3-hydroxypropyl)(5-oxo-5-(undecyloxy)pentyl)amino)propyl)azepinediyl)dipentanoate
[0510] Step 1: Synthesis of 5,5′-((3-((5-oxo-5-(undecanyloxy)pentyl)amino)propyl)azahexyl)dipentanoate
[0511] Using undecyl 5-bromovalerate and 1,3-propylenediamine as starting materials, the reaction was carried out in accordance with the second step of Example 19 to obtain diundecyl 5,5′-((3-((5-oxo-5-(undedecyloxy)pentyl)amino)propyl)azahexyl)bis(pentanoate). The crude product was purified by column chromatography to obtain the target molecule.
[0512] ESI-MS m / z:cald for C 51 H 101 N2O6[M+H] + :838.0, found 838.0.
[0513] Step 2: Synthesis of 5,5′-((3-((3-hydroxypropyl)(5-oxo-5-(undecyloxy)pentyl)amino)propyl)azadiyl)bis(pentyl)valerate
[0514] Using 5,5′-((3-((5-oxo-5-(undecyloxy)pentyl)amino)propyl)azahexyl)dipentanoate and 3-chloro-1-propanol as raw materials, the reaction was carried out by referring to the third step of Example 19 to obtain 5,5′-((3-((3-hydroxypropyl)(5-oxo-5-(undecyloxy)pentyl)amino)propyl)azadiyl)dipentanoate. The crude product was purified by column chromatography to obtain 130 mg of the target molecule in a yield of 52.0%.
[0515] ESI-MS m / z:cald for C 54 H 107 N2O7[M+H] + :896.0, found 896.0.
[0516] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 3.77 (t, J=5.1Hz, 2H), 2.62 (t, J=5.6Hz, 2H), 2.47-2.36 (m, 10H), 2.3 4-2.28 (m, 6H), 1.63 (tt, J=13.8, 6.1Hz, 18H), 1.54-1.39 (m, 7H), 1.28 (d, J=17.4Hz, 46H), 0.88 (t, J=6.7Hz, 9H).
[0517] Example 43
[0518] 5,5′-((3-((4-hydroxybutyl)(5-oxo-5-(undecanyloxy)pentyl)amino)propyl)azahexyl)diundecyl valerate
[0519] Step 1: Synthesis of 5,5′-((3-((4-hydroxybutyl)(5-oxo-5-(undecanyloxy)pentyl)amino)propyl)azahexyl)dipentanoate
[0520] Using 5,5′-((3-((5-oxo-5-(undecanyloxy)pentyl)amino)propyl)azahexyl)diundecyl)pentanoate and 4-chloro-1-butanol as raw materials, the reaction was carried out by referring to the third step of Example 19 to obtain 5,5′-((3-((4-hydroxybutyl)(5-oxo-5-(undecanyloxy)pentyl)amino)propyl)azahexyl)diundecyl)pentanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0521] ESI-MS m / z:cald for C 55 H 109 N2O7[M+H] + :910.0, found 910.0.
[0522] Example 44
[0523] Behenyl 6,6′-((3-((6-(dodecyloxy)-6-oxohexyl)(2-hydroxyethyl)amino)propyl)azahexyl)dihexanoate
[0524] Step 1: Synthesis of dodecyl 6-bromohexanoate
[0525] Using dodecan-1-ol and 6-bromohexanoic acid as raw materials, the first step of Example 19 was followed to obtain dodecyl 6-bromohexanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0526] Step 2: Synthesis of docosyl 6,6′-((3-((6-(dodecyloxy)-6-oxohexyl)(2-hydroxyethyl)amino)propyl)azahexyl)dihexanoate
[0527] Using dodecyl 6-bromohexanoate and 2-((3-aminopropyl)amino)ethan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain docosyl 6,6′-((3-((6-(dodecyloxy)-6-oxohexyl)(2-hydroxyethyl)amino)propyl)azahexyl)dihexanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0528] ESI-MS m / z:cald for C 59 H 117 N2O7[M+H] + :966.0, found 966.0.
[0529] Example 45
[0530] Behenyl 6,6′-((3-((6-(dodecyloxy)-6-oxohexyl)(3-hydroxypropyl)amino)propyl)azahexyl)dihexanoate
[0531] Step 1: Synthesis of docosyl 6,6′-((3-((6-(dodecyloxy)-6-oxohexyl)amino)propyl)azahexyl)dihexanoate
[0532] Using dodecyl 6-bromohexanoate and 1,3-propylenediamine as starting materials, the same procedure as in Example 19, Step 2, was followed to obtain docosyl 6,6′-((3-((6-(dodecyloxy)-6-oxohexyl)amino)propyl)azahexyl)dihexanoate. The crude product was purified by column chromatography to yield the target molecule.
[0533] ESI-MS m / z:cald for C 57 H 113 N2O6[M+H] + :922.0, found 922.0.
[0534] Step 3: Synthesis of 5,5′-((3-((4-hydroxybutyl)(5-oxo-5-(undecanyloxy)pentyl)amino)propyl)azahexyl)dipentanoate
[0535] Using docosyl 6,6′-((3-((6-(dodecyloxy)-6-oxohexyl)amino)propyl)azahexyl)dihexanoate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 19 to obtain 5,5′-((3-((4-hydroxybutyl)(5-oxo-5-(undecyloxy)pentyl)amino)propyl)azahexyl)dipentanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0536] ESI-MS m / z:cald for C 60 H 119 N2O7[M+H] + :980.0, found 980.0.
[0537] Example 46
[0538] Dodecyl 6,6′-((3-((6-(dodecyloxy)-6-carbonylhexyl)(4-hydroxybutyl)amino)propyl)azanediyl)dihexanoate
[0539] Step 1: Synthesis of dodecyl 6-bromohexanoate
[0540] Using dodecan-1-ol and 6-bromohexanoic acid as raw materials, the first step of Example 3 was followed to obtain dodecyl 6-bromohexanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0541] Step 2: Synthesis of docosyl 6,6′-((3-((6-(dodecyloxy)-6-carbonylhexyl)amino)propyl)azanediyl)dihexanoate
[0542] Using dodecyl 6-bromohexanoate and 1,3-propylenediamine as starting materials, the same procedure as in Example 18, Step 2, was followed to obtain docosyl 6,6′-((3-((6-(dodecyloxy)-6-carbonylhexyl)amino)propyl)azanediyl)dihexanoate. The crude product was purified by column chromatography to yield the target molecule.
[0543] ESI-MS m / z:cald for C 57 H 113 N2O6[M+H] + :922.5, found 922.5.
[0544] Step 3: Synthesis of docosyl 6,6′-((3-((6-(dodecyloxy)-6-carbonylhexyl)(4-hydroxybutyl)amino)propyl)azanediyl)dihexanoate
[0545] Using docosyl 6,6′-((3-((6-(dodecyloxy)-6-carbonylhexyl)amino)propyl)azanediyl)dihexanoate and 4-chloro-1-butanol as raw materials, the method was followed by reference to Step 3 of Example 18 to obtain docosyl 6,6′-((3-((6-(dodecyloxy)-6-carbonylhexyl)(4-hydroxybutyl)amino)propyl)azanediyl)dihexanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0546] ESI-MS m / z:cald for C 61 H 121 N2O7[M+H] + :922.5, found 922.5.
[0547] Example 47
[0548] Docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)(2-hydroxyethyl)amino)propyl)azanediyl)diheptanoate
[0549] Step 1: Synthesis of dodecyl 7-bromoheptanoate
[0550] Using dodecan-1-ol and 7-bromoheptanoic acid as raw materials, dodecyl 7-bromoheptanoate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0551] Step 2: Synthesis of docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)(2-hydroxyethyl)amino)propyl)azanediyl)diheptanoate
[0552] Using dodecyl 7-bromoheptanoate as the starting material, the same procedure as in Step 2 of Example 3 was followed to obtain docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)(2-hydroxyethyl)amino)propyl)azanediyl)diheptanoate. The crude product was purified by column chromatography to yield the target molecule.
[0553] ESI-MS m / z:cald for C 62 H 123 N2O7[M+H] + :1008.7, found 1008.7.
[0554] Example 48
[0555] Docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)(3-hydroxypropyl)amino)propyl)azanediyl)diheptanoate
[0556] Step 1: Synthesis of docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)amino)propyl)azanediyl) diheptanoate
[0557] Using dodecyl 7-bromoheptanoate and 1,3-propylenediamine as starting materials, the same procedure as in Step 2 of Example 18 was followed to obtain docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)amino)propyl)azanediyl)diheptanoate. The crude product was purified by column chromatography to yield the target molecule.
[0558] ESI-MS m / z:cald for C 60 H 119 N2O6[M+H] + :964.6,found 964.6.
[0559] Step 2: Synthesis of docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)(3-hydroxypropyl)amino)propyl)azanediyl)diheptanoate
[0560] Using docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)amino)propyl)azanediyl)diheptanoate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 18 to obtain docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)(3-hydroxypropyl)amino)propyl)azanediyl)diheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0561] ESI-MS m / z:cald for C 63 H 125 N2O7[M+H] + :1022.7, found 1022.7.
[0562] Example 49
[0563] Docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)(4-hydroxybutyl)amino)propyl)azanediyl)diheptanoate
[0564] Step 1: Synthesis of docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)(4-hydroxybutyl)amino)propyl)azanediyl)diheptanoate
[0565] Using docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)amino)propyl)azanediyl)diheptanoate and 4-chloro-1-butanol as starting materials, the reaction was carried out by referring to the third step of Example 18 to obtain docosyl 7,7′-((3-((7-(dodecyloxy)-7-carbonylheptyl)(4-hydroxybutyl)amino)propyl)azanediyl)diheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0566] ESI-MS m / z:cald for C 64 H 127 N2O7[M+H] + :1036.7, found 1036.7.
[0567] Example 50
[0568] Docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl)dioctanoate
[0569] Step 1: Synthesis of dodecyl 8-bromooctanoate
[0570] Using dodecan-1-ol and 8-bromooctanoic acid as raw materials, the method of step 1 of Example 3 was followed to obtain dodecyl 8-bromooctanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0571] Step 2: Synthesis of docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl)dioctanoate
[0572] Using dodecyl 8-bromooctanoate as the starting material, the same procedure as in Step 2 of Example 3 was followed to obtain docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)(2-hydroxyethyl)amino)propyl)azanediyl)dioctanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0573] ESI-MS m / z:cald for C 65 H 129 N2O7[M+H] + :1050.7, found 1050.7.
[0574] Example 51
[0575] Docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)(3-hydroxypropyl)amino)propyl)azanediyl)dioctanoate
[0576] Step 1: Synthesis of docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate
[0577] Using dodecyl 8-bromooctanoate and 1,3-propylenediamine as starting materials, the same procedure as in Example 18, Step 2, was followed to obtain docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate. The crude product was purified by column chromatography to yield the target molecule.
[0578] ESI-MS m / z:cald for C 63 H 125 N2O6[M+H] + :1006.7, found 1006.7.
[0579] Step 2: Synthesis of docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)(3-hydroxypropyl)amino)propyl)azanediyl)dioctanoate
[0580] Using docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate and 3-chloro-1-propanol as raw materials, the method was followed by reference to Step 3 of Example 18 to obtain docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)(3-hydroxypropyl)amino)propyl)azanediyl)dioctanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0581] ESI-MS m / z:cald for C 66 H 131 N2O7[M+H] + :1064.8, found 1064.8.
[0582] Example 52
[0583] Docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)(4-hydroxybutyl)amino)propyl)azanediyl)dioctanoate
[0584] Step 1: Synthesis of docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)(4-hydroxybutyl)amino)propyl)azanediyl)dioctanoate
[0585] Using docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)amino)propyl)azanediyl)dioctanoate and 4-chloro-1-butanol as raw materials, the method was followed by reference to Step 3 of Example 18 to obtain docosyl 8,8′-((3-((8-(dodecyloxy)-8-carbonyloctyl)(4-hydroxybutyl)amino)propyl)azanediyl)dioctanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0586] ESI-MS m / z:cald for C 67 H 133 N2O7[M+H] + :1078.8, found 1078.8.
[0587] Example 53
[0588] Tetracosyl 6,6′-((3-((2-hydroxyethyl)(6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate
[0589] Step 1: Synthesis of Tetradecyl 6-bromohexanoate
[0590] Tetradecane-1-ol and 6-bromohexanoic acid were used as raw materials, and tetradecyl 6-bromohexanoate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0591] Step 2: Synthesis of Tetracosyl 6,6′-((3-((2-hydroxyethyl)(6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate
[0592] Using tetradecyl 6-bromohexanoate and 2-((3-aminopropyl)amino)ethan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain tetracosyl 6,6′-((3-((2-hydroxyethyl)(6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0593] ESI-MS m / z:cald for C 65 H 129 N2O7[M+H] + :1050.8, found 1050.8.
[0594] Example 54
[0595] 6,6′-((3-((3-hydroxypropyl)(6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate
[0596] Step 1: Synthesis of Tetracosyl 6,6′-((3-((6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate
[0597] Using tetradecyl 6-bromohexanoate and 1,3-propylenediamine as starting materials, the same procedure as in Example 18, Step 2, was followed to obtain tetracosyl 6,6′-((3-((6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate. The crude product was purified by column chromatography to yield the target molecule.
[0598] ESI-MS m / z:cald for C 63 H 125 N2O6[M+H] + :1006.7, found 1006.7.
[0599] Step 2: Synthesis of Tetracosyl 6,6′-((3-((3-hydroxypropyl)(6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate
[0600] Using tetracosyl 6,6′-((3-((6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate and 3-chloro-1-propanol as raw materials, the reaction was carried out by referring to the third step of Example 18 to obtain tetracosyl 6,6′-((3-((3-hydroxypropyl)(6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0601] ESI-MS m / z:cald for C 66 H 131 N2O7[M+H] + :1064.8, found 1064.8.
[0602] Example 55
[0603] Tetracosyl 6,6′-((3-((4-hydroxybutyl)(6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate
[0604] Step 1: Synthesis of Tetracosyl 6,6′-((3-((4-hydroxybutyl)(6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate
[0605] Using tetracosyl 6,6′-((3-((6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate and 4-chloro-1-butanol as raw materials, the reaction was carried out by referring to the third step of Example 18 to obtain tetracosyl 6,6′-((3-((4-hydroxybutyl)(6-carbonyl-6-(tetradecyloxy)hexyl)amino)propyl)azanediyl)dihexanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0606] ESI-MS m / z:cald for C 67 H 133 N2O7[M+H] + :1078.8, found 1078.8.
[0607] Example 56
[0608] Tetracosyl 7,7′-((3-((2-hydroxyethyl)(7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate
[0609] Step 1: Synthesis of Tetradecyl 7-bromoheptanoate
[0610] Tetradecane-1-ol and 7-bromoheptanoic acid were used as raw materials, and tetradecyl 7-bromoheptanoate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0611] Step 2: Synthesis of Tetracosyl 7,7′-((3-((2-hydroxyethyl)(7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate
[0612] Using tetradecyl 7-bromoheptanoate as the starting material, the same procedure as in Step 2 of Example 3 was followed to obtain tetracosyl 7,7′-((3-((2-hydroxyethyl)(7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate. The crude product was purified by column chromatography to yield the target molecule.
[0613] ESI-MS m / z:cald for C 68 H 135 N2O7[M+H] + :1092.8, found 1092.8.
[0614] Example 57
[0615] Tetracosyl 7,7′-((3-((3-hydroxypropyl)(7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate
[0616] Step 1: Synthesis of Tetracosyl 7,7′-((3-((7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl) diheptanoate
[0617] Using dodecyl 7-bromoheptanoate and 1,3-propylenediamine as starting materials, the same procedure as in Example 18, Step 2, was followed to obtain tetracosyl 7,7′-((3-((7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate. The crude product was purified by column chromatography to yield the target molecule.
[0618] ESI-MS m / z:cald for C 66 H 131 N2O6[M+H] + :1048.8, found 1048.8.
[0619] Step 2: Synthesis of Tetracosyl 7,7′-((3-((3-hydroxypropyl)(7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate
[0620] Using tetracosyl 7,7′-((3-((7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 18 to obtain tetracosyl 7,7′-((3-((3-hydroxypropyl)(7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0621] ESI-MS m / z:cald for C 69 H 137 N2O7[M+H] + :1106.9, found 1106.9.
[0622] Example 58
[0623] Tetracosyl 7,7′-((3-((4-hydroxybutyl)(7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate
[0624] Step 1: Synthesis of Tetracosyl 7,7′-((3-((4-hydroxybutyl)(7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate
[0625] Using tetracosyl 7,7′-((3-((7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate and 4-chloro-1-butanol as raw materials, the reaction was carried out by referring to the third step of Example 18 to obtain tetracosyl 7,7′-((3-((4-hydroxybutyl)(7-carbonyl-7-(tetradecyloxy)heptyl)amino)propyl)azanediyl)diheptanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0626] ESI-MS m / z:cald for C 70 H 139 N2O7[M+H] + :1120.9, found 1120.9.
[0627] Example 59
[0628] Tetracosyl 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0629] Step 1: Synthesis of Tetradecyl 8-bromooctanoate
[0630] Tetradecane-1-ol and 8-bromooctanoic acid were used as raw materials, and tetradecyl 8-bromooctanoate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0631] Step 2: Synthesis of Tetracosyl 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0632] Using tetradecyl 8-bromooctanoate as the starting material, the same procedure as in Step 2 of Example 3 was followed to obtain tetracosyl 8,8′-((3-((2-hydroxyethyl)(8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate. The crude product was purified by column chromatography to yield the target molecule.
[0633] ESI-MS m / z:cald for C 71 H 141 N2O7[M+H] + :1134.9, found 1134.9.
[0634] Example 60
[0635] Tetracosyl 8,8′-((3-((3-hydroxypropyl)(8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0636] Step 1: Synthesis of Tetracosyl 8,8′-((3-((8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0637] Using tetradecyl 8-bromooctanoate and 1,3-propylenediamine as starting materials, the same procedure as in Example 18, Step 2, was followed to obtain tetracosyl 8,8′-((3-((8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate. The crude product was purified by column chromatography to yield the target molecule.
[0638] ESI-MS m / z:cald for C 69 H 137 N2O6[M+H] + :1090.9, found 1090.9.
[0639] Step 2: Synthesis of Tetracosyl 8,8′-((3-((3-hydroxypropyl)(8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0640] Using tetracosyl 8,8′-((3-((8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate and 3-chloro-1-propanol as raw materials, the reaction was carried out by referring to the third step of Example 18 to obtain tetracosyl 8,8′-((3-((3-hydroxypropyl)(8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0641] ESI-MS m / z:cald for C 72 H 143 N2O7[M+H] + :1148.9, found 1148.9.
[0642] Example 61
[0643] Tetracosyl 8,8′-((3-((4-hydroxybutyl)(8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0644] Step 1: Synthesis of Tetracosyl 8,8′-((3-((4-hydroxybutyl)(8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate
[0645] Using tetracosyl 8,8′-((3-((8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate and 4-chloro-1-butanol as raw materials, the reaction was carried out by referring to the third step of Example 18 to obtain tetracosyl 8,8′-((3-((4-hydroxybutyl)(8-carbonyl-8-(tetradecyloxy)octyl)amino)propyl)azanediyl)dioctanoate. The crude product was purified by column chromatography to obtain the target molecule.
[0646] ESI-MS m / z:cald for C 73 H 145 N2O7[M+H] + :1163.0, found 1163.0.
[0647] Example 62
[0648] Tricosyl 4,4′-((3-((2-hydroxyethyl)(4-carbonyl-4-(tridecyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0649] Step 1: Synthesis of tridecyl 4-bromobutyrate
[0650] Tridecane-1-ol and 4-bromobutyric acid were used as raw materials, and tridecyl 4-bromobutyrate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain 8.3 g of the target molecule, with a yield of 95.4%.
[0651] 1 H NMR (400MHz, CDCl3) δ4.07 (t, J=6.8Hz, 2H), 3.47 (t, J=6.5Hz, 2H), 2.50 (t, J=7.2Hz, 2H), 2.22-2.12 (m, 2H), 1.67-1.57 (m, 2H), 1.33-1.22 (m, 20H), 0.88 (t, J=6.7Hz, 3H).
[0652] Step 2: Synthesis of tricosyl 4,4′-((3-((2-hydroxyethyl)(4-carbonyl-4-(tridecyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0653] Using tridecyl 4-bromobutyrate and 2-((3-aminopropyl)amino)ethan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain tricosyl 4,4′-((3-((2-hydroxyethyl)(4-carbonyl-4-(tridecyloxy)butyl)amino)propyl)azanediyl)dibutyrate. The crude product was purified by column chromatography to obtain 110 mg of the target molecule in a yield of 23.4%.
[0654] ESI-MS m / z:cald for C 56 H 111 N2O7[M+H] + :923.8, found 923.8.
[0655] 1 H NMR (400MHz, CDCl3) δ4.11-4.01 (m, 6H), 3.55 (t, J=5.2Hz, 2H), 2.57 (t, J=5.2Hz, 2H), 2.52-2.38 (m, 10H), 2.35-2.27(m, 6H), 1.81-1.69(m, 6H), 1.61(m, 8H), 1.32-1.23(m, 61H), 0.88(t, J=6.7Hz, 9H).
[0656] Example 63
[0657] Tricosyl 4,4′-((3-((3-hydroxypropyl)(4-carbonyl-4-(tridecyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0658] Step 1: Synthesis of tridecyl 4-bromobutyrate
[0659] Using tridecane-1-ol and 4-bromobutyric acid as raw materials, the first step of Example 3 was followed to obtain tridecyl 4-bromobutyrate. The crude product was purified by column chromatography to obtain the target molecule.
[0660] Step 2: Tricosyl 4,4′-((3-((3-hydroxypropyl)(4-carbonyl-4-(tridecyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0661] Using tridecyl 4-bromobutyrate and 3-((3-aminopropyl)amino)propan-1-ol as starting materials, the reaction was carried out in the second step of Example 3 to obtain tricosyl 4,4′-((3-((3-hydroxypropyl)(4-carbonyl-4-(tridecyloxy)butyl)amino)propyl)azanediyl)dibutyrate. The crude product was purified by column chromatography to obtain 106 mg of the target molecule in a yield of 16.6%.
[0662] ESI-MS m / z:cald for C 57 H 113 N2O7[M+H] + :937.8, found 937.8.
[0663] 1 H NMR (400MHz, CDCl3) δ4.04 (t, J=6.8Hz, 6H), 3.78 (t, J=5.2Hz, 2H), 2.67-2.60 (m, 2H), 2.50-2.36(m, 14H), 2.34-2.28(m, 8H), 1.74-1.58(m, 21H), 1.26(m, 50H), 0.88(s, 9H).
[0664] Example 64
[0665] Heneicosyl 4,4′-((3-((3-hydroxypropyl)(4-carbonyl-4-(undecanyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0666] Step 1: Synthesis of undecyl 4-bromobutyrate
[0667] Undecane-1-ol and 4-bromobutyric acid were used as raw materials, and undecyl 4-bromobutyrate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0668] Step 2: Synthesis of heneicosyl 4,4′-((3-((3-hydroxypropyl)(4-carbonyl-4-(undecanyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0669] Using undecyl 4-bromobutyrate and 3-((3-aminopropyl)amino)propan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain heneicosyl 4,4′-((3-((3-hydroxypropyl)(4-carbonyl-4-(undecanyloxy)butyl)amino)propyl)azanediyl)dibutyrate. The crude product was purified by column chromatography to obtain 93 mg of the target molecule in a yield of 13.9%.
[0670] ESI-MS m / z:cald for C 51 H 101 N2O7[M+H] + :853.7, found 853.7.
[0671] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 3.78 (t, J=5.2Hz, 2H), 2.64 (t, J=5.6Hz, 2H), 2.50-2. 36 (m, 10H), 2.31 (t, J=7.5Hz, 6H), 1.78-1.57 (m, 16H), 1.33-1.22 (m, 49H), 0.88 (t, J=6.8Hz, 9H).
[0672] Example 65
[0673] Tricosyl 4,4′-((3-((4-hydroxybutyl)(4-carbonyl-4-(tridecyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0674] Step 1: Synthesis of tridecyl 4-bromobutyrate
[0675] Using tridecane-1-ol and 4-bromobutyric acid as raw materials, the first step of Example 3 was followed to obtain tridecyl 4-bromobutyrate. The crude product was purified by column chromatography to obtain the target molecule.
[0676] Step 2: Synthesis of tricosyl 4,4′-((3-((4-hydroxybutyl)(4-carbonyl-4-(tridecyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0677] Using tridecyl 4-bromobutyrate and 4-((3-aminopropyl)amino)butan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain tricosyl 4,4′-((3-((4-hydroxybutyl)(4-carbonyl-4-(tridecyloxy)butyl)amino)propyl)azanediyl)dibutyrate. The crude product was purified by column chromatography to obtain the target molecule.
[0678] ESI-MS m / z:cald for C 58 H 115 N2O7[M+H] + :951.8,found 951.8.
[0679] Example 66
[0680] Heneicosyl 4,4′-((3-((4-hydroxybutyl)(4-carbonyl-4-(undecanyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0681] Step 1: Synthesis of undecyl 4-bromobutyrate
[0682] Undecane-1-ol and 4-bromobutyric acid were used as raw materials, and undecyl 4-bromobutyrate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0683] Step 2: Heneicosyl 4,4′-((3-((4-hydroxybutyl)(4-carbonyl-4-(undecyloxy)butyl)amino)propyl)azanediyl)dibutyrate
[0684] Using undecyl 4-bromobutyrate and 4-((3-aminopropyl)amino)butan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain heneicosyl 4,4′-((3-((4-hydroxybutyl)(4-carbonyl-4-(undecanyloxy)butyl)amino)propyl)azanediyl)dibutyrate. The crude product was purified by column chromatography to obtain the target molecule.
[0685] ESI-MS m / z:cald for C 52 H 103 N2O7[M+H] + : 868.4, found 869.4.
[0686] Example 67
[0687] Heneicosyl 3,3′-((3-((2-hydroxyethyl)(3-carbonyl-3-(undecanyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0688] Step 1: Synthesis of undecyl 3-bromopropionate
[0689] Undecane-1-ol and 3-bromopropionic acid were used as raw materials, and undecyl 3-bromopropionate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain 4 g of the target molecule in a yield of 44.89%.
[0690] Step 2: Synthesis of heneicosyl 3,3′-((3-((2-hydroxyethyl)(3-carbonyl-3-(undecanyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0691] Using undecyl 3-bromopropionate and 2-((3-aminopropyl)amino)ethan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain heneicosyl 3,3′-((3-((2-hydroxyethyl)(3-carbonyl-3-(undecanyloxy)propyl)amino)propyl)azanediyl)dipropionate. The crude product was purified by column chromatography to obtain 0.15 g of the target molecule in a yield of 14.7%.
[0692] ESI-MS m / z:cald for C 47 H 93 N2O7[M+H] + :797.7, found 797.7.
[0693] 1 H NMR (400MHz, CDCl3) δ4.06 (m, 6H), 3.56 (t, J = 5.1Hz, 2H), 2.85-2.69 (m, 6H), 2.61-2.54 ( m, 2H), 2.54-2.35 (m, 10H), 1.72-1.52 (m, 8H), 1.41-1.18 (m, 49H), 0.88 (t, J=6.8Hz, 9H).
[0694] Example 68
[0695] Heneicosyl 3,3′-((3-((3-hydroxypropyl)(3-carbonyl-3-(undecanyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0696] Step 1: Synthesis of undecyl 3-bromopropionate
[0697] Undecane-1-ol and 3-bromopropionic acid were used as raw materials, and undecyl 3-bromopropionate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0698] Step 2: Synthesis of heneicosyl 3,3′-((3-((3-hydroxypropyl)(3-carbonyl-3-(undecanyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0699] Using undecyl 3-bromopropionate and 3-((3-aminopropyl)amino)propan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain heneicosyl 3,3′-((3-((3-hydroxypropyl)(3-carbonyl-3-(undecanyloxy)propyl)amino)propyl)azanediyl)dipropionate. The crude product was purified by column chromatography to obtain the target molecule.
[0700] ESI-MS m / z:cald for C 48 H 95 N2O7[M+H] + :811.7, found 811.7.
[0701] Example 69
[0702] Heneicosyl 3,3′-((3-((4-hydroxybutyl)(3-carbonyl-3-(undecanyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0703] Step 1: Synthesis of undecyl 3-bromopropionate
[0704] Undecane-1-ol and 3-bromopropionic acid were used as raw materials, and undecyl 3-bromopropionate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0705] Step 2: Synthesis of heneicosyl 3,3′-((3-((4-hydroxybutyl)(3-carbonyl-3-(undecanyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0706] Using undecyl 3-bromopropionate and 4-((3-aminopropyl)amino)butan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain heneicosyl 3,3′-((3-((4-hydroxybutyl)(3-carbonyl-3-(undecanyloxy)propyl)amino)propyl)azanediyl)dipropionate. The crude product was purified by column chromatography to obtain the target molecule.
[0707] ESI-MS m / z:cald for C 49 H 97 N2O7[M+H] + :825.7, found 825.7.
[0708] Example 70
[0709] Tricosyl 3,3′-((3-((2-hydroxyethyl)(3-carbonyl-3-(tridecyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0710] Step 1: Synthesis of tridecyl 3-bromopropionate
[0711] Tridecyl 3-bromopropionate was obtained by using tridecane-1-ol and 3-bromopropionic acid as raw materials according to the first step of Example 3. The crude product was purified by column chromatography to obtain 1.8 g of the target molecule in a yield of 41.35%.
[0712] Step 2: Tricosyl 3,3′-((3-((2-hydroxyethyl)(3-carbonyl-3-(tridecyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0713] Using tridecyl 3-bromopropionate and 2-((3-aminopropyl)amino)ethan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain tricosyl 3,3′-((3-((2-hydroxyethyl)(3-carbonyl-3-(tridecyloxy)propyl)amino)propyl)azanediyl)dipropionate. The crude product was purified by column chromatography to obtain 0.18 g of the target molecule in a yield of 20.42%.
[0714] ESI-MS m / z:cald for C 53 H 105 N2O7[M+H] + :881.8, found 881.8.
[0715] 1 H NMR (400MHz, CDCl3) δ4.06 (m, 6H), 3.56 (t, J=5.0Hz, 2H), 2.90-2.69 (m, 6H), 2.65-2.53 ( m, 2H), 2.52-2.35 (m, 10H), 1.73-1.50 (m, 8H), 1.45-1.16 (m, 61H), 0.88 (t, J=6.8Hz, 9H).
[0716] Example 71
[0717] Tricosyl 3,3′-((3-((3-hydroxypropyl)(3-carbonyl-3-(tridecyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0718] Step 1: Synthesis of tridecyl 3-bromopropionate
[0719] Tridecane-1-ol and 3-bromopropionic acid were used as raw materials, and tridecyl 3-bromopropionate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0720] Step 2: Synthesis of tricosyl 3,3′-((3-((3-hydroxypropyl)(3-carbonyl-3-(tridecyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0721] Using tridecyl 3-bromopropionate and 3-((3-aminopropyl)amino)propan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain tricosyl 3,3′-((3-((3-hydroxypropyl)(3-carbonyl-3-(tridecyloxy)propyl)amino)propyl)azanediyl)dipropionate. The crude product was purified by column chromatography to obtain the target molecule.
[0722] ESI-MS m / z:cald for C 54 H 107 N2O7[M+H] + :895.8, found 895.8.
[0723] Example 72
[0724] Tricosyl 3,3′-((3-((4-hydroxybutyl)(3-carbonyl-3-(tridecyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0725] Step 1: Synthesis of tridecyl 3-bromopropionate
[0726] Tridecane-1-ol and 3-bromopropionic acid were used as raw materials, and tridecyl 3-bromopropionate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0727] Step 2: Synthesis of tricosyl 3,3′-((3-((4-hydroxybutyl)(3-carbonyl-3-(tridecyloxy)propyl)amino)propyl)azanediyl)dipropionate
[0728] Using tridecyl 3-bromopropionate and 4-((3-aminopropyl)amino)butan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain tricosyl 3,3′-((3-((4-hydroxybutyl)(3-carbonyl-3-(tridecyloxy)propyl)amino)propyl)azanediyl)dipropionate. The crude product was purified by column chromatography to obtain the target molecule.
[0729] ESI-MS m / z:cald for C 55 H 109 N2O7[M+H] + :909.8, found 909.8.
[0730] Example 73
[0731] Heneicosyl 2,2′-((3-((2-hydroxyethyl)(2-carbonyl-2-(undecanyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0732] Step 1: Synthesis of undecyl 2-bromoacetate
[0733] Undecane-1-ol and 3-bromoacetic acid were used as raw materials, and undecyl 2-bromoacetate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0734] Step 2: Synthesis of heneicosyl 2,2′-((3-((2-hydroxyethyl)(2-carbonyl-2-(undecanyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0735] Using undecyl 2-bromoacetate and 2-((3-aminopropyl)amino)ethan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain heneicosyl 2,2′-((3-((2-hydroxyethyl)(2-carbonyl-2-(undecanyloxy)ethyl)amino)propyl)azanediyl)diacetate. The crude product was purified by column chromatography to obtain the target molecule.
[0736] ESI-MS m / z:cald for C 44 H 87 N2O7[M+H] + :755.6, found 755.6.
[0737] Example 74
[0738] Heneicosyl 2,2′-((3-((3-hydroxypropyl)(2-carbonyl-2-(undecanyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0739] Step 1: Synthesis of undecyl 2-bromoacetate
[0740] Undecane-1-ol and 3-bromoacetic acid were used as raw materials, and undecyl 2-bromoacetate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0741] Step 2: Synthesis of heneicosyl 2,2′-((3-((2-hydroxyethyl)(2-carbonyl-2-(undecanyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0742] Using undecyl 2-bromoacetate and 3-((3-aminopropyl)amino)propan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain heneicosyl 2,2′-((3-((2-hydroxyethyl)(2-carbonyl-2-(undecanyloxy)ethyl)amino)propyl)azanediyl)diacetate. The crude product was purified by column chromatography to obtain the target molecule.
[0743] ESI-MS m / z:cald for C 45 H 89 N2O7[M+H] + :769.6, found 769.6.
[0744] Example 75
[0745] Heneicosyl 2,2′-((3-((4-hydroxybutyl)(2-carbonyl-2-(undecanyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0746] Step 1: Synthesis of undecyl 2-bromoacetate
[0747] Undecane-1-ol and 3-bromoacetic acid were used as raw materials, and undecyl 2-bromoacetate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0748] Step 2: Synthesis of heneicosyl 2,2′-((3-((4-hydroxybutyl)(2-carbonyl-2-(undecanyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0749] Using undecyl 2-bromoacetate and 4-((3-aminopropyl)amino)butan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain heneicosyl 2,2′-((3-((4-hydroxybutyl)(2-carbonyl-2-(undecanyloxy)ethyl)amino)propyl)azanediyl)diacetate. The crude product was purified by column chromatography to obtain the target molecule.
[0750] ESI-MS m / z:cald for C46 H 91 N2O7[M+H] + :783.6,found 783.6.
[0751] Example 76
[0752] Tricosyl 2,2′-((3-((2-hydroxyethyl)(2-carbonyl-2-(tridecyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0753] Step 1: Synthesis of tridecyl 2-bromoacetate
[0754] Using tridecane-1-ol and 2-bromoacetic acid as raw materials, the synthesis of tridecyl 2-bromoacetate was achieved by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0755] Step 2: Tricosyl 2,2′-((3-((2-hydroxyethyl)(2-carbonyl-2-(tridecyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0756] Using tridecyl 2-bromoacetate and 2-((3-aminopropyl)amino)ethane-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain tricosyl 2,2′-((3-((2-hydroxyethyl)(2-carbonyl-2-(tridecyloxy)ethyl)amino)propyl)azanediyl)diacetate. The crude product was purified by column chromatography to obtain the target molecule.
[0757] ESI-MS m / z:cald for C 50 H 99 N2O7[M+H] + :834.7, found 834.7.
[0758] Example 77
[0759] Tricosyl 2,2′-((3-((3-hydroxypropyl)(2-carbonyl-2-(tridecyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0760] Step 1: Synthesis of tridecyl 2-bromoacetate
[0761] Using tridecane-1-ol and 2-bromoacetic acid as raw materials, the synthesis of tridecyl 2-bromoacetate was achieved by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0762] Step 2: Synthesis of tricosyl 2,2′-((3-((3-hydroxypropyl)(2-carbonyl-2-(tridecyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0763] Using tridecyl 2-bromoacetate and 3-((3-aminopropyl)amino)propan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain tricosyl 2,2′-((3-((3-hydroxypropyl)(2-carbonyl-2-(tridecyloxy)ethyl)amino)propyl)azanediyl)diacetate. The crude product was purified by column chromatography to obtain the target molecule.
[0764] ESI-MS m / z:cald for C 51 H 101 N2O7[M+H] + :853.7, found 853.7.
[0765] Example 78
[0766] Tricosyl 2,2′-((3-((4-hydroxybutyl)(2-carbonyl-2-(tridecyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0767] Step 1: Synthesis of tridecyl 2-bromoacetate
[0768] Using tridecane-1-ol and 2-bromoacetic acid as raw materials, tridecyl 2-bromoacetate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain the target molecule.
[0769] Step 2: Synthesis of tricosyl 2,2′-((3-((4-hydroxybutyl)(2-carbonyl-2-(tridecyloxy)ethyl)amino)propyl)azanediyl)diacetate
[0770] Using tridecyl 2-bromoacetate and 4-((3-aminopropyl)amino)butan-1-ol as starting materials, the reaction was carried out according to the second step of Example 3 to obtain tricosyl 2,2′-((3-((4-hydroxybutyl)(2-carbonyl-2-(tridecyloxy)ethyl)amino)propyl)azanediyl)diacetate. The crude product was purified by column chromatography to obtain the target molecule.
[0771] ESI-MS m / z:cald for C 52 H 103 N2O7[M+H] + :867.7, found 867.7.
[0772] Example 79
[0773] Di((9Z,12Z)-octadeca-9,12-dien-1-yl)8,8′-((3-(2-hydroxyethyl)(8-((9Z,12Z)-tetradec-9,13-dien-1-yl)oxy)-8-oxooctyl)amino)propyl)azepinediyl)dioctanoic acid
[0774] Step 1: (9Z, 12Z)-octadeca-9,12-dien-1-yl 8-bromooctanoic acid
[0775] Mix (9Z,12Z)-octadeca-9,12-dien-1-ol (1.0 g, 3.6 mmol) and 8-bromooctanoic acid (1.0 g, 4.5 mmol), heat the temperature to 60°C, add concentrated sulfuric acid (0.1 mL), and stir at this temperature for 6 hours. TLC shows that the starting material is completely consumed. The sample is directly mixed and eluted by column chromatography with PE:EA=30:1 to obtain 1.6 g of colorless oily product, with a yield of 92.1%.
[0776] ESI-MS m / z:cald for C 26 H 47 BrO2[M+H] + :471.6,found 471.6.
[0777] 1H-NMR (400MHz, CDCl3) δ5.43-5.27 (m, 4H), 4.05 (t, J=6.7Hz, 2H), 3.40 (t, J=6.8Hz, 2H), 2.77 (t, J=6.4Hz, 2H), 2.29 (t, J=7.5 Hz, 2H), 2.09-1.99 (m, 4H), 1.90-1.79 (m, 2H), 1.67-1.58 (m, 4H), 1.48-1.39 (m, 2H), 1.37-1.26 (m, 20H), 0.89 (t, J=6.8Hz, 3H).
[0778] Step 2: Di((9Z,12Z)-octadec-9,12-dien-1-yl)8,8′-((3-(2-hydroxyethyl)(8-((9Z,12Z)-tetradec-9,13-dien-1-yl)oxy)-8-oxooctyl)amino)propyl)azadiyl)dioctanoic acid
[0779] N-(2-Hydroxyethyl)-1,3-propylenediamine (60 mg, 0.5 mmol) was dissolved in acetonitrile (10 mL), and (9Z,12Z)-octadec-9,12-dien-1-yl 8-bromooctanoic acid (1.0 g, 2.0 mmol), K2CO3 (0.4 g, 2.6 mmol) and KI (10 mg) were added respectively, and the mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and DCM (30 mL x 3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was eluted by column chromatography with DCM:MeOH=30:1 to give 220 mg of the product as a colorless oil, in a yield of 33.5%.
[0780] ESI-MS m / z:cald for C 83 H 152 N2O7[M+H] + :1290.1, found 1290.1.
[0781] 1 H-NMR (400MHz, CDCl3) δ5.43-5.27 (m, 12H), 4.05 (t, J=6.8Hz, 6H), 3.54 (t, J=5.2Hz, 2H), 2.77 (t, J=6.4Hz, 6H), 2.57-2.34 (m, 11H ), 2.28 (t, J=7.6Hz, 6H), 2.08-2.01 (m, 12H), 1.61 (t, J=7.1Hz, 12H), 1.47-1.39 (m, 6H), 1.36-1.24 (m, 70H), 0.89 (t, J=6.8Hz, 9H).
[0782] Example 80
[0783] Di((9Z,12Z)-octadeca-9,12-dien-1-yl) 4,4′-((3-((2-hydroxyethyl)(4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-carbonylbutyl)amino)propyl)azanediyl)dibutyrate
[0784] Step 1: Synthesis of (10Z, 13Z)-octadeca-10,13-dien-1-yl 4-bromobutyrate
[0785] Using (10Z,13Z)-octadeca-10,13-dien-1-ol and 4-bromobutyric acid as starting materials, the method of Example 3, Step 1, was followed to obtain (10Z,13Z)-octadeca-10,13-dien-1-yl 4-bromobutyrate. The crude product was purified by column chromatography to obtain 4.2 g of the target molecule in an 88.7% yield.
[0786] 1 H NMR (400MHz, CDCl3) δ5.44-5.28 (m, 4H), 4.07 (t, J=6.7Hz, 2H), 3.47 (t, J=6.5Hz, 2H), 2.77 (t, J=6.5Hz, 2H), 2.50 (t , J=7.2Hz, 2H), 2.25-2.11(m, 2H), 2.10-1.98(m, 4H), 1.67-1.58(m, 2H), 1.37-1.27(m, 16H), 0.89(t, J=6.8Hz, 3H).
[0787] Step 2: Synthesis of bis((9Z,12Z)-octadeca-9,12-dien-1-yl)4,4′-((3-((2-hydroxyethyl)(4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-carbonylbutyl)amino)propyl)azanediyl)dibutyrate
[0788] Using (10Z,13Z)-octadeca-10,13-dien-1-yl 4-bromobutyrate as the starting material, the reaction was carried out by referring to the second step of Example 3 to obtain di((9Z,12Z)-octadeca-9,12-dien-1-yl) 4,4′-((3-((2-hydroxyethyl)(4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-carbonylbutyl)amino)propyl)azanediyl)dibutyrate. The crude product was purified by column chromatography to obtain 82 mg of the target molecule in a yield of 14.3%.
[0789] ESI-MS m / z:cald for C 71 H 128 N2O7[M+H] + :1121.8, found 1121.9.
[0790] 1 H NMR (400MHz, CDCl3) δ 5.45-5.22 (m, 12H), 4.09-3.98 (m, 6H), 3.54 (t, J = 5.2Hz, 2H), 2.77 (t, J = 6.5Hz, 6H), 2.56 (t, J = 5.2Hz, 2H), 2.47 (t, J = 7.2Hz, 4H), 2.41 (t, J=7.2Hz, 6H), 2.35-2.25 (m, 6H), 2.18-1.92 (m, 12H), 1.80-1 .69(m, 6H), 1.65-1.54(m, 8H), 1.35-1.26(m, 49H), 0.89(t, J=6.7Hz, 9H).
[0791] Example 81
[0792] Di((9Z,12Z)-octadeca-9,12-dien-1-yl) 4,4′-((3-((3-hydroxypropyl)(4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-carbonylbutyl)amino)propyl)azanediyl)dibutyrate
[0793] Step 1: Synthesis of di((9Z,12Z)-octadeca-9,12-dien-1-yl)4,4′-((3-((4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-carbonylbutyl)amino)propyl)azanediyl)dibutyrate
[0794] Using (10Z,13Z)-octadeca-10,13-dien-1-yl 4-bromobutyrate and 1,3-propylenediamine as starting materials, the reaction was carried out by referring to the second step of Example 18 to obtain di((9Z,12Z)-octadeca-9,12-dien-1-yl) 4,4′-((3-((4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-carbonylbutyl)amino)propyl)azanediyl)dibutyrate. The crude product was purified by column chromatography to obtain the target molecule.
[0795] ESI-MS m / z:cald for C 69 H 124 N2O6[M+H] + : 1077.8, found 1077.9.
[0796] Step 2: Synthesis of bis((9Z,12Z)-octadeca-9,12-dien-1-yl)4,4′-((3-((3-hydroxypropyl)(4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-carbonylbutyl)amino)propyl)azanediyl)dibutyrate
[0797] Using di((9Z,12Z)-octadec-9,12-dien-1-yl)4,4′-((3-((4-(((9Z,12Z)-octadec-9,12-dien-1-yl)oxy)-4-carbonylbutyl)amino)propyl)azanediyl)dibutyrate and 3-chloro-1-propanol as raw materials, the reaction mixture was prepared by referring to the third step of Example 18 to obtain di((9Z,12Z)-octadec-9,12-dien-1-yl)4,4′-((3-((3-hydroxypropyl)(4-(((9Z,12Z)-octadec-9,12-dien-1-yl)oxy)-4-carbonylbutyl)amino)propyl)azanediyl)dibutyrate. The crude product was purified by column chromatography to obtain the target molecule.
[0798] ESI-MS m / z:cald for C 72 H 130 N2O7[M+H] + : 1135.8, found 1135.9.
[0799] 1 H NMR (400MHz, CDCl3) δ5.46-5.25 (m, 12H), 4.12-3.99 (m, 6H), 3.78 (t, J=5.2Hz, 2H), 2.77 (t, J=6.5Hz, 6H), 2.64 (t, J=5.7Hz, 2H), 2.53-2.3 5 (m, 10H), 2.31 (t, J=7.4Hz, 6H), 2.05 (q, J=6.8Hz, 12H), 1.86-1.66 (m, 11H), 1.64-1.59 (m, 6H), 1.42-1.23 (m, 48H), 0.89 (t, J=6.8Hz, 9H).
[0800] Example 82
[0801] Heneicosyl 4,4′-((4-((3-hydroxypropyl)(4-carbonyl-4-(undecanyloxy)butyl)amino)butyl)azanediyl)dibutyrate
[0802] Step 1: Synthesis of undecyl 4-bromobutyrate
[0803] 4-Bromobutyric acid (4.6 g, 27.8 mmol) and undecanol (4.0 g, 23.2 mmol) were stirred at 60°C for 0.5 hour, then dissolved. Two drops of concentrated sulfuric acid were added. The mixture was reacted at 60°C for 6 hours. TLC indicated complete consumption of the starting material. The sample was directly mixed and column chromatography was performed using PE:EA = 20:1 as the eluent to give 6.7 g of the product as a colorless oil, with a yield of 89.3%.
[0804] Step 2: Synthesis of heneicosyl 4,4′-((4-((4-carbonyl-4-(undecanyloxy)butyl)amino)butyl)azanediyl)dibutyrate
[0805] Butane-1,4-diamine (274 mg, 3.1 mmol) was dissolved in ACN (40 mL), and undecyl 4-bromobutyrate (3.0 g, 9.3 mmol), K2CO3 (2.1 g, 15.6 mmol), and KI (50 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and EA (80 mL x 3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 10:1 to afford 390 mg of the product as a colorless oil, yield: 15.6%.
[0806] ESI-MS m / z:cald for C 49 H 96 N2O6[M+H] + :809.3, found 809.3.
[0807] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 2.85-2.65 (m, 4H), 2.52-2.44 (m, 5H), 2.43-2.37 (m, 3H), 2.32 (t, J=7.2Hz, 4H ), 1.90-1.85(m, 2H), 1.80-1.68(m, 5H), 1.64-1.55(m, 6H), 1.56-1.48(m, 2H), 1.32-1.21(m, 50H), 0.88(t, J=6.8Hz, 9H).
[0808] Step 3: Heneicosyl 4,4′-((4-((3-hydroxypropyl)(4-carbonyl-4-(undecyloxy)butyl)amino)butyl)azanediyl)dibutyrate
[0809] Diheneicosyl 4,4′-((4-((4-carbonyl-4-(undecanyloxy)butyl)amino)butyl)azanediyl)dibutyrate (390 mg, 0.5 mmol) was dissolved in DMF (8 mL), and 3-chloro-1-propanol (137 mg, 1.4 mmol), KCO (333 mg, 2.4 mmol), and KI (20 mg) were added, respectively. The mixture was stirred at 90°C for 16 hours. EA (80 mL*3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 10:1 to afford 82 mg of the product as a colorless oil (yield: 19.3%).
[0810] ESI-MS m / z:cald for C 52 H 102 N2O7[M+H] + : 867.4, found 867.9.
[0811] 1 H NMR (400MHz, CDCl3) δ4.06 (td, J=6.8, 2.5Hz, 6H), 3.78 (t, J=5.2Hz, 2H), 2.67 (s, 2H), 2.45 (s, 9H), 2.32 (t, J=7.3Hz, 6H), 1.87-1.66 (m, 10H), 1.61 (t, J=7.1Hz, 6H), 1.43 (d, J=6.0Hz, 4H), 1.28 (d, J=16.9Hz, 48H), 0.88 (t, J=6.7Hz, 9H).
[0812] Example 83
[0813] Dinonyl 4,4′-(5-((3-hydroxypropyl)(4-oxo-4-(undecyloxy)butyl)amino)pentyl)azahexyl)dibutyrate
[0814] Step 1: Synthesis of undecyl 4-bromobutyrate
[0815] 4-Bromobutyric acid (10 g, 59.88 mmol) and undecanol (10.32 g, 59.88 mmol) were stirred at 60°C for 0.5 hour, then dissolved. Two drops of concentrated sulfuric acid were added. The mixture was reacted at 60°C for 6 hours. TLC indicated complete consumption of the starting material. The sample was directly mixed and eluted by column chromatography using PE:EA = 20:1 to obtain 15 g of the product as a colorless oil, with a yield of 78%.
[0816] Step 2: Synthesis of dinonyl-4,4′-(5-((4-oxo-4-(undecyloxy)butyl)amino)pentyl)azahexyl)dibutyrate
[0817] 1,5-Diaminopentane (787.2 mg, 7.7 mmol) was dissolved in DMF (50 mL), and undecyl 4-bromobutyrate (7.426 g, 23.11 mmol), K2CO3 (4.79 g, 34.66 mmol), and KI (50 mg) were added, respectively. The mixture was stirred at 60°C for 6 hours. An appropriate amount of water was added, and EA (120 mL x 3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 10:1 as the eluent to give 650 mg of the product as a colorless oil, with a yield of 10.25%.
[0818] ESI-MS m / z:cald for C 50 H 98 N2O6[M+H] + :824.3, found 824.3.
[0819] Step 3: Dinonyl-4,4′-(5-((3-hydroxypropyl)(4-oxo-4-(undecyloxy)butyl)amino)pentyl)azahexyl)dibutyrate
[0820] Dinonyl 4,4′-(5-((4-oxo-4-(undecyloxy)butyl)amino)pentyl)azahexyl)dibutyrate (650 mg, 0.789 mmol) was dissolved in DMF (10 mL), and 3-chloro-1-propanol (147 mg, 1.5 mmol), K2CO3 (414.6 mg, 3 mmol), and KI (20 mg) were added, respectively, and stirred at 90°C for 16 hours. EA (80 mL*3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 10:1 to give 120 mg of the product as a colorless oil, in a yield of 17.25%.
[0821] ESI-MS m / z:cald for C 53 H 104 N2O7[M+H] + :882.4, found 882.4.
[0822] 1H NMR (400MHz, CDCl3) δ4.10 (m, 6H), 3.83 (t, J=5.2Hz, 2H), 2.69 (t, J=5.6Hz, 2H), 2 .54-2.27(m, 15H), 1.91-1.58(m, 20H), 1.43-1.22(m, 50H), 0.92(t, J=6.7Hz, 9H).
[0823] Example 84
[0824] 4,4′-(4-((4-(dodecyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azetidine dibutyl ester
[0825] Step 1: Docosyl 4,4′-(4-((4-(dodecyloxy)-4-oxobutyl)amino)butyl)azetidinyl)dibutyrate
[0826] Using dodecyl 4-bromobutyrate and 1,4-butanediamine as starting materials, the reaction was carried out in the second step of Example 82 to obtain docosyl 4,4′-(4-((4-dodecyloxy)-4-oxobutyl)amino)butyl)azetidinyl)dibutyrate. The crude product was purified by column chromatography to obtain the target molecule.
[0827] ESI-MS m / z:cald for C 52 H 103 N2O6[M+H] + :852.4, found 852.6.
[0828] Step 2: Synthesis of 4,4′-(4-((4-(dodecyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azetidine dibutyl ester
[0829] Using docosyl 4,4′-(4-((4-dodecyloxy)-4-oxobutyl)amino)butyl)azetidinyl)dibutyrate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 82 to obtain 4,4′-(4-((4-dodecyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azetidinyl dibutyl ester. The crude product was purified by column chromatography to obtain the target molecule.
[0830] ESI-MS m / z:cald for C 55 H 109 N2O7[M+H] + : 909.5, found 909.7.
[0831] Example 85
[0832] 4,4′-((4-((3-hydroxypropyl)(4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyric acid diester
[0833] Step 1: 4,4′-(4-(4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyric acid diester
[0834] Using tridecyl 4-bromobutyrate and 1,4-butanediamine as starting materials, the same procedure as in Example 82, Step 2, was followed to obtain diester 4,4′-(4-(4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyrate. The crude product was purified by column chromatography to yield the target molecule.
[0835] ESI-MS m / z:cald for C 55 H 109 N2O6[M+H] + : 893.5, found 893.7.
[0836] Step 2: Synthesis of 4,4′-((4-((3-hydroxypropyl)(4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyric acid diester
[0837] Using 4,4′-(4-(4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyrate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 82 to obtain 4,4′-((4-((3-hydroxypropyl) (4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyrate. The crude product was purified by column chromatography to obtain the target molecule.
[0838] ESI-MS m / z:cald for C 58 H 115 N2O7[M+H] + : 951.6, found 951.8.
[0839] Example 86
[0840] 4,4′-((4-(Decyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azepinediyl)dibutyric acid didecyl ester
[0841] Step 1: 4,4′-(4-((4-(decyloxy)-4-oxobutyl)amino)butyl)azepinediyl)dibutyric acid didecyl ester
[0842] Using decyl 4-bromobutyrate and 1,4-butanediamine as starting materials, the reaction was followed by the second step of Example 82 to obtain didecyl 4,4′-(4-((4-(decyloxy)-4-oxobutyl)amino)butyl)azepinediyl)dibutyrate. The crude product was purified by column chromatography to yield the target molecule.
[0843] ESI-MS m / z:cald for C 46 H 91 N2O6[M+H] + : 767.2, found 767.4.
[0844] Step 2: Synthesis of didecyl 4,4′-((4-(decyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azepinediyl)dibutyrate
[0845] Using didecyl 4,4′-(4-((4-(decyloxy)-4-oxobutyl)amino)butyl)azepinediyl)dibutyrate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 82 to obtain didecyl 4,4′-((4-(decyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azepinediyl)dibutyrate. The crude product was purified by column chromatography to obtain the target molecule.
[0846] ESI-MS m / z:cald for C 49 H 97 N2O7[M+H] + : 825.3, found 825.5.
[0847] Example 87
[0848] Dinonyl 4,4′-((4-((2-hydroxyethyl)(4-oxo-4-(undecanyloxy)butyl)amino)butyl)azepinediyl)dibutyrate
[0849] Step 1: Synthesis of 4-bromobutyric acid undecyl ester
[0850] Undecane-1-ol and 4-bromobutyric acid were used as raw materials, and undecyl 6-bromohexanoate was obtained by referring to the first step of Example 19. The crude product was purified by column chromatography to obtain 3.3 g of the target molecule in a yield of 88.5%.
[0851] 1H NMR (400MHz, CDCl3) δ4.07 (t, J=6.7Hz, 2H), 3.46 (t, J=6.4Hz, 2H), 2.49 (t, J=7.2Hz, 2H), 2.22-2.11(m, 2H), 1.66-1.59(m, 2H), 1.35-1.23(m, 16H), 0.88(t, J=6.7Hz, 3H).
[0852] Step 2: Synthesis of dinonyl-4,4′-(3-((4-oxo-4-(undecanyloxy)butyl)amino)propyl)azetidinyl)dibutyrate
[0853] Using undecyl 4-bromobutyrate and 1,4-butanediamine as starting materials, the reaction was carried out as described in Example 19, Step 2, to obtain dinonyl 4,4′-(3-((4-oxo-4-(undecyloxy)butyl)amino)propyl)azetidinyl)dibutyrate. The crude product was purified by column chromatography to obtain 390 mg of the target molecule in a 16.0% yield.
[0854] ESI-MS m / z:cald for C 49 H 97 N2O6[M+H] + :809.7, found 809.2.
[0855] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 2.85-2.65 (m, 4H), 2.52-2.44 (m, 5H), 2.40 (m, 3H), 2.32 (m, 4H), 2.04 -1.88(m, 2H), 1.80-1.68(m, 5H), 1.64-1.57(m, 6H), 1.55-1.47(m, 2H), 1.32-1.21(m, 50H), 0.88(t, J=6.8Hz, 9H).
[0856] Step 3: Synthesis of dinonyl-4,4′-((4-((2-hydroxyethyl)(4-oxo-4-(undecanyloxy)butyl)amino)butyl)azetidinyl)dibutyrate
[0857] Using dinonyl-4,4′-(3-((4-oxo-4-(undecyloxy)butyl)amino)propyl)azetidinyl)dibutyrate and bromoethanol as starting materials, the reaction was carried out according to the third step of Example 19 to obtain dinonyl-4,4′-((4-((2-hydroxyethyl)(4-oxo-4-(undecyloxy)butyl)amino)butyl)azetidinyl)dibutyrate. The crude product was purified by column chromatography to obtain 63 mg of the target molecule in a yield of 17.1%.
[0858] ESI-MS m / z:cald for C 51 H 101 N2O7[M+H] + :853.7, found 853.2.
[0859] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 3.54 (t, J=5.4Hz, 2H), 2.59 (m, 2H), 2.52-2.37 (m, 11H ), 2.31(m, 7H), 1.83-1.67(m, 7H), 1.61(m, 7H), 1.40(m, 4H), 1.27(m, 45H), 0.88(t, J=6.8Hz, 9H).
[0860] Example 88
[0861] Dinonyl 5,5′-((4-((3-hydroxypropyl)(5-oxo-5-(undecanyloxy)pentyl)amino)butyl)azetidinyl)divalerate
[0862] Step 1: Synthesis of Undecyl 5-bromovalerate
[0863] Undecane-1-ol and 5-bromovaleric acid were used as raw materials, and undecyl 5-bromovaleric acid was obtained by referring to the first step of Example 19. The crude product was purified by column chromatography to obtain 1.8 g of the target molecule in a yield of 92.8%.
[0864] 1 H NMR (400MHz, CDCl3) δ4.06 (t, J=6.7Hz, 2H), 3.41 (t, J=6.6Hz, 2H), 2.34 (t, J=7.3Hz, 2H), 1.95-1 .85 (m, 2H), 1.84-1.73 (m, 2H), 1.62 (t, J=7.1Hz, 2H), 1.33-1.23 (m, 16H), 0.88 (t, J=6.7Hz, 3H).
[0865] Step 2: Synthesis of tert-butyl (4-((3-((tert-butyldimethylsilyl)oxy)propyl)amino)butyl)carbamate
[0866] (3-Bromopropoxy)(tert-butyl)dimethylsilane (2.0 g, 7.9 mmol) was dissolved in acetonitrile (40 mL), and tert-butyl (4-aminobutyl)carbamate (1.8 g, 9.5 mmol), K2CO3 (3.3 g, 23.7 mmol), and KI (130 mg, 0.8 mmol) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and DCM (50 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 20:1 as the eluent to give 1.5 g of the product as a colorless oil, with a yield of 54.1%.
[0867] ESI-MS m / z:cald for C 18 H 41 N2O3Si[M+H] + : 361.6, found 361.8.
[0868] 1 H NMR (400MHz, CDCl3) δ3.68 (t, J=6.1Hz, 2H), 3.11 (m, 2H), 2.69 (t, J=6.9Hz, 2H), 2.64-2.58 (m, 2H) , 1.79-1.64 (m, 4H), 1.54-1.48 (m, 4H), 1.43 (s, 9H), 0.88 (d, J = 1.1Hz, 9H), 0.04 (d, J = 1.1Hz, 6H).
[0869] Step 3: Synthesis of 5-((4-(tert-butyloxycarbonyl)amino)butyl)(3-((tert-butyldimethylsilyl)oxy)propyl)amino)pentanoic acid undecyl ester
[0870] Tert-butyl (4-((3-((tert-butyldimethylsilyl)oxy)propyl)amino)butyl)carbamate (300 mg, 0.8 mmol) was dissolved in acetonitrile (10 mL), and undecyl 5-bromovalerate (279 mg, 0.8 mmol), potassium carbonate (345 mg, 2.5 mmol), and KI (13.8 mg, 0.08 mmol) were added, respectively, and stirred at 85°C for 16 hours. An appropriate amount of water was added, and then DCM (20 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 30:1 as the eluent to give 0.5 g of the product as a colorless oil, with a yield of 97.7%.
[0871] ESI-MS m / z:cald for C 34 H 71 N2O5Si[M+H] + : 616.0, found 616.1.
[0872] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 2H), 3.62 (t, J=6.3Hz, 2H), 3.16-3.04 (m, 2H), 2.43 (d, J=29. 8Hz, 5H), 2.30 (t, J=7.4Hz, 2H), 1.62 (m, 8H), 1.45 (m, 14H), 1.28 (m, 17H), 0.88 (s, 12H), 0.04 (s, 6H).
[0873] Step 4: Synthesis of 5-((4-aminobutyl)(3-hydroxypropyl)amino)pentanoic acid undecyl ester
[0874] 5-((4-(tert-Butoxycarbonyl)amino)butyl)(3-((tert-butyldimethylsilyl)oxy)propyl)amino)pentanoic acid undecyl ester (500 mg, 0.8 mmol) was dissolved in DCM (20 mL), TMSOTf (368 mg, 1.6 mmol) was added, and the mixture was stirred at room temperature for 1.5 hours. Saturated sodium bicarbonate solution was added dropwise under ice bath to neutralize the mixture, and an appropriate amount of water was added. The mixture was extracted with DCM (20 mL*3), the combined organic phases were dried, evaporated to dryness, and the mixture was passed through a column, eluted with DCM:MeOH(NH3)=10:1 to give 256 mg of the product as a colorless oil, with a yield of 78.6%.
[0875] ESI-MS m / z:cald for C 23 H 49 N2O3[M+H] + :401.6,found401.8.
[0876] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 2H), 3.83-3.74 (m, 2H), 2.71 (t, J=6.7Hz, 2H), 2.63 (t, J=5.6Hz, 2H), 2.47-2.38 (m, 5H ), 2.32 (t, J=7.2Hz, 2H), 1.70-1.65 (m, 2H), 1.64-1.57 (m, 4H), 1.54-1.41 (m, 6H), 1.35-1.23 (m, 18H), 0.87 (t, J=6.8Hz, 3H).
[0877] Step 5: Synthesis of dinonyl 5,5′-((4-((3-hydroxypropyl)(5-oxo-5-(undecanyloxy)pentyl)amino)butyl)azetidinyl)divalerate
[0878] Undecyl 5-((4-aminobutyl)(3-hydroxypropyl)amino)pentanoate (256 mg, 0.6 mmol) was dissolved in acetonitrile (10 mL), and undecyl 5-bromovalerate (536 mg, 1.9 mmol), potassium carbonate (265 mg, 1.9 mmol), and KI (10.6 mg, 0.06 mmol) were added, respectively, and stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with DCM (20 mL*3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 30:1 as the eluent to give 210 mg of the product as a colorless oil, with a yield of 36.1%.
[0879] ESI-MS m / z:cald for C 55 H 109 N2O7[M+H] + :909.8, found 909.8.
[0880] 1 H NMR (400MHz, CDCl3) δ4.10-4.00 (m, 6H), 3.78 (t, J=5.1Hz, 2H), 2.63 (t, J=5.6Hz, 2H), 2.46-2.35 (m, 10H), 2.34-2.28(m, 6H), 1.68-1.57(m, 17H), 1.52-1.37(m, 10H), 1.27(d, J=8.3Hz, 46H), 0.88(t, J=6.8Hz, 9H).
[0881] Example 89
[0882] Di((9Z,12Z)-octadeca-9,12-dien-1-yl) 4,4′-(4-(3-hydroxypropyl)(4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-oxobutyl)amino)butyl)nitridinediyl) dibutyrate
[0883] Step 1: Synthesis of di((9Z,12Z)-octadeca-9,12-dien-1-yl)4,4′-(4-(4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-oxobutyl)amino)butyl)nitrogendiyl)dibutyrate
[0884] Using (10Z,13Z)-octadeca-10,13-dien-1-yl 4-bromobutyrate and 1,4-butanediamine as starting materials, the reaction was carried out by referring to the second step of Example 82 to obtain di((9Z,12Z)-octadeca-9,12-dien-1-yl) 4,4′-(4-(4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-oxobutyl)amino)butyl)nitrogendiyl)dibutyrate. The crude product was purified by column chromatography to obtain the target molecule.
[0885] ESI-MS m / z:cald for C 70 H 127 N2O6[M+H] + : 1091.8, found 1091.6.
[0886] Step 2: Synthesis of bis((9Z,12Z)-octadec-9,12-dien-1-yl)-4,4′-(4-(3-hydroxypropyl)(4-(((9Z,12Z)-octadec-9,12-dien-1-yl)oxy)-4-oxobutyl)amino)butyl)nitrogendiyl)dibutyrate
[0887] Using di((9Z,12Z)-octadec-9,12-dien-1-yl)-4,4′-(4-(4-(((9Z,12Z)-octadec-9,12-dien-1-yl)oxy)-4-oxobutyl)amino)butyl)nitridine dibutyrate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 82 to obtain di((9Z,12Z)-octadec-9,12-dien-1-yl)-4,4′-(4-(3-hydroxypropyl)(4-(((9Z,12Z)-octadec-9,12-dien-1-yl)oxy)-4-oxobutyl)amino)butyl)nitridine dibutyrate. The crude product was purified by column chromatography to obtain the target molecule.
[0888] ESI-MS m / z:cald for C 73 H 133 N2O7[M+H] + : 1150.9, found 1150.7.
[0889] 1H NMR (400MHz, CDCl3) δ5.41-5.29 (m, 12H), 4.07-4.03 (m, 6H), 3.78 (t, J=5.2Hz, 2H), 2.76 (t, J=6.5Hz, 6H), 2.64 (t, J=5.8Hz, 2H ), 2.52-2.36 (m, 10H), 2.32 (t, J=7.4Hz, 6H), 2.15-2.0 (m, 13H), 1.86-1.5 (m, 20H), 1.31-1.25 (m, 46H), 0.86 (t, J=6.8Hz, 9H).
[0890] Example 90
[0891] Tridecyl 8-(29-hydroxy-15-oxyidene-23-(8-oxyidene-8-(tridecyloxy)octyl)-23,27-diaza-14-oxanonacosan-27-yl)octanoate
[0892] Step 1: Synthesis of tridecyl 8-bromooctanoate
[0893] 8-Bromooctanoic acid (5 g, 22.41 mmol) was dissolved in 100 mL of DCM, and oxalyl chloride (8.53 g, 67.23 mmol) was slowly added. The resulting mixture was refluxed for 4 hours and then dried to give 12 g of crude product. DCM (150 mL) was added, TEA (3.28 g, 32.4 mmol) was dissolved, and 1-tridecanol (4.49 g, 22.41 mmol) was added. The mixture was stirred at 40° C. for 4 hours. TLC showed that the starting material was completely consumed. The sample was directly mixed and eluted by column chromatography with PE:EA=10:1 to give 2.44 g of the product as a colorless oil, with a yield of 26.8%.
[0894] Step 2: Synthesis of tridecyl 8-(29-hydroxy-15-oxyidene-23-(8-oxyidene-8-(tridecyloxy)octyl)-23,27-diaza-14-oxa-nonacosan-27-yl)octanoate
[0895] 2-((3-aminopropyl)amino)ethane-1-ol (0.1 g, 846.17 μmol) was dissolved in 20 mL of MeCN. 8-bromooctanoic acid tridecyl ester (1.2 g, 2.96 mmol), potassium carbonate (0.82 g, 5.92 mmol), and KI (10 mg) were added, and the mixture was stirred at 85°C overnight. 50 mL of water and 50 mL of EA were added, and the organic phase was washed with saturated brine after separation, dried over anhydrous sodium sulfate, and then spin-dried through a column. Column chromatography was performed using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as eluent to give 340 mg of the product as a light yellow oil, in a yield of 36.8%.
[0896] ESI-MS m / z:cald for C 68 H 135 N2O7[M+H] + :1092.0,found 1092.1.
[0897] Example 91
[0898] 10-(29-hydroxy-13-oxyidene-23-(10-oxyidene-10-(undecyl)oxydecyl)-23,27-diaza-12-oxanonacosan-27-yl)decanoic acid undecyl ester
[0899] Step 1: Synthesis of undecyl 10-bromodecanoate
[0900] 10-Bromodecanoic acid (5 g, 19.91 mmol) was dissolved in 100 mL of DCM, and oxalyl chloride (7.58 g, 59.723 mmol) was slowly added. The resulting mixture was refluxed for 4 hours and then dried to give 12.3 g of crude product. DCM (150 mL) was added, and TEA (5 g) was dissolved. 1-Undecanol (3.43 g, 19.91 mmol) was added and stirred at 40° C. for 4 hours. TLC showed that the starting material was completely consumed. The sample was directly mixed and eluted by column chromatography with PE:EA = 10:1 to give 1.96 g of the product as a colorless oil, with a yield of 24.3%.
[0901] Step 2: Synthesis of 10-(29-hydroxy-13-oxyidene-23-(10-oxyidene-10-(undecyloxy)decyl)-23,27-diaza-12-oxanonacosan-27-yl)decanoate
[0902] 2-((3-Aminopropyl)amino)ethan-1-ol (0.1 g, 846.17 μmol) was dissolved in 20 mL of MeCN, and undecyl 10-bromodecaneate (1.2 g, 2.96 mmol), potassium carbonate (0.82 g, 5.92 mmol), and KI (10 mg) were added. The mixture was stirred at 85°C overnight. 50 mL of water and 50 mL of EA were added, and the organic phase was washed with saturated brine after separation, dried over anhydrous sodium sulfate, and then spin-dried. Column chromatography was performed using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to afford 310 mg of the product as a light yellow oil (yield: 33.6%).
[0903] ESI-MS m / z:cald for C 68 H 135 N2O7[M+H] + :1092.0,found 1092.1.
[0904] Example 92
[0905] 10-((7Z)-27-hydroxy-21-(10-(((2Z)-non-2-enyl)oxy)-10-oxyylidenedecyl)-11-oxyylidene-21,25-diaza-10-oxacosaccharin-7-en-25-yl)decanoic acid-(2Z)-non-2-en-1-yl ester
[0906] Step 1: Synthesis of (2Z)-non-2-en-1-yl 10-bromodecanoate
[0907] 10-Bromodecanoic acid (5 g, 19.91 mmol) was dissolved in 100 mL of DCM, and oxalyl chloride (7.58 g, 59.723 mmol) was slowly added. The resulting mixture was refluxed for 4 hours and then dried to give 12.3 g of crude product. DCM (150 mL) and TEA (5 g) were added to dissolve the mixture, followed by the addition of (2Z)-non-2-en-1-ol (2.83 g, 19.91 mmol). The mixture was stirred at 40°C for 4 hours. TLC indicated complete consumption of the starting material. The sample was directly mixed and eluted by column chromatography using PE:EA = 10:1 to give 3.3 g of the product as a colorless oil, with a yield of 52.6%.
[0908] Step 2: Synthesis of 10-((7Z)-27-hydroxy-21-(10-(((2Z)-non-2-enyl)oxy)-10-oxyylidenedecyl)-11-oxyylidene-21,25-diaza-10-oxacosaccharin-7-en-25-yl)decanoic acid-(2Z)-non-2-en-1-yl ester
[0909] 2-((3-Aminopropyl)amino)ethan-1-ol (0.1 g, 846.17 μmol) was dissolved in 20 mL of MeCN, and 10-bromodecanoic acid-(2Z)-non-2-en-1-yl ester (1.11 g, 2.96 mmol), potassium carbonate (0.82 g, 5.92 mmol), and KI (10 mg) were added. The mixture was stirred at 85°C overnight. 50 mL of water and 50 mL of EA were added, and the organic phase was washed with saturated brine after separation, dried over anhydrous sodium sulfate, and then spin-dried through a column. Column chromatography was performed using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 190 mg of the product as a light yellow oil, in a yield of 22.4%.
[0910] ESI-MS m / z:cald for C 62 H 117 N2O7[M+H] + :1001.9,found 1001.9.
[0911] Example 93
[0912] Decyl 4-(20-(2-hydroxyethyl)-12,24-dioxyylidene-16,20-diaza-11,25-dioxapentatriacont-16-yl)butanoate
[0913] Step 1: Synthesis of 4-bromobutyric acid decyl ester
[0914] Combine decane-1-ol (10 g, 63.18 mmol) and 4-bromobutyric acid (11.61 g, 69.49 mmol) and heat to 65°C. After the reaction mixture is completely melted, add 3 drops of concentrated sulfuric acid and continue stirring at 65°C overnight. After the reaction is complete, stop heating and add 100 mL of EA and 100 mL of a saturated NaHCO3 solution for washing. Remove the aqueous phase, wash the organic phase with saturated brine, dry it over anhydrous sodium sulfate, and spin dry it through a column. Column chromatography using PE:EA = 10:1 eluent yields 15.2 g of the product as a colorless oil in a 78.3% yield.
[0915] Step 2: Synthesis of 4-(20-(2-hydroxyethyl)-12,24-dioxy-16,20-diaza-11,25-dioxapentatriacont-16-yl)butyrate
[0916] 2-((3-Aminopropyl)amino)ethan-1-ol (1 g, 8.46 mmol) was dissolved in 50 mL of MeCN. 4-Decanyl bromobutyrate (9.10 g, 29.62 mmol), potassium carbonate (7.02 g, 50.77 mmol), and KI (20 mg) were added and stirred at 85°C overnight. 100 mL of water and 100 mL of EA were added. After separation, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and then dried by column chromatography. Column chromatography was performed using DCM (containing 5% EA):MeOH = 50:1 to 5:1 to afford 302.4 mg of the product as a light yellow oil (yield: 4.44%).
[0917] ESI-MS m / z :cald for C 47 H 93 N2O7[M+H] + :797.7, found 798.45.
[0918] Example 94
[0919] Dodecyl 4-(22-(2-hydroxyethyl)-14,26-dioxyylidene-18,22-diaza-13,27-dioxatriacont-18-yl)butanoate
[0920] Step 1: Synthesis of dodecyl 4-bromobutyrate
[0921] Combine dodecan-1-ol (12.0 mL, 53.67 mmol) and 4-bromobutyric acid (9.86 g, 59.03 mmol) and heat to 65°C. Once the reaction mixture is completely melted, add 3 drops of concentrated sulfuric acid and continue stirring at 65°C overnight. After the reaction is complete, stop heating and add 100 mL of EA and 100 mL of a saturated NaHCO3 solution for washing. Remove the aqueous phase, wash the organic phase with saturated brine, dry it over anhydrous sodium sulfate, and spin dry it through a column. Column chromatography using PE:EA = 10:1 eluent yields 17.8 g of the product as a colorless oil in a 98.9% yield.
[0922] Step 2: 4-(22-(2-hydroxyethyl)-14,26-dioxyylidene-18,22-diaza-13,27-dioxatriacont-18-yl)butyric acid dodecyl ester
[0923] 2-((3-Aminopropyl)amino)ethan-1-ol (1 g, 8.46 mmol) was dissolved in 50 mL of MeCN. Dodecyl 4-bromobutyrate (9.93 g, 29.62 mmol), potassium carbonate (7.02 g, 50.77 mmol), and KI (20 mg) were added and stirred at 85°C overnight. 100 mL of water and 100 mL of EA were added. After separation, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and then dried by column chromatography. Column chromatography was performed using DCM (containing 5% EA):MeOH = 50:1 to 5:1 to give 3.64 g of the product as a light yellow oil, with a yield of 48.45%.
[0924] ESI-MS m / z:cald for C 53 H 105 N2O7[M+H] + :881.8, found 881.8.
[0925] Example 95
[0926] 8-((6Z,10Z,50Z,53Z)-32-(3-hydroxypropyl)-20,40-dioxyylidene-28,32-diaza-19,41-dioxapenta-6,9,50,53-tetraen-28-yl)octanoate-(10Z,12Z)-octadeca-9,12-dien-1-yl
[0927] Step 1: Synthesis of 8-bromooctanoic acid-(10Z,12Z)-octadeca-9,12-dien-1-yl ester
[0928] With (10Z, 12Z)-18-9,12-diene-1-alcohol (2g, 7.51mmol), mix with 8-bromooctanoic acid (1.67g, 8.26mmol), be heated to 65 degree.After the question reaction mixture melts completely, add 3 drops of concentrated sulfuric acid, 65 degree continue stirring and spend the night.After question reaction finishes, stop heating, add 100mL EA and 100mL NaHCO saturated solution washing.Remove water, organic phase is spin-dried for post with anhydrous sodium sulfate drying after saturated common salt water washing.Column chromatography PE: EA=10: 1 wash-out obtains colorless oil product 1.98g, productive rate 55.9%.
[0929] Step 2: Synthesis of 8-((30Z,33Z)-8-(8-(((10Z,12Z)-octadeca-9,12-dienyl)oxy)-8-oxyideneoctyl)-2,2,3,3-tetramethyl-20-oxyidene-8,12-diaza-4,21-dioxa-3-silanitrile-30,33-dien-12-yl)octanoic acid-(10Z,12Z)-octadeca-9,12-dien-1-yl ester
[0930] 3-((2,2,3,3-Tetramethyl-4-oxa-3-silaheptan-7-yl)amino)propan-1-amine (200 mg, 0.81 mmol) was dissolved in 20 mL of MeCN. 8-bromooctanoic acid-(10Z,12Z)-octadec-9,12-dien-1-yl ester (1.3 g, 2.84 mmol), potassium carbonate (672.5 mg, 4.87 mmol), and KI (10 mg) were added, and the mixture was stirred at 85°C overnight. 50 mL of water and 50 mL of EA were added, and the organic phase was washed with saturated brine after separation, dried over anhydrous sodium sulfate, and then spin-dried through a column. Column chromatography was performed using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as eluent to give 759.2 mg of the product as a light yellow oil, in a 66% yield.
[0931] Step 3: Synthesis of 8-((6Z,10Z,50Z,53Z)-32-(3-hydroxypropyl)-20,40-dioxy-28,32-diaza-19,41-dioxapenta-6,9,50,53-tetraen-28-yl)octanoic acid-(10Z,12Z)-octadeca-9,12-dien-1-yl ester
[0932] 8-((30Z,33Z)-8-(8-((10Z,12Z)-octadeca-9,12-dienyl)oxy}-8-oxyideneoctyl)-2,2,3,3-tetramethyl-20-oxyidene-8,12-diaza-4,21-dioxa-3-silanaptriaconta-30,33-dien-12-yl)octanoate-(10Z,12Z)-octadeca-9,12-dien-1-yl ester (759.2 mg, 0.54 mmol) was dissolved in 10 mL of THF, TBAF (198.42 mg, 0.76 mmol) was added, and the mixture was stirred at room temperature overnight. Column chromatography was performed using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 566 mg of the product as a light yellow oil, in a yield of 80.9%.
[0933] ESI-MS m / z:cald for C 84 H 155 N2O7[M+H] +:1304.2,found 1304.65.
[0934] Example 96
[0935] 8-((6Z,10Z,46Z,49Z)-30-(3-hydroxypropyl)-20,36-dioxyylidene-26,30-diaza-19,37-dioxapenta-6,9,46,49-tetraen-26-yl)octanoate-(7Z,10Z)-hexadec-7,10-dien-1-yl
[0936] Step 1: Synthesis of 6-bromohexanoic acid-(10Z,12Z)-octadeca-9,12-dien-1-yl ester
[0937] With (10Z, 12Z)-18-9,12-diene-1-ol (2g, 7.51mmol), mix with 6-bromohexanoic acid (1.61g, 8.26mmol), be heated to 65 degree.After the question reaction mixture melts completely, add 3 drops of concentrated sulfuric acid, 65 degree continue stirring and spend the night.After question reaction finishes, stop heating, add 100mL EA and 100mL NaHCO saturated solution washing.Remove water, organic phase is dried over anhydrous sodium sulfate after saturated common salt water washing, be spin-dried for post. Column chromatography PE: EA=10: 1 wash-out obtains colorless oily product 1.67g, productive rate 51%.
[0938] Step 2: Synthesis of 8-((28Z,31Z)-8-(6-(((10Z,12Z)-octadeca-9,12-dienyl)oxy)-6-oxyylidenehexyl)-2,2,3,3-tetramethyl-18-oxyylidene-8,12-diaza-4,19-dioxa-3-silanisotriacontahedita-28,31-dien-12-yl)octanoate-(7Z,10Z)-hexadecane-7,10-dien-1-yl ester
[0939] 3-((2,2,3,3-Tetramethyl-4-oxa-3-silaheptan-7-yl)amino)propan-1-amine (200 mg, 0.81 mmol) was dissolved in 20 mL of MeCN. 6-bromohexanoic acid-(10Z,12Z)-octadeca-9,12-dien-1-yl ester (1.3 g, 2.84 mmol), potassium carbonate (672.5 mg, 4.87 mmol), and KI (10 mg) were added, and the mixture was stirred at 85°C overnight. 50 mL of water and 50 mL of EA were added, and the organic phase was washed with saturated brine after separation, dried over anhydrous sodium sulfate, and then spin-dried through a column. Column chromatography was performed using DCM (containing 5% EA):MeOH = 50:1 to 5:1 to give 675 mg of the product as a light yellow oil, in a yield of 62.5%.
[0940] Step 3: Synthesis of 8-(6Z,10Z,46Z,49Z)-30-(3-hydroxypropyl)-20,36-dioxy-26,30-diaza-19,37-dioxapenta-6,9,46,49-tetraen-26-yl)octanoic acid-(7Z,10Z)-hexa-7,10-dien-1-yl ester
[0941] 8-(((28Z,31Z)-8-(6-((10Z,12Z)-octadeca-9,12-dienyl)oxy)-6-oxyidenehexyl)-2,2,3,3-tetramethyl-18-oxyidene-8,12-diaza-4,19-dioxa-3-silatintriacontahedita-28,31-dien-12-yl)octanoate-(7Z,10Z)-hexadecane-7,10-dien-1-yl ester (675 mg, 0.51 mmol) was dissolved in 10 mL of THF, TBAF (198 mg, 0.76 mmol) was added, and the mixture was stirred at room temperature overnight. Column chromatography was performed using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 457 mg of the product as a light yellow oil, in a yield of 73.8%.
[0942] ESI-MS m / z:cald for C 78 H 143 N2O7[M+H] + :1220.1, found 1220.75.
[0943] Example 97
[0944] 8,8′-(3-((2-hydroxyethyl)(8-oxo-8-((Z)-pent-2-en-1-oxy)oxy)octyl)amino)propyl)azepinediyl)dioctanoate
[0945] Step 1: Synthesis of (Z)8-bromooctanoic acid pent-2-en-1-yl ester
[0946] 8-Bromooctanoic acid (7.23 g, 32.4 mmol) was dissolved in 100 mL of DCM, and oxalyl chloride (4.94 g, 38.89 mmol) was slowly added. The resulting mixture was refluxed for 4 hours and then dried to give a crude product. Half of the mixture was added to DCM (150 mL), dissolved in TEA (3.28 g, 32.4 mmol), and then cis-2-penten-1-ol (1.40 g, 16.2 mmol) was added. The mixture was stirred at 40°C for 4 hours. TLC indicated complete consumption of the starting material. The sample was directly mixed and eluted by column chromatography using PE:EA = 15:1 to obtain 4.0 g of the target molecule in a yield of 84.78%.
[0947] Step 2: Synthesis of 8,8′-(3-((2-hydroxyethyl)(8-oxo-8-((Z)-pent-2-en-1-oxy)oxy)octyl)amino)propyl)azadiyl)dioctanoate
[0948] N-(2-Hydroxyethyl)-1,3-propanediamine (59.1 mg, 0.5 mmol) was dissolved in DMF (5 mL), and (Z)-8-bromooctanoic acid pent-2-en-1-yl ester (509 mg, 1.75 mmol), potassium carbonate (345 mg, 2.5 mmol), and KI (13 mg) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with EA (50 mL x 3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to obtain 0.1 g of the target molecule in a yield of 26.7%.
[0949] ESI-MS m / z:cald for C 44 H 81 N2O7[M+H] + :749.6, found 749.45
[0950] 1 H NMR (400MHz, CDCl3) δ5.71-5.59(m, 3H), 5.55-5.43(m, 3H), 4.62(m, 6H), 3.67( t, J=5.0Hz, 2H), 2.99-2.90 (m, 1H), 2.87-2.78 (m, 4H), 2.74-2.65 (m, 4H), 2.61 -2.51 (m, 2H), 2.31 (t, J=7.5Hz, 6H), 2.17-2.07 (m, 6H), 2.02-1.88 (m, 2H), 1.7 0-1.56 (m, 10H), 1.54-1.44 (m, 2H), 1.39-1.24 (m, 20H), 1.00 (t, J=7.5Hz, 9H).
[0951] Example 98
[0952] 8,8′,8″,8″-(((3-hydroxypropyl)azodiyl)bis(propane-3,1-diyl))bis(azotriyl)tetradecanoate
[0953] Step 1: Synthesis of 8,8′,8″,8″-((azadiylbis(propane-3,1-diyl))bis(azatriyl))tetradecanoate
[0954] Bis(3-aminopropyl)amine (191.32 mg, 1.46 mmol) was dissolved in DMF (5 mL), and 8-bromooctanoic acid undecyl ester (2.2 g, 5.83 mmol), potassium carbonate (1 g, 7.29 mmol), and KI (50 mg) were added, respectively. The mixture was stirred at 60°C for 6 hours. An appropriate amount of water was added, and EA (100 mL x 3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 0.62 g of the product as a colorless oil, with a yield of 32.28%.
[0955] ESI-MS m / z:cald for C 82 H 162 N3O8[M+H] + :1317.2,found 1317.2
[0956] Step 2: Synthesis of 8,8′,8″,8″-(((3-hydroxypropyl)azodiyl)bis(propane-3,1-diyl))bis(azotriyl)tetradecanoate
[0957] Tetradecyl 8,8′,8″,8″-((azadiylbis(propane-3,1-diyl))bis(azatriyl))tetraoctanoate (620 mg, 0.47 mmol) was dissolved in DMF (5 mL), and 3-chloro-1-propanol (88.87 mg, 0.94 mmol), potassium carbonate (276.4 mg, 2 mmol), and KI (50 mg) were added, respectively. The mixture was stirred at 90°C for 16 hours. EA (80 mL*3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 to obtain 0.14 g of the target molecule in a yield of 21.66%.
[0958] ESI-MS m / z:cald for C 85 H 168 N3O9[M+H] + :1375.3, found 1375.15
[0959] 1H NMR (400MHz, CDCl3) δ4.04 (t, J=6.8Hz, 8H), 3.80-3.65 (m, 3H), 2.83-2.67 (m, 9H), 2.83-2.37 (m, 12H), 2.28 (t, J= 7.5Hz, 8H), 1.91-1.71 (m, 5H), 1.67-1.52 (m, 20H), 1.50-1.40 (m, 3H), 1.44-1.17 (m, 87H), 0.87 (t, J=6.7Hz, 12H).
[0960] Example 99
[0961] 8,8′,8″,8″-(((3-hydroxypropyl)azodiyl)bis(propane-3,1-diyl))bis(azotriyl)tetradecanoate
[0962] Step 1: Synthesis of tridecyl 8,8′,8″,8″-((azadiylbis(propane-3,1-diyl))bis(azatriyl))tetraoctanoate
[0963] Bis(3-aminopropyl)amine (243 mg, 1.85 mmol) was dissolved in DMF (8 mL), and tridecyl 8-bromooctanoate (3 g, 7.4 mmol), potassium carbonate (1.28 g, 9.25 mmol), and KI (50 mg) were added, respectively. The mixture was stirred at 60°C for 6 hours. An appropriate amount of water was added, and EA (100 mL x 3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to obtain 0.76 g of the target molecule in a yield of 28.74%.
[0964] ESI-MS m / z:cald for C 90 H 178 N3O8[M+H] + :1429.4, found 1429.4
[0965] Step 2: Synthesis of tridecyl 8,8′,8″,8″-(((3-hydroxypropyl)azodiyl)bis(propane-3,1-diyl))bis(azotriyl)tetraoctanoate
[0966] 8,8′,8″,8″-((azadiylbis(propane-3,1-diyl))bis(azatriyl))tetradecanoate (760 mg, 0.53 mmol) was dissolved in DMF (5 mL), and 3-chloro-1-propanol (100.2 mg, 1.06 mmol), potassium carbonate (276.4 mg, 2 mmol) and KI (50 mg) were added respectively, and the mixture was stirred at 90°C for 16 hours. EA (80 mL*3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was eluted by column chromatography with DCM (containing 5% EA):MeOH = 50:1 to 5:1 to obtain 0.16 g of the target molecule, with a yield of 20.29%.
[0967] ESI-MS m / z:cald for C 93 H 184 N3O9[M+H] + : 1487.4, found 1488.4
[0968] 1 H NMR (400MHz, CDCl3) δ4.04 (t, J=6.8Hz, 8H), 3.77 (t, J=5.1Hz, 2H), 2.62 (t, J=5.5Hz, 3H), 2.50-2.32 (m, 16H) , 2.28 (t, J=7.5Hz, 8H), 1.74-1.52 (m, 22H), 1.51-1.35 (m, 10H), 1.34-1.20 (m, 102H), 0.87 (t, J=6.7Hz, 12H).
[0969] Example 100
[0970] 4,4′-Tricosyl((5-((3-hydroxypropyl)(4-oxo-4-(tridecyloxy)butyl)amino)pentyl)azetidinyl)dibutyrate
[0971] Step 1: Synthesis of 4-bromobutyrate tridecyl
[0972] Using tridecan-1-ol and 4-bromobutyric acid as raw materials, the method of step 1 of Example 3 was followed to obtain tridecyl 4-bromobutyrate. The crude product was purified by column chromatography to obtain 14 g of the target molecule in a yield of 66.9%.
[0973] Step 2: Synthesis of 4,4′-tricosyl((5-(4-oxo-4-(tridecyloxy)butyl)amino)pentyl)azetidinyl)dibutyrate
[0974] 1,5-Pentanediamine (633.7 mg, 6.2 mmol) was dissolved in DMF (35 mL), and tridecyl 4-bromobutyrate (6.5 g, 18.6 mmol), potassium carbonate (3.73 g, 26.96 mmol), and KI (50 mg) were added, respectively. The mixture was stirred at 60°C for 6 hours. An appropriate amount of water was added, and EA (100 mL x 3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to obtain 565 mg of the desired product in a yield of 10.04%.
[0975] ESI-MS m / z:cald for C 56 H 111 N2O6[M+H] + :907.8,found 907.8
[0976] Step 3: Synthesis of 4,4′-tricosyl((5-((3-hydroxypropyl)(4-oxo-4-(tridecyloxy)butyl)amino)pentyl)azetidinyl)dibutyrate
[0977] 4,4′-Tricosyl((5-(4-oxo-4-(tridecyloxy)butyl)amino)pentyl)azetidinyl)dibutyrate (565 mg, 0.62 mmol) was dissolved in DMF (5 mL), and 3-chloro-1-propanol (118 mg, 1.25 mmol), potassium carbonate (258 mg, 1.87 mmol), and KI (50 mg) were added, respectively. The mixture was stirred at 90°C for 16 hours. EA (80 mL*3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to obtain 0.06 g of the desired product in a yield of 9.97%.
[0978] ESI-MS m / z:cald for C 59 H 117 N2O7[M+H] + :965.9, found 965.8
[0979] 1H NMR (400MHz, CDCl3) δ4.11-4.00 (m, 6H), 3.82-3.64 (m, 2H), 2.68-2.62 (m, 1H), 2.52-2.32 (m, 10H), 2.31-2.2 0 (m, 6H), 2.10-1.87 (m, 2H), 1.85-1.66 (m, 9H), 1.65-1.55 (m, 6H), 1.38-1.16 (m, 65H), 0.88 (t, J=6.7Hz, 9H).
[0980] Example 101
[0981] 4,4′-Tricosyl((4-((3-hydroxypropyl)(4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyrate
[0982] Step 1: Synthesis of 4,4′-tricosyl((4-(4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyrate
[0983] Using tridecyl-4-bromobutyrate and 1,4-butanediamine as starting materials, the reaction was carried out according to the second step of Example 19 to obtain 4,4′-tricosyl((4-(4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyrate. The crude product was purified by column chromatography to obtain 1 g of the target molecule in a yield of 14.84%.
[0984] ESI-MS m / z:cald for C 55 H 109 N2O6[M+H] + :893.8,found 893.8
[0985] Step 2: Synthesis of 4,4′-tricosyl((4-((3-hydroxypropyl)(4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyrate
[0986] Using 4,4′-tricosyl((4-(4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyrate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 19 to obtain 4,4′-tricosyl((4-((3-hydroxypropyl)(4-oxo-4-(tridecyloxy)butyl)amino)butyl)azetidinyl)dibutyrate. The crude product was purified by column chromatography to obtain 0.06 g of the target molecule in a yield of 6.3%.
[0987] ESI-MS m / z:cald for C 58 H 115 N2O7[M+H] + :951.9, found 951.8
[0988] 1 H NMR (400MHz, CDCl3) δ4.12-3.94 (m, 6H), 3.78 (t, J=5.2Hz, 2H), 2.73-2.59 (m, 2H), 2.51-2.36 (m, 9H), 2.31 (t, J=7.4Hz, 6H ), 1.89-1.78(m, 2H), 1.77-1.65(m, 6H), 1.64-1.54(m, 6H), 1.50-1.35(m, 6H), 1.35-1.17(m, 60H), 0.88(t, J=6.7Hz, 9H).
[0989] Example 102
[0990] 4,4′-didecyl((4-(decyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azetidinyl)dibutyrate
[0991] Step 1: Synthesis of 4-decyl bromobutyrate
[0992] Using decan-1-ol and 4-bromobutyric acid as raw materials, the method of step 1 of Example 3 was followed to obtain decyl 4-bromobutyrate. The crude product was purified by column chromatography to obtain 0.06 g of the target molecule in a yield of 6.3%.
[0993] Step 2: Synthesis of 4,4′-tricosyl((5-(4-oxo-4-(tridecyloxy)butyl)amino)pentyl)azetidinyl)dibutyrate
[0994] Using decyl 4-bromobutyrate and 1,4-butanediamine as starting materials, the reaction was carried out according to the second step of Example 19 to obtain 4,4′-tricosyl((5-(4-oxo-4-(tridecyloxy)butyl)amino)pentyl)azetidinyl)dibutyrate. The crude product was purified by column chromatography to obtain 700 mg of the target molecule in a yield of 9.35%.
[0995] ESI-MS m / z:cald for C 46 H 91 N2O6[M+H] + :767.7,found 767.7
[0996] Step 3: Synthesis of 4,4′-didecyl((4-(decyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azetidinyl)dibutyrate
[0997] Using 4,4′-tricosyl((5-(4-oxo-4-(tridecyloxy)butyl)amino)pentyl)azetidinyl)dibutyrate and 3-chloro-1-propanol as starting materials, the reaction was carried out by referring to the third step of Example 19 to obtain 4,4′-didecyl((4-(decyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azetidinyl)dibutyrate. The crude product was purified by column chromatography to obtain 0.1 g of the target molecule in a yield of 13.29%.
[0998] ESI-MS m / z:cald for C 58 H 115 N2O7[M+H] + :951.9,found 951.9
[0999] 1 H NMR (400MHz, CDCl3) δ4.05 (m, 2.7H z, 6H), 3.78 (t, J=5.2Hz, 2H), 2.71-2.62 (m, 2H), 2.52-2.36 (m, 10H), 2.31 (t, J=7.3Hz, 6H), 1.85-1.78 (m , 2H), 1.78-1.66 (m, 6H), 1.66-1.56 (m, 6H), 1.49-1.39 (m, 4H), 1.39-1.18 (m, 61H), 0.88 (t, J=6.7Hz, 9H).
[1000] Example 103
[1001] 4,4′-docosyl((4-(dodecyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azetidinyl)dibutyrate
[1002] Step 1: Synthesis of 4-bromobutyrate
[1003] Using dodecan-1-ol and 4-bromobutyric acid as raw materials, dodecyl 4-bromobutyrate was obtained by referring to the first step of Example 3. The crude product was purified by column chromatography to obtain 10.25 g of the target molecule, with a yield of 91.87%.
[1004] Step 2: Synthesis of 4,4′-docosyl((4-(dodecyloxy)-4-oxobutyl)amino)butyl)azetidinyl)dibutyrate
[1005] Using dodecyl 4-bromobutyrate and 1,4-butanediamine as starting materials, the reaction was carried out according to the second step of Example 19 to obtain 4,4′-docosyl((4-(dodecyloxy)-4-oxobutyl)amino)butyl)azetidinyl)dibutyrate. The crude product was purified by column chromatography to obtain 900 mg of the target molecule in a yield of 10.37%.
[1006] ESI-MS m / z:cald for C 52 H 103 N2O6[M+H] + :851.8,found 851.8
[1007] Step 3: Synthesis of 4,4′-docosyl((4-(dodecyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azetidinyl)dibutyrate
[1008] Using 4,4′-docosyl((4-(dodecyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azetidinyl)dibutyrate and 3-chloro-1-propanol as starting materials, the reaction was carried out according to the third step of Example 19 to obtain 4,4′-docosyl((4-(dodecyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)butyl)azetidinyl)dibutyrate. The crude product was purified by column chromatography to obtain 85 mg of the target molecule in an 8.84% yield.
[1009] ESI-MS m / z:cald for C 55 H 109 N2O7[M+H] + :909.8,found 909.8
[1010] 1 H NMR (400MHz, CDCl3) δ4.12-3.93(m, 6H), 3.78(t, J=5.2Hz, 2H), 2.73-2.62(m , 2H), 2.56-2.37(m, 9H), 2.35-2.27(m, 7H), 1.89-1.65(m, 8H), 1.66-1.54(m, 6H), 1.51-1.36 (m, 4H), 1.37-1.17 (m, 55H), 0.88 (t, J=6.8Hz, 9H).
[1011] Example 104
[1012] Di((9Z,12Z)-octadeca-9,12-dien-1-yl) 4,4′-((4-(3-hydroxypropyl)(4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-oxobutyl)amino)butyl)azetidinyl)dibutyrate
[1013] Step 1: Synthesis of (9Z,12Z)-octadeca-9,12-dien-1-yl 4-bromobutyrate
[1014] 4-Bromobutyric acid (12.5 g, 74.85 mmol) and (9Z,12Z)-octadeca-9,12-dien-1-ol (19.95 g, 74.85 mmol) were stirred at 60°C for 0.5 hour to dissolve the mixture. Three drops of concentrated sulfuric acid were added and the mixture was allowed to react at 60°C for 6 hours. TLC indicated complete consumption of the starting material. The sample was then stirred and eluted by column chromatography using PE:EA = 15:1 to obtain 23 g of the desired product in a yield of 76.55%.
[1015] Step 2: Synthesis of tert-butyl (4-((3-((tert-butyldimethylsilyl)oxy)propyl)amino)butyl)carbamate
[1016] Methyl 2-methylpropan-2-yl[(4-aminobutyl)amino]formate (4.13 g, 21.96 mmol) was dissolved in DMF (100 mL). 7-Bromo-2,2,3,3-tetramethyl-4-oxo-3-silahnane (5.56 g, 21.96 mmol), potassium carbonate (6.07 g, 43.91 mmol), and KI (0.36 g, 2.20 mmol) were added, respectively. The mixture was stirred at 80°C for 18 hours. 500 mL of water was added, and the mixture was extracted with EA (100 mL x 3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to obtain 2.74 g of the desired product in a yield of 34.6%.
[1017] ESI-MS m / z:cald for C 18 H 41 N2O3Si[M+H] + :361.3,found 361.3
[1018] Step 3: Synthesis of tert-butyl (4-((3-((tert-butyldimethylsilyl)oxy)propyl)amino)butyl)carbamate
[1019] Tert-butyl (4-((3-((tert-butyldimethylsilyl)oxy)propyl)amino)butyl)carbamate (5.33 g, 14.78 mmol) was dissolved in DMF (70 mL), and (9Z,12Z)-octadec-9,12-dien-1-yl 4-bromobutyrate (6.14 g, 14.78 mmol), potassium carbonate (4.09 g, 29.56 mmol), and KI (250 mg, 1.478 mmol) were added, respectively, and stirred at 85°C for 16 hours. After cooling to room temperature, the mixture was diluted with 200 mL of water and extracted with EA (100 mL*3). The organic phase was dried and then spin-dried. The crude product was eluted by column chromatography with DCM (containing 5% EA):MeOH = 50:1 to 5:1 to obtain 7.81 g of a colorless oily product in a yield of 76.0%.
[1020] ESI-MS m / z:cald for C 40 H 79 N2O5Si[M+H] + :695.6,found 695.6
[1021] Step 4: Synthesis of (9Z,12Z)-octadeca-9,12-dien-1-yl-4-((4-aminobutyl)(3-hydroxypropyl)amino)butyrate
[1022] (9Z,12Z)-octadec-9,12-dien-1-yl-4-((4-((tert-butoxycarbonyl)amino)butyl)(3-(((tert-butyldimethylsilyl)oxy)propyl)amino)butanoate (7.81 g, 11.23 mmol) was dissolved in DCM (50 mL), and trimethylsilyl trifluoromethanesulfonate (4.99 g, 22.46 mmol) was added. The mixture was stirred at room temperature for 16 hours. The mixture was diluted with 50 mL of DCM and washed twice with saturated aqueous sodium bicarbonate solution. The organic phase was dried and spin-dried. The crude product was eluted by column chromatography with DCM (containing 5% EA):MeOH=50:1 to 5:1 to obtain 2.58 g of the desired product in a yield of 47.8%.
[1023] ESI-MS m / z:cald for C 29 H 57 N2O3[M+H] + :481.4,found 481.4
[1024] Step 5: Synthesis of bis((9Z,12Z)-octadeca-9,12-dien-1-yl)4,4′-((4-(3-hydroxypropyl)(4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-oxobutyl)amino)butyl)azetidinyl)dibutyrate
[1025] (9Z,12Z)-octadec-9,12-dien-1-yl-4-((4-aminobutyl)(3-hydroxypropyl)amino)butyrate (2.58 g, 5.366 mmol) and (9Z,12Z)-octadec-9,12-dien-1-yl-4-bromobutyrate (5.57 g, 13.4 mmol) were added to a 100 mL single-necked bottle, followed by 30 mL of DMF, potassium carbonate (2.22 g, 16.1 mmol), and potassium iodide (50 mg). The mixture was stirred at 85°C for 16 hours. After cooling to room temperature, the mixture was diluted with 100 mL of water and extracted three times with EA (100 mL * 3). The combined organic phases were washed twice with saturated aqueous sodium bicarbonate solution. The organic phase was dried and then spin-dried. The crude product was eluted by column chromatography with DCM (containing 5% EA): MeOH = 50:1 to 5:1 to obtain 2.5 g of the target product in a yield of 40.5%.
[1026] ESI-MS m / z:cald for C 73 H 133 N2O7[M+H] + :1150.0,found 1150.0
[1027] 1 H NMR (400MHz, CDCl3) δ5.56-5.16 (m, 12H), 4.17-3.95 (m, 6H), 3.78 (t, J=5.2Hz, 2H), 2.77 (t, J=6.5Hz, 6H), 2.64 (t, J=5.7Hz, 2H), 2.53-2.3 6 (m, 10H), 2.31 (t, J=7.4Hz, 6H), 2.05 (q, J=6.9Hz, 12H), 1.84-1.64 (m, 10H), 1.64-1.56 (m, 6H), 1.52-1.19 (m, 51H), 0.89 (t, J=6.7Hz, 9H).
[1028] Example 105
[1029] 4,4′-(3-(((2-hydroxyethyl)((E)-4-oxo-4-(undecanyloxy)but-2-en-1-yl)amino)propyl)azepinediyl)(2E,2′E)-bis(but-2-enoic acid)
[1030] Step 1: Synthesis of Undecyl (E)-4-bromobut-2-enoic acid
[1031] 4-Bromocrotonic acid (4.79 g, 29 mmol) and undecanol (5 g, 29 mmol) were stirred at 60°C for 0.5 hour, then dissolved. 3 drops of concentrated sulfuric acid were added. The mixture was reacted at 60°C for 6 hours. TLC indicated complete consumption of the starting material. The sample was directly mixed and column chromatography was performed using PE:EA = 15:1 as the eluent to afford 7.7 g of the product as a colorless oil, yield: 83.11%.
[1032] Step 2: Synthesis of bis(2-hexyldecyl)4,4′-((3-(bis(2-hydroxyethyl)amino)propyl)azadiyl)dibutyrate
[1033] Undecyl (E)-4-bromobut-2-enoic acid (4.225 g, 13.327 mmol) was dissolved in DMF (15 mL). 2-(3-aminopropyl)amino)ethane-1-ol (350 mg, 2.96 mmol), potassium carbonate (2.05 g, 14.8 mmol), and KI (50 mg) were added, respectively, and the mixture was stirred at 85°C for 5 hours. EA (80 mL x 3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using a PE:EA gradient elution to 50% to afford 0.185 g of the product as a light yellow oil, in a yield of 7.5%.
[1034] ESI-MS m / z:cald for C 50 H 93 N2O7[M+H] + :833.7,found 833.7
[1035] 1 H NMR (400MHz, CDCl3) δ6.90 (m, 2H), 5.98 (m, 2H), 4.17-3.98 (m, 6H), 3.98-3.89 (m, 1H), 3 .87-3.76(m, 1H), 3.70-3.55(m, 1H), 3.21(m, 3H), 2.84-2.71(m, 1H), 2.70-2.57(m, 1H), 2.57-2.43(m, 2H), 2.42-2.38(m, 1H), 2.38-2.20(m, 2H), 2.17-2.00(m, 1H), 1.90-1.78( m, 1H), 1.78-1.68 (m, 3H), 1.67-1.46 (m, 8H), 1.45-1.05 (m, 50H), 0.87 (t, J=6.8Hz, 9H).
[1036] Example 106
[1037] 4,4′-(3-((3-hydroxypropyl)((E)-4-oxo-4-(undecanyloxy)but-2-en-1-yl)amino)propyl)azepinediyl)(2E,2′E)-bis(but-2-enoic acid)
[1038] Step 1: Synthesis of undecyl (E)-2,2,3,3-tetramethyl-8,12-bis((E)-4-oxo-4-(undecanyloxy)but-2-en-1-yl)-4-oxo-8,12-diaza-3-silane-hexadecatetradecenoate
[1039] Undecyl (E)-4-bromobut-2-enoic acid (3.5 g, 10.96 mmol) was dissolved in DMF (45 mL). N1-(3-((tert-butyldimethylsilyl)oxy)propyl)propane-1,3-diamine (600 mg, 2.43 mmol), potassium carbonate (1.68 g, 12.17 mmol), and KI (40 mg) were added, respectively, and stirred at 85°C for 5 hours. EA (80 mL x 3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using a PE:EA gradient elution to 40% to obtain 1.4 g of the desired product in a yield of 59.82%.
[1040] ESI-MS m / z:cald for C 57 H 109 N2O7Si[M+H] + :961.8,found 961.8
[1041] 1 H NMR (400MHz, CDCl3) δ6.99-6.77 (m, 3H), 5.98 (d, J=15.9Hz, 3H), 4.34-4.00 (m, 6H), 3.62 (t, J=6.2Hz, 2H), 3. 28-3.15(m, 6H), 2.58-2.23(m, 6H), 1.72-1.61(m, 9H), 1.42-1.17(m, 49H), 0.97-0.80(m, 18H), 0.04(s, 6H).
[1042] Step 3: Synthesis of 4,4′-(3-((3-hydroxypropyl)((E)-4-oxo-4-(undecanyloxy)but-2-en-1-yl)amino)propyl)azepinediyl)(2E,2′E)-bis(but-2-enoic acid)
[1043] Undecyl (E)-2,2,3,3-tetramethyl-8,12-bis((E)-4-oxo-4-(undecanyloxy)but-2-en-1-yl)-4-oxo-8,12-diaza-3-silane hexadecatetradecenoate (900 mg, 0.94 mmol) was dissolved in DCM (25 mL), and TMSOTf (416 mg, 1.87 mmol) was added and stirred at room temperature for 1 hour. The mixture was diluted with DCM and washed with saturated sodium bicarbonate. The organic phase was dried and spin-dried. The crude product was purified by column chromatography using a PE:EA gradient elution to 60% to obtain 0.72 g of the product as a light yellow oil, with a yield of 90.79%.
[1044] ESI-MS m / z:cald for C 51 H 95 N2O7[M+H] + :847.7,found 847.7
[1045] 1 H NMR (400MHz, CDCl3) δ6.91 (m, 3H), 6.32-5.68 (m, 3H), 4.12 (t, J=6.8Hz, 6H), 3.75 (t, J=5.3Hz, 2H), 3.7-3.3 (m, 6H), 2.64 (t, J=5.9Hz, 2H), 2.47 (m, 4H), 1.85-1.44 (m, 13H), 1.43-1.13 (m, 46H), 0.87 (t, J=6.7Hz, 9H).
[1046] Example 107
[1047] Dinonyl 5,5′-((3-((2-hydroxyethyl)(5-oxo-5-(undecanyloxy)pentyl)amino)propyl)azepinediyl)divalerate
[1048] Step 1: Synthesis of Undecyl 5-bromovalerate
[1049] 5-Bromopentanoic acid (1.3 g, 7.0 mmol) and undecanol (1.0 g, 5.8 mmol) were dissolved by stirring at 60°C. One drop of concentrated sulfuric acid was added and the mixture was reacted at 60°C for 6 hours. TLC indicated complete consumption of the starting material. The sample was directly mixed and eluted by column chromatography using PE:EA = 30:1 to give 1.8 g of the product as a colorless oil, with a yield of 92.8%.
[1050] 1H NMR (400MHz, CDCl3) δ4.06 (t, J=6.7Hz, 2H), 3.41 (t, J=6.6Hz, 2H), 2.34 (t, J=7.3Hz, 2H), 1. 95-1.85 (m, 2H), 1.84-1.73 (m, 2H), 1.62 (m, 2H), 1.33-1.23 (m, 16H), 0.88 (t, J=6.7Hz, 3H).
[1051] Step 2: Synthesis of dinonyl 5,5′-((3-((2-hydroxyethyl)(5-oxo-5-(undecanyloxy)pentyl)amino)propyl)azepinediyl)dipentanoate
[1052] Undecyl 5-bromovalerate (684 mg, 2.0 mmol) was dissolved in MeCN (10 mL), and 2-((3-aminopropyl)amino)ethan-1-ol (60 mg, 0.5 mmol), potassium carbonate (352 mg, 2.6 mmol), and KI (8.3 mg, 0.05 mmol) were added, respectively. The mixture was stirred at 85°C for 16 hours. DCM (30 mL*3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to afford 114 mg of the product as a colorless oil (yield: 25.3%).
[1053] ESI-MS m / z:cald for C 53 H 105 N2O7[M+H] + : 881.8, found 881.6.
[1054] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8Hz, 6H), 3.54 (t, J=5.2Hz, 2H), 2.55 (t, J=5.2Hz, 2H), 2.51-2.35 (m, 1 0H), 2.31 (t, J=7.6Hz, 6H), 1.65-1.55 (m, 14H), 1.50-1.41 (m, 6H), 1.33-1.23 (m, 49H), 1.06-0.71 (m, 9H).
[1055] Example 108
[1056] di((9Z,12Z)-octadeca-9,12-dien-1-yl) 4,4′-(3-(3-hydroxypropyl)(4-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-4-oxobutyl)amino)propyl)nitrogendiyl)dibutyrate
[1057] Step 1: Synthesis of (9Z, 12Z)-octadeca-9,12-dien-1-yl 4-bromobutyrate:
[1058] Mix (9Z,12Z)-octadec-9,12-dien-1-ol (10.0 g, 37.5 mmol) and 4-bromobutyric acid (7.5 g, 45.0 mmol), heat the temperature to 60°C, add concentrated sulfuric acid (0.1 mL), and stir at this temperature for 16 hours. TLC shows that the starting material is almost completely consumed. Add an appropriate amount of water and extract with EA (30 mL*3) to combine the organic phases. After evaporating the solvent, mix the sample and pass it directly through a column. Elute with PE:EA=30:1 to obtain 7.9 g of a colorless oily product with a yield of 50.7%.
[1059] 1 H NMR (400MHz, CDCl3) δ5.46-5.27 (m, 4H), 4.08 (t, J=6.7Hz, 2H), 3.47 (t, J=6.5Hz, 2H), 2.77 (t, J=6.4Hz, 2H), 2.50 (t , J=7.2Hz, 2H), 2.24-2.11 (m, 2H), 2.09-2.00 (m, 4H), 1.67-1.58 (m, 2H), 1.41-1.24 (m, 16H), 0.89 (t, J=6.7Hz, 3H).
[1060] Step 2: Synthesis of N1-(3-((tert-butyldimethylsilyl)oxy)propyl)propane-1,3-diamine:
[1061] Propane-1,3-diamine (2.9 g, 39.5 mmol) was dissolved in methanol (30 mL), and (3-bromopropoxy)(tert-butyl)dimethylsilane (2.0 g, 7.9 mL) dissolved in methanol (20 mL) was added dropwise with stirring. The mixture was stirred at room temperature for 18 hours. After evaporating the solvent, the sample was directly mixed and passed through a column. 1.0 g of colorless oily product was eluted with DCM:MeOH(NH3) = 10:1, with a yield of 50.4%.
[1062] ESI-MS m / z:cald for C 12 H 31 N2OSi[M+H] + : 247.2, found 247.4.
[1063] 1H NMR (400MHz, CDCl3) 3.68 (t, J=6.1Hz, 2H), 2.76 (t, J=6.9Hz, 2H), 2.72-2.62 (m, 4H), 1.74-1.59 (m, 4H), 1.53 (s, 3H), 0.88 (s, 9H), 0.04 (s, 6H).
[1064] Step 3: Synthesis of (9Z, 12Z)-octadec-9,12-dien-1-yl 2,2,3,3-tetramethyl-8-(4-(((6Z, 9Z)-heptadeca-6,9-dien-1-yl)oxy)-4-oxobutyl)-12-(4-((9Z, 12Z)-octadec-9,12-dien-1-yl)oxy)-4-oxobutyl)-4-oxo-8,12-diaza-3-silahexadecane-16-oate
[1065] N1-(3-((tert-Butyldimethylsilyl)oxy)propyl)propane-1,3-diamine (0.5 g, 1.9 mmol) was dissolved in MeCN (27 mL), and (9Z,12Z)-octadec-9,12-dien-1-yl 4-bromobutyrate (2.7 g, 6.5 mmol), potassium carbonate (1.6 g, 11.2 mmol), and KI (31 mg, 0.2 mmol) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and EA (20 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using A:B = 30% (A: PE / EA = 5 / 1, B: DCM / MeOH(NH3) = 10 / 1) as the eluent to give 1.5 g of the product as a colorless oil, with a yield of 64.3%.
[1066] ESI-MS m / z:cald for C 78 H 145 N2O7Si[M+H] + :1250.1, found 1250.3.
[1067] 1 H NMR (400MHz, CDCl3) δ5.45-5.26 (m, 12H), 4.04 (t, J=6.8Hz, 6H), 3.62 (t, J=6.3Hz, 2H), 2.77 (t, J=6.5Hz, 6H), 2.54-2.36 (m, 11H), 2.33-2.27(m, 6H), 2.08-2.01(m, 12H), 1.78-1.67(m, 7H), 1.64-1.57(m, 8H), 1.37-1.26(m, 50H), 0.96-0.82(m, 18H), 0.04(s, 6H).
[1068] Step 4: Synthesis of bis((9Z,12Z)-octadeca-9,12-dien-1-yl)4,4′-((3-(3-hydroxypropyl)(4-(((6Z,9Z)-heptadeca-6,9-dien-1-yloxy)-4-oxobutyl)amino)propyl)nitrogendiyl)dibutyrate
[1069] (9Z, 12Z)-octadec-9,12-dien-1-yl 2,2,3,3-tetramethyl-8-(4-(((6Z, 9Z)-heptadeca-6,9-dien-1-yl)oxy)-4-oxobutyl)-12-(4-((9Z, 12Z)-octadec-9,12-dien-1-yl)oxy)-4-oxobutyl)-4-oxo-8,12-diaza-3-silahexadecane-16-acid (3.0 g, 2.4 mmol) was dissolved in THF (20 mL), and then 1.0 M TBAF tetrahydrofuran solution (4.8 mL, 4.8 mmol) was added, stirred at room temperature for 3 hours, an appropriate amount of water was added, and the organic phases were extracted with EA (20 mL*3), dried, and evaporated to dryness. The sample was mixed and passed through the column, and 0.8 g of colorless oily product was eluted with A:B = 10%-30% (A: PE / EA = 5 / 1, B: DCM / MeOH(NH3) = 10 / 1), with a yield of 27.9%.
[1070] ESI-MS m / z:cald for C 72 H 131 N2O7[M+H] + :1136.0, found 1136.2.
[1071] 1 H NMR (400MHz, CDCl3) δ5.46-5.25(m, 12H), 4.12-3.99(m, 6H), 3.78(t, J=5.2Hz, 2H), 2.77(t, J=6.5Hz, 6H), 2.64(m, 2H), 2.53-2.35(m , 10H), 2.31 (t, J=7.4Hz, 6H), 2.11-1.98 (m, 12H), 1.86-1.66 (m, 11H), 1.64-1.59 (m, 6H), 1.42-1.23 (m, 48H), 0.89 (t, J=6.8Hz, 9H).
[1072] Example 109
[1073] 4-(3-((2-hydroxyethyl)(4-oxo-4-(undecyloxy)butyl)amino)propyl)(4-oxido-4-(undecyloxy)butyl)amino)-4-oxobutanoate
[1074] Step 1: Synthesis of 4-oxo-4-(undecanyloxy)butanoic acid
[1075] Dihydrofuran-2,5-dione (1.0 g, 10.0 mmol) and undecanol (1.7 g, 10.0 mmol) were dissolved in DMF (10 mL), and DMAP (1.2 g, 10.0 mmol) was added and stirred at room temperature for 16 hours. An appropriate amount of 1N hydrochloric acid was added, and then DCM (30 mL*3) was added for extraction. The organic phase was dried and then spin-dried to give 2.7 g of crude product, with a yield of 99.2%.
[1076] 1 H NMR (400MHz, CDCl3) δ4.08 (t, J=6.7Hz, 2H), 2.70-2.64 (m, 2H), 2.57-2.63 (m, 2H), 1.67-1.55 (m, 2H), 1.33-1.22 (m, 16H), 0.87 (t, J=6.8Hz, 3H).
[1077] Step 2: Synthesis of tert-butyl (3-((2-((tert-butyldimethylsilyl)oxy)ethyl)amino)propyl)carbamate
[1078] Dissolve (2-bromoethoxy)(tert-butyl)dimethylsilane (4.8 g, 20.1 mmol) in acetonitrile (100 mL), add tert-butyl (3-aminopropyl)carbamate (3.5 g, 20.1 mmol) and potassium carbonate (5.5 g, 40.2 mmol), and stir at 80°C for 18 hours. Add an appropriate amount of water, and extract with DCM (30 mL x 3). The organic phase is dried and then spin-dried. The crude product is purified by column chromatography using DCM:MeOH = 20:1 as the eluent to obtain 2.8 g of the product as a colorless oil, with a yield of 41.9%.
[1079] ESI-MS m / z:cald for C 16 H 37 N2O3Si[M+H] + : 333.3, found 333.1.
[1080] 1 H NMR (400MHz, CDCl3) δ5.18 (br.s, 1H), 3.75 (t, J=5.3Hz, 2H), 3.22 (d, J=6.5Hz, 2 H), 2.77-2.69(m, 4H), 1.75-1.67(m, 2H), 1.44(s, 9H), 0.90(s, 9H), 0.07(s, 6H).
[1081] Step 3: Synthesis of 4-((3-((tert-Butoxycarbonyl)amino)propyl)(2-((tert-Butyldimethylsilyl)oxy)ethyl)amino)butanoic acid undecyl ester
[1082] Tert-butyl (3-((2-((tert-butyldimethylsilyl)oxy)ethyl)amino)propyl)carbamate (1.5 g, 4.5 mmol) was dissolved in acetonitrile (60 mL), and undecyl 4-bromobutyrate (2.2 g, 6.8 mmol), potassium carbonate (1.2 g, 9.0 mmol), and KI (83 mg, 0.5 mmol) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and DCM (20 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 30:1 as the eluent to give 2.1 g of the product as a colorless oil, in a yield of 81.3%.
[1083] ESI-MS m / z:cald for C 31 H 65 N2O5Si[M+H] + : 573.5, found 573.7.
[1084] 1 H NMR (400MHz, CDCl3) δ4.09-4.02 (m, 2H), 3.65 (t, J=6.5Hz, 2H), 3.17 (d, J=6.3Hz, 2H), 2.58-2.40 (m, 6H), 2.32 (t, J=7.4Hz, 2H), 1.81-1.69(m, 2H), 1.68-1.54(m, 6H), 1.43(s, 9H), 1.26(s, 15H), 0.92-0.86(m, 12H), 0.05(s, 6H).
[1085] Step 4: Synthesis of 4-(3-aminopropyl)(2-((tert-butyldimethylsilyl)oxy)ethyl)amino)butyric acid undecyl ester
[1086] 4-((3-((tert-Butoxycarbonyl)amino)propyl)(2-((tert-butyldimethylsilyl)oxy)ethyl)amino)butanoic acid undecyl ester (1.5 g, 2.6 mmol) was dissolved in DCM (50 mL), TMSOTf (0.6 g, 2.6 mmol) was added, and the mixture was stirred at room temperature for 0.5 hour. Saturated sodium bicarbonate solution was added dropwise under ice bath to neutralize the mixture, and then an appropriate amount of water was added. The mixture was extracted with DCM (20 mL*3), the combined organic phases were dried, evaporated to dryness, and the sample was passed through a column, eluted with DCM:MeOH(NH3)=20:1 to obtain 1.1 g of colorless oily product, yield: 88.9%.
[1087] ESI-MS m / z:cald for C 26 H 57 N2O3Si[M+H] + :473.4,found473.6.
[1088] 1 H NMR (400MHz, CDCl3) δ4.04 (t, J=6.8Hz, 2H), 3.64 (m, 2H), 2.73 (t, J=6.7Hz, 1H), 2.60-2.43 (m, 6H), 2.31 (t, J=7.4 Hz, 2H), 1.95 (m, 2H), 1.79-1.69 (m, 2H), 1.66-1.52 (m, 4H), 1.38-1.16 (m, 17H), 0.90-0.84 (m, 12H), 0.05 (s, 6H).
[1089] Step 5: Synthesis of 2,2,3,3-tetramethyl-7-(4-oxo-4-(undecyloxy)butyl)-4-oxo-7,11-oxadiazole-3-silapentadecan-15-undecyl ester
[1090] Undecyl 4-(3-aminopropyl)(2-((tert-butyldimethylsilyl)oxy)ethyl)amino)butanoate (1.1 g, 2.3 mmol) was dissolved in acetonitrile (50 mL), and undecyl 4-bromobutyrate (0.8 g, 2.3 mmol), potassium carbonate (0.6 g, 4.6 mmol), and KI (10.6 mg, 0.06 mmol) were added, respectively, and stirred at 85°C for 16 hours. An appropriate amount of water was added, and then DCM (30 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was eluted by column chromatography with DCM:MeOH = 30:1 to obtain 800 mg of the product as a colorless oil, with a yield of 48.2%.
[1091] ESI-MS m / z:cald for C 41 H 85N2O5Si[M+H] + : 713.6, found 713.4.
[1092] 1 H NMR (400MHz, CDCl3) δ4.07-4.01(m, 4H), 3.69-3.60(m, 2H), 2.72-2.63(m, 3H), 2.61-2.44(m, 6H), 2.39- 2.27(m, 4H), 1.88-1.71(m, 3H), 1.69-1.53(m, 6H), 1.41-1.18(m, 35H), 0.90-0.85(m, 15H), 0.05(s, 6H).
[1093] Step 6: Synthesis of 2,2,3,3-tetramethyl-12-oxo-7,11-bis(4-oxo-4-(undecyloxy)butyl)-4-oxo-7,11-oxadiazole-3-silapentadecan-15-oic acid undecyl ester
[1094] 2,2,3,3-Tetramethyl-7-(4-oxo-4-(undecyloxy)butyl)-4-oxo-7,11-triazole-3-silapentadecan-15-undecyl ester (300 mg, 0.4 mmol) was dissolved in DMF (20 mL). 4-Oxo-4-(undecyloxy)butanoic acid (120 mg, 0.4 mmol), DIEA (163 mg, 1.3 mmol), and HATU (176 mg, 0.5 mmol) were added, respectively, and the mixture was stirred at room temperature for 2 hours. An appropriate amount of water was added, and the mixture was extracted with DCM (30 mL x 3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM:MeOH = 30:1 as the eluent to give 250 mg of the product as a colorless oil, in a yield of 61.4%.
[1095] ESI-MS m / z:cald for C 56 H 111 N2O8Si[M+H] + : 967.8, found 967.6.
[1096] 1H NMR (400MHz, CDCl3) δ4.10-3.99 (m, 6H), 3.67-3.59 (m, 2H), 3.38-3.25 (m, 4H), 2.69-2.52 (m, 6H), 2.51-2.40 (m, 4H), 2.36-2.24 (m, 4H), 1.95-1.78 (m, 2H), 1.7 7-1.67(m, 3H), 1.65-1.57(m, 8H), 1.31-1.23(m, 47H), 0.90-0.85(m, 18H), 0.04(s, 6H).
[1097] Step 7: Synthesis of 4-(3-((2-hydroxyethyl)(4-oxo-4-(undecyloxy)butyl)amino)propyl)(4-oxido-4-(undecyloxy)butyl)amino)-4-oxobutanoate
[1098] 2,2,3,3-Tetramethyl-12-oxo-7,11-bis(4-oxo-4-(undecanyloxy)butyl)-4-oxo-7,11-triazole-3-silopentadecane-15-oic acid undecyl ester (240 mg, 0.3 mmol) was dissolved in THF (5 mL), TBAF (97 mg, 0.4 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Saturated sodium bicarbonate solution was added dropwise under ice bath to neutralize the mixture, and then an appropriate amount of water was added. The mixture was extracted with DCM (20 mL*3), the combined organic phases were dried and evaporated to dryness, and the sample was passed through a column, and eluted with DCM:MeOH(NH3)=25:1 to obtain 150 mg of colorless oily product, with a yield of 70.9%.
[1099] ESI-MS m / z:cald for C 50 H 97 N2O8[M+H] + :853.7, found 853.5.
[1100] 1 H NMR (400MHz, CDCl3) δ4.13-3.98 (m, 6H), 3.60-3.49 (m, 2H), 3.40-3.28 (m, 4H), 2.72-2.52 (m, 6H), 2.52-2.41 (m, 4H), 2.39-2.25 (m, 4H), 2.01-1.91 (m, 1H), 1.91-1.85 (m, 1H), 1.85-1.76 (m, 3H), 1.75-1.58 (m, 8H), 1.32-1.24 (m, 48H), 0.88 (t, J=6.7Hz, 9H).
[1101] Example 110
[1102] 4,4′-(4-((4-hydroxybutyl)(4-oxo-4-(undecanyloxy)butyl)amino)butyl)azetidine dibutyl ester
[1103] Step 1: Synthesis of 4,4′-(4-((4-hydroxybutyl)(4-oxo-4-(undecanyloxy)butyl)amino)butyl)azetidine dibutyl ester
[1104] Dinonyl 4,4′-(3-((4-oxo-4-(undecanyloxy)butyl)amino)propyl)azetidinyl)dibutyrate (350 mg, 0.4 mmol) was dissolved in DMF (8 mL), and 1-chloro-4-butanol (98 mg, 0.9 mmol), potassium carbonate (179 mg, 1.3 mmol), and KI (21.6 mg, 0.1 mmol) were added, respectively, and stirred at 85° C. for 16 hours. DCM (50 mL*3) was then added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using DCM (containing 5% EA):MeOH = 50:1 to 5:1 as the eluent to give 142 mg of the product as a colorless oil, in a yield of 40.3%.
[1105] ESI-MS m / z:cald for C 53 H 105 N2O7[M+H]+: 881.8, found 881.6.
[1106] 1 H NMR (400MHz, CDCl3) δ4.12-3.98 (m, 6H), 3.55 (t, J=4.8Hz, 2H), 2.49-2.36 (m, 12H), 2.31 (t, J=7.4Hz, 6H), 1.88-1 .80 (m, 2H), 1.80-1.72 (m, 5H), 1.72-1.57 (m, 12H), 1.54-1.45 (m, 2H), 1.45-1.23 (m, 47H), 0.88 (t, J=6.7Hz, 9H).
[1107] Example 111
[1108] Di((9Z,12Z)-octadeca-9,12-dien-1-yl) 5,5′-((3-((3-hydroxypropyl)(5-((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-5-oxopentyl)amino)propyl)azodiyl)divalerate
[1109] Step 1: Synthesis of (9Z, 12Z)-octadeca-9,12-dien-1-yl 5-bromovalerate:
[1110] Mix (9Z,12Z)-octadeca-9,12-dien-1-ol (5.0 g, 18.8 mmol) and 5-bromovaleric acid (3.7 g, 20.6 mmol), heat the temperature to 60°C, add 2 drops of concentrated sulfuric acid, and stir at this temperature for 16 hours. TLC shows that the starting material is almost completely consumed. Add an appropriate amount of water, extract with EA (30 mL*3), and combine the organic phases. After evaporation to dryness, mix the sample and pass it through a column. Elution with PE:EA = 30:1 gives 7.2 g of a colorless oily product, with a yield of 89.3%.
[1111] 1 H NMR (400MHz, CDCl3) δ5.43-5.28 (m, 4H), 4.06 (t, J=6.7Hz, 2H), 3.41 (t, J=6.6Hz, 2H), 2.77 (t, J=6.4Hz, 2H), 2.34 (t, J=7.2Hz , 2H), 2.10-1.99(m, 4H), 1.95-1.85(m, 2H), 1.84-1.73(m, 2H), 1.67-1.58(m, 2H), 1.37-1.26(m, 16H), 0.89(t, J=6.7Hz, 3H).
[1112] Step 2: Synthesis of (9Z, 12Z)-octadec-9,12-dien-1-yl 2,2,3,3-tetramethyl-8-(5-(((6Z, 9Z)-octadec-6,9-dien-1-yl)oxy)-5-oxopentyl)-12-(5-((((9Z, 12Z)-heptadeca-9,12-dien-1-yl(oxy))-5-oxopentyl)-4-oxo-8,12-diaza-3-silylheptadecan-17-oic acid ester:
[1113] N1-(3-((tert-Butyldimethylsilyl)oxy)propyl)propane-1,3-diamine (100 mg, 0.4 mmol) was dissolved in MeCN (15 mL), and (9Z,12Z)-octadec-9,12-dien-1-yl 5-bromovalerate (575 mg, 1.3 mmol), potassium carbonate (280 mg, 2.0 mmol), and KI (10 mg, 0.04 mmol) were added, respectively, and stirred at 85°C for 16 hours. An appropriate amount of water was added, and EA (20 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using A:B = 30% (A: PE / EA = 5 / 1, B: DCM / MeOH(NH3) = 10 / 1) as the eluent to give 400 mg of the product as a colorless oil, in a yield of 76.3%.
[1114] ESI-MS m / z:cald for C 81 H151 N2O7Si[M+H] + :1292.1, found 1292.3.
[1115] 1 H NMR (400MHz, CDCl3) δ5.48-5.23 (m, 12H), 4.05 (t, J=6.8Hz, 6H), 3.62 (t, J=6.4Hz, 2H), 2.77 (t, J=6.5Hz, 6H), 2.50-2.34 (m, 11H), 2. 30(t, J=7.5Hz, 6H), 2.10-1.98(m, 12H), 1.70-1.53(m, 18H), 1.49-1.40(m, 6H), 1.37-1.26(m, 47H), 0.93-0.83(m, 18H), 0.04(s, 6H).
[1116] Step 3: Synthesis of di((9Z,12Z)-octadeca-9,12-dien-1-yl)5,5′-((3-((3-hydroxypropyl)(5-((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-5-oxopentyl)amino)propyl)nitrogendiyl)divalerate
[1117] (9Z,12Z)-octadec-9,12-dien-1-yl 2,2,3,3-tetramethyl-8-(5-(((6Z,9Z)-octadec-6,9-dien-1-yl)oxy)-5-oxopentyl)-12-(5-((((9Z,12Z)-heptadeca-9,12-dien-1-yl(oxy))-5-oxopentyl)-4-oxo-8,12-diaza-3-silaten-17-oate (400 mg, 0 .3mmol) was dissolved in THF (10mL), and then TBAF (196mg, 0.6mmol) was added. The mixture was stirred at room temperature for 2 hours. An appropriate amount of water was added and the organic phases were extracted with EA (20mL*3). The combined organic phases were dried, evaporated to dryness, and passed through a column. 200mg of colorless oily product was eluted with A:B=10%-30% (A:PE / EA=5 / 1, B:DCM / MeOH(NH3)=10 / 1), with a yield of 54.9%.
[1118] ESI-MS m / z:cald for C 75 H 137 N2O7[M+H] + : 1178.0, found 1178.2.
[1119] 1H NMR (400MHz, CDCl3) δ5.45-5.26 (m, 12H), 4.05 (t, J=6.8Hz, 6H), 3.77 (t, J=5.2Hz, 2H), 2.77 (t, J=6.5Hz, 6H), 2.63 (t, J=5.7Hz, 2H), 2.50-2.35 (m, 10H), 2.34-2.28 (m, 6H), 2.10-1 .99 (m, 13H), 1.75-1.69 (m, 2H), 1.69-1.59 (m, 16H), 1.59-1.44 (m, 7H), 1.37-1.29 (m, 45H), 0.89 (t, J=6.7Hz, 9H).
[1120] Example 112
[1121] 4,4′-docosyl((3-((4-(dodecyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)propyl)azetidinyl)dibutyrate
[1122] Step 1: Synthesis of 2,2,3,3-tetramethyl-8,12-bis(5-oxo-5-(undecyloxy)pentyl)-4-oxo-8,12-diaza-3-silaheptadecane-17-undecyl ester
[1123] N1-(3-((tert-Butyldimethylsilyl)oxy)propyl)propane-1,3-diamine (100 mg, 0.4 mmol) was dissolved in MeCN (15 mL), and dodecyl 4-bromobutyrate (449 mg, 1.3 mmol), potassium carbonate (280 mg, 2.0 mmol), and KI (10 mg, 0.04 mmol) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and EA (20 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using A:B = 30% (A: PE / EA = 5 / 1, B: DCM / MeOH(NH3) = 10 / 1) as the eluent to give 300 mg of the product as a colorless oil, with a yield of 73.2%.
[1124] ESI-MS m / z:cald for C 60 H 121 N2O7Si[M+H] + :1009.9,found 1009.7.
[1125] 1H NMR (400MHz, CDCl3) δ4.04 (t, J=6.8Hz, 6H), 3.62 (t, J=6.3Hz, 2H), 2.54-2.47 (m, 2H), 2.47-2.35 (m, 10H), 2.34-2.25 ( m, 6H), 1.80-1.67 (m, 10H), 1.70-1.60 (m, 9H), 1.60-1.51 (m, 2H), 1.30-1.24 (m, 49H), 0.89-0.85 (m, 18H), 0.04 (s, 6H).
[1126] Step 2: Synthesis of 4,4′-docosyl((3-((4-(dodecyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)propyl)azetidinyl)dibutyrate
[1127] 2,2,3,3-Tetramethyl-8,12-bis(5-oxo-5-(undecanyloxy)pentyl)-4-oxo-8,12-diaza-3-silaheptadecane-17-undecanyl ester (300 mg, 0.3 mmol) was dissolved in THF (10 mL), and then TBAF (155 mg, 0.6 mmol) was added. The mixture was stirred at room temperature for 2 hours. An appropriate amount of water was added and the organic phases were extracted with EA (20 mL*3). The combined organic phases were dried, evaporated to dryness, and passed through a column. 210 mg of colorless oily product was eluted with A:B=10%-30% (A: PE / EA=5 / 1, B: DCM / MeOH(NH3)=10 / 1), with a yield of 78.9%.
[1128] ESI-MS m / z:cald for C 54 H 107 N2O7[M+H] + : 895.8, found 895.6.
[1129] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8, Hz, 6H), 3.78 (t, J=5.2Hz, 2H), 2.64 (t, J=5.7Hz, 2H), 2.50-2.36 (m, 10H), 2.3 4-2.27(m, 6H), 1.88-1.80(m, 2H), 1.80-1.69(m, 8H), 1.69-1.56(m, 9H), 1.32-1.24(m, 52H), 0.88(t, J=6.7Hz, 9H).
[1130] Example 113
[1131] 4,4′-((3-((4-(decyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)propyl)azetidinyl)dibutyric acid didecyl ester
[1132] Step 1: Synthesis of 8,12-bis(4-(decyloxy)-4-oxobutyl)-2,2,3,3-tetramethyl-4-oxo-8,12-diaza-3-silahexadecane-16-oic acid decyl ester
[1133] N1-(3-((tert-Butyldimethylsilyl)oxy)propyl)propane-1,3-diamine (100 mg, 0.4 mmol) was dissolved in MeCN (15 mL), and dodecyl 4-bromobutyrate (374 mg, 1.2 mmol), potassium carbonate (280 mg, 2.0 mmol), and KI (10 mg, 0.04 mmol) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and EA (20 mL*3) was added for extraction. The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using A:B = 30% (A: PE / EA = 5 / 1, B: DCM / MeOH(NH3) = 10 / 1) as the eluent to give 295 mg of the product as a colorless oil, in a yield of 78.6%.
[1134] ESI-MS m / z:cald for C 54 H 109 N2O7Si[M+H] + :925.8,found 925.6.
[1135] 1 H NMR (400MHz, CDCl3) δ4.04 (t, J=6.8Hz, 6H), 3.62 (t, J=6.3Hz, 2H), 2.56-2.48 (m, 2H), 2.48-2.34 (m, 10H), 2.33-2.26 ( m, 6H), 1.85-1.70 (m, 9H), 1.70-1.60 (m, 9H), 1.60-1.50 (m, 2H), 1.33-1.25 (m, 38H), 1.05-0.68 (m, 18H), 0.04 (s, 6H).
[1136] Step 2: Synthesis of didecyl 4,4′-((3-((4-(decyloxy)-4-oxobutyl)(3-hydroxypropyl)amino)propyl)azetidinyl)dibutyrate
[1137] 8,12-Bis(4-(decyloxy)-4-oxobutyl)-2,2,3,3-tetramethyl-4-oxo-8,12-diaza-3-silahexadecane-16-oic acid decyl ester (295 mg, 0.3 mmol) was dissolved in THF (10 mL), and then TBAF (167 mg, 0.6 mmol) was added. The mixture was stirred at room temperature for 2 hours, and an appropriate amount of water was added. The organic phases were combined, dried, evaporated to dryness, and the sample was mixed and passed through a column. 190 mg of colorless oily product was eluted with A:B=10%-30% (A: PE / EA=5 / 1, B: DCM / MeOH(NH3)=10 / 1), with a yield of 73.5%.
[1138] ESI-MS m / z:cald for C 48 H 95 N2O7[M+H] + :811.7, found 811.5.
[1139] 1 H NMR (400MHz, CDCl3) δ4.05 (t, J=6.8, Hz, 6H), 3.78 (t, J=5.2Hz, 2H), 2.64 (t, J=5.7Hz, 2H), 2.53-2.36 (m , 10H), 2.35-2.26(m, 6H), 1.84-1.67(m, 9H), 1.64-1.56(m, 8H), 1.33-1.24(m, 42H), 0.90-0.84(m, 9H).
[1140] Example 114
[1141] Di((9Z,12Z)-octadeca-9,12-dien-1-yl) 7,7′-((3-(3-hydroxypropyl)(7-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-7-oxoheptyl)amino)propyl)azacyclopentyl)diheptanoate
[1142] Step 1: Synthesis of (9Z, 12Z)-octadeca-9,12-dien-1-yl 7-bromoheptanoate:
[1143] Mix (9Z,12Z)-octadeca-9,12-dien-1-ol (2.0 g, 7.5 mmol) and 7-bromoheptanoic acid (1.7 g, 8.3 mmol), heat the temperature to 60°C, add 2 drops of concentrated sulfuric acid, and stir at this temperature for 16 hours. TLC shows that the starting material is almost completely consumed. Add an appropriate amount of water, extract with EA (30 mL*3), and combine the organic phases. After evaporation, mix the sample and pass it through a column. Elution with PE:EA=30:1 gives 3.2 g of colorless oily product, with a yield of 93.2%.
[1144] 1 H NMR (400MHz, CDCl3) δ5.45-5.27 (m, 4H), 4.06 (t, J=6.8Hz, 2H), 3.40 (t, J=6.8Hz, 2H), 2.77 (t, J=6.6Hz, 2H), 2.30 (t, J=7.5Hz , 2H), 2.10-1.99(m, 4H), 1.91-1.80(m, 2H), 1.69-1.58(m, 4H), 1.50-1.41(m, 2H), 1.38-1.28(m, 18H), 0.89(t, J=6.8Hz, 3H).
[1145] Step 2: Synthesis of (9Z, 12Z)-octadec-9,12-dien-1-yl 2,2,3,3-tetramethyl-8,12-bis(7-(((9Z, 12Z)octadec-9,112-dien-1-yl)oxy)-7-oxoheptyl)-4-oxo-8,12-aza-3-silanonyl-19-carboxylate
[1146] N1-(3-((tert-Butyldimethylsilyl)oxy)propyl)propane-1,3-diamine (100 mg, 0.4 mmol) was dissolved in MeCN (30 mL), and (9Z,12Z)-octadec-9,12-dien-1-yl 7-bromoheptanoate (650 mg, 1.4 mmol), potassium carbonate (280 mg, 2.0 mmol), and KI (10 mg, 0.04 mmol) were added, respectively. The mixture was stirred at 85°C for 16 hours. An appropriate amount of water was added, and the mixture was extracted with EA (20 mL*3). The organic phase was dried and then spin-dried. The crude product was purified by column chromatography using A:B = 30% (A: PE / EA = 5 / 1, B: DCM / MeOH(NH3) = 10 / 1) as the eluent to give 300 mg of the product as a colorless oil, in a yield of 53.7%.
[1147] ESI-MS m / z:cald for C 87 H 163 N2O7Si[M+H] + :1376.2,found 1376.4.
[1148] 1 H NMR (400MHz, CDCl3) δ5.46-5.32 (m, 12H), 4.08 (t, J=6.8Hz, 6H), 3.66 (t, J=6.3Hz, 2H), 2.81 (t, J=6.5Hz, 6H), 2.51 (m, 2H), 2.41 (m, 9H), 2.32 (t, J=7.5Hz, 6H), 2.1 8-1.98(m, 12H), 1.73-1.55(m, 21H), 1.52-1.31(m, 62H), 1.03-0.77(m, 18H), 0.08(s, 6H).
[1149] Step 3: Synthesis of bis((9Z,12Z)-octadec-9,12-dien-1-yl)7,7′-((3-(3-hydroxypropyl)(7-(((9Z,12Z)-octadec-9,12-dien-1-yl)oxy)-7-oxoheptyl)amino)propyl)azacyclopentyl)diheptanoate
[1150] (9Z, 12Z)-octadec-9,12-dien-1-yl 2,2,3,3-tetramethyl-8,12-bis(7-(((9Z, 12Z)octacarbon-9,112-dien-1-yl)oxy)-7-oxoheptyl)-4-oxo-8,12-aza-3-silanonyl-19-ester (300 mg, 0.2 mmol) was dissolved in THF (10 mL), and then TBAF (114 mg, 0.4 mmol) was added. The mixture was stirred at room temperature for 3 hours, and an appropriate amount of water was added. The organic phases were combined, dried, evaporated to dryness, and the sample was passed through a column. 132 mg of colorless oily product was eluted with A:B = 10%-30% (A: PE / EA = 5 / 1, B: DCM / MeOH(NH3) = 10 / 1), with a yield of 48.0%.
[1151] ESI-MS m / z:cald for C 81 H 149 N2O7[M+H] + : 1262.1, found 1262.3.
[1152] 1H NMR (400MHz, CDCl3) δ5.48-5.23 (m, 12H), 4.05 (t, J=6.8Hz, 6H), 3.78 (t, J=5.1Hz, 2H), 2.77 (t, i=6.5Hz, 6H), 2.63 (t, J=5.5Hz, 2H), 2.48-2.34 (m, 10H), 2.29 (t, J=7.5Hz, 7H), 2.13-1.97 (m, 14H), 1.72-1.54 (m, 20H), 1.50-1.40 (m, 6H), 1.34-1.27 (m, 54H), 0.89 (t, J=6.7Hz, 9H).
[1153] Example 2: Preparation and detection of lipid nanoparticles (LNP preparations)
[1154] The ionizable lipid compound of Example 1 and Yangshen 1 were dissolved in ethanol with DOPE, cholesterol and DMG-PEG2000 (all purchased from Avituo (Shanghai) Pharmaceutical Technology Co., Ltd.) at a molar ratio of 50:10:48.25:1.25 to prepare an ethanol lipid solution, and enhanced green fluorescent protein (eGFP) mRNA was diluted in 20mM citrate buffer (pH=6.1) to obtain an mRNA aqueous solution. By using a microfluidic device (Maianna (Shanghai) Instrument Technology Co., Ltd., model: INano TM L) Lipid nanoparticles were prepared by mixing the ethanolic lipid solution and the mRNA aqueous solution in a volume ratio of 1:3 to a total lipid to mRNA ratio of 1:2. The solution was then replaced by ultrafiltration, the ethanol removed, and the volume was fixed with DPBS. Finally, the lipid nanoparticles were filtered through a 0.2 μm sterile filter to obtain an LNP formulation encapsulating eGFP mRNA using an ionizable lipid / DOPE / cholesterol / DMG-PEG2000 (50 / 10 / 48.25 / 1.25 mol%) solution. The mRNA content ranged from 0.002 mg / ml to 0.5 mg / ml.
[1155] The size and polydispersity index (PDI) of lipid nanoparticles were determined by dynamic light scattering using a Malvern Zetasizer Nano ZS (Malvern UK) in 173° backscattering detection mode. The encapsulation efficiency was determined by the Ribogreen assay. The test results are shown in Table 1.
[1156] Example 3: In vitro cell transfection experiment with lipid nanoparticles (LNP preparations)
[1157] In this example, mouse bone marrow-derived dendritic cells (DC2.4) (purchased from Millipore) were used as the validation cell line for lipid nanoparticle transfection experiments. DC2.4 cells grew adherently. All cell culture procedures strictly adhered to the established procedures, using sterile reagents and performed aseptically under a sterile workbench. The main steps involved are as follows:
[1158] 1) Cell recovery: Remove the stored cell cryopreservation solution from the -80°C freezer and immediately place it in a 37°C water bath with rapid and continuous shaking to completely thaw it within one minute. Add fresh culture medium to a 15mL centrifuge tube in advance and add the cell solution to the centrifuge tube in a biosafety cabinet. Take a centrifuge tube of the same mass and place it symmetrically in a centrifuge. Centrifuge at a low speed of 1200rpm for 5 minutes. After centrifugation, remove the supernatant and slowly add an appropriate amount of culture medium along the wall of the tube. After the cells are gently blown and evenly dispersed, pipette the cell suspension into the culture flask prepared in advance. Observe the status and distribution of the cells in the early stage of recovery under a microscope. Place the culture flask in a 5% CO2 incubator at 37°C and record the recovery time.
[1159] 2) Cell passaging: Under a microscope, if the cell density in the field of view reaches 80%-90%, the cells can be subcultured. Adherent cells need to be digested with trypsin. In order to avoid the residual serum in the culture medium reducing the activity of trypsin, add DPBS solution to wash once after removing the original culture medium. After aspirating the DPBS solution, add trypsin to degrade the protein at the junction between cells, thereby separating the cells and facilitating further culture. After gently shaking evenly, place in the incubator for digestion for 2-3 minutes. After digestion is completed, immediately add an appropriate amount of culture medium to the original culture dish to terminate digestion. Finally, use a pipette to carefully blow off the cells and blow until they are evenly dispersed. They can then be inoculated and subcultured in a certain proportion according to experimental requirements. Suspended cells do not require a trypsin digestion step.
[1160] Transfection of DC2.4 cells
[1161] 1) DC2.4 cell recovery: Remove frozen DC2.4 cells from a -80°C freezer and immediately thaw them in a 37°C water bath. After thawing, add the cells to prewarmed culture medium and centrifuge at 1200 rpm for 5 min. Discard the supernatant and resuspend the recovered DC2.4 cells in an appropriate amount of DMEM medium containing 10% FBS. Place the cells in a 37°C, 5% CO2 incubator for activation and culture.
[1162] 2) According to the experimental requirements, DC2.4 cells were plated in 24-well plates for cell transfection one day in advance. The cell number and cell viability were recorded by cell counting. 2×10 5Take the cell suspension from each cell, add a certain volume of DMEM culture medium containing 10% FBS and mix evenly, add 1 mL to each well for subsequent transfection experiments.
[1163] 3) After 24 hours, gently remove the culture medium with a pipette 30 minutes in advance, add 1 mL of DPBS to each well for washing, then aspirate the medium. Then add 300 μL of serum-free Opti-MEM medium to each well for subsequent transfection experiments.
[1164] 4) The LNP preparation prepared in Example 2 was diluted with Opti-MEM medium to an mRNA concentration of 1 μg / ml.
[1165] 5) Add 200 μl of the diluted mixture evenly along the top of each well, containing 200 ng of mRNA per well. Incubate the cells in a 37°C, 5% CO2 incubator for activation.
[1166] 6) After 24 hours, cell viability (%), eGFP positivity rate (%), and mean fluorescence intensity data were obtained through cell fluorescence imaging and flow cytometry.
[1167] Experimental results
[1168] Table 1 shows the characteristics of the lipid nanoparticles prepared in Example 2, and the expression level of eGFP-mRNA on DC2.4 after 24 hours, which was normalized based on Example 11.
[1169] Table 1
[1170] Example 4: Lipid Nanoparticle (LNP Preparation) In Vivo Transfection Experiment
[1171] According to the method in Example 2, LNP lipid nanoparticles containing Fluc-mRNA (high-quality FLuc mRNA, 1 mg / mL), SM-102 (CAS No.: 2089251-47-6, Avituo (Shanghai) Pharmaceutical Technology Co., Ltd.), and Yangshen 1 (US10195156B2, prepared according to the method of the above example, with the main difference being that 2-((3-aminopropyl)amino)ethane-1-ol was replaced with 2-((2-aminoethyl)amino)ethane-1-ol, structure shown in Figure 1) were prepared. Specific parameters are shown in Table 2. Cholesterol (Chol), DSPC, DOPE, and DMG-PEG2000 were purchased from Avituo (Shanghai) Pharmaceutical Technology Co., Ltd. Mice were randomly selected and administered the lipid nanoparticles intravenously and intramuscularly at a dose of 0.5 mg / kg (4 mice per group). Direct injection of Tris and Fluc-mRNA served as controls. Six hours later, each mouse was injected with 200 μl of 10 mg / ml D-luciferin potassium salt via the tail vein. Ten minutes later, the mice were placed under an in vivo imaging system, and the total fluorescence intensity of each mouse was observed and photographed. Twenty-four hours later, the mice were again placed under the in vivo imaging system, and the total fluorescence intensity of each mouse was observed and photographed.
[1172] Table 2. Preparation parameters of each LNP
[1173] With intramuscular injection, some lipid nanoparticles remain at the injection site, while the remainder primarily resides in the liver. With intravenous injection, all lipid nanoparticles migrate to the chest and abdomen. As shown in Figures 2-9, the fluorescence intensities of Examples 11, 12, and 21 were stronger than those of Yangshen 1 and comparable to those of SM-102. In particular, Examples 11, 12, and 21 maintained high fluorescence intensities after intramuscular injection, and the expression of 12 and 21 in the chest and abdomen was much lower than that of SM-102.
[1174] According to the method in Example 2, LNP lipid nanoparticles of Fluc-mRNA were prepared respectively. Specific parameters are shown in Table 3. Mice were randomly selected and injected intramuscularly (2 mice per group) with 0.5 mg / kg of lipid nanoparticles. Direct injection of Tris was used as a control. After 6 hours, 200 μl of 10 mg / ml of D-luciferin potassium salt was injected into each mouse body through the tail vein. After 10 minutes, the mice were placed under the in vivo imaging system, and the total fluorescence intensity of each mouse was observed, and photographed and recorded. After 24 hours, the mice were again placed under the in vivo imaging system, and the total fluorescence intensity of each mouse was observed, and photographed and recorded.
[1175] Table 3. Preparation parameters of each LNP
[1176] When injected intramuscularly, some lipid nanoparticles remain at the injection site, with the remainder primarily residing in the liver. As shown in Figures 10-13, the systemic expression of the above examples is superior to that of Yangshen 1, and Examples 1, 12, and 81 are even superior to SM-102. In terms of injection site, the examples are superior to Yangshen 1 and SM-102. Therefore, using DSPC instead of DOPE demonstrates superior expression in the above examples, allowing for further exploration of process-related TFF techniques.
[1177] The LNP lipid nanoparticles of Fluc-mRNA were prepared respectively according to the method in Example 2. Specific parameters are as shown in Table 4. Mice were randomly selected and injected intramuscularly (3 mice per group) with the lipid nanoparticles at a dosage of 0.5 mg / kg. Direct injection of Tris was used as a control. After 6 hours, 200 ul of 10 mg / ml of D-luciferin potassium salt was injected into each mouse body through the tail vein. After 10 minutes, the mice were placed under the in vivo imaging system, and the total fluorescence intensity of each mouse was observed, and photographed and recorded. After 24 hours, the mice were again placed under the in vivo imaging system, and the total fluorescence intensity of each mouse was observed, and photographed and recorded.
[1178] Table 4. Preparation parameters of each LNP
[1179] When injected intramuscularly, some of the lipid nanoparticles remain at the injection site, while the remainder primarily resides in the liver. As shown in Figures 14-17, Example 89 is superior to Yangshen 1 and SM-102 in terms of systemic expression and injection site.
Claims
1. A compound represented by the following formula I, its stereoisomers, tautomers, pharmaceutically acceptable salts, prodrugs or solvates: In the formula, L1, L2, L3 are each independently selected from optionally substituted alkylene, optionally substituted alkenylene and optionally substituted alkynylene; M1, M2, M3 are each independently selected from -C(O)O- and -OC(O)-; R1, R2, R3 are each independently selected from optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl; L4 is selected from optionally substituted alkylene, optionally substituted alkenylene, and optionally substituted alkynylene; R4 is -OR5, R5 is selected from H, optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl; m is an integer of 3-6.
2. The compound according to claim 1 or its stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate, characterized in that: L1, L2, L3 are each independently selected from optionally substituted C 1-24 Alkylene, optionally substituted C 2-24 Alkenylene and optionally substituted C 2-24 Alkynylidene; R1, R2, R3 are each independently selected from optionally substituted C 1-24 Alkyl, optionally substituted C 2-24 Alkenyl and optionally substituted C 2-24 Alkynyl; L4 is selected from optionally substituted C 1-6 Alkylene, optionally substituted C 2-6 Alkenylene and optionally substituted C 2- 6-Alkynylidene; R5 is selected from H, optionally substituted C 1-6 Alkyl, optionally substituted C 2-6 Alkenyl and optionally substituted C 2- 6 alkynyl.
3. The compound according to claim 1 or 2, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate thereof, characterized in that: L1, L2, L3 are each independently selected from -(CH2) n -, n is an integer of 1-24, preferably an integer of 2-24, more preferably an integer of 3-15; L4 is selected from -(CH2) o -,in o is an integer of 1-6, preferably an integer of 2-5, more preferably an integer of 2-4; R5 is selected from H and C 1-6 alkyl.
4. The compound according to any one of claims 1 to 3 or its stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate, characterized in that: R1, R2, R3 are each independently selected from: optionally with one or more C 1-24 Alkyl substituted C 1-24 Alkyl, optionally substituted with one or more C 1-24 Alkyl substituted C 2-24 Alkenyl, preferably, the alkenyl contains 1-4 carbon-carbon double bonds.
5. The compound according to any one of claims 1 to 4 or its stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate, characterized in that: R1, R2, R3 are each independently selected from: Wherein, a is an integer from 1 to 24, R 1a and R 2a H or C independently at each occurrence 1-24 Alkyl; or each R 1a Independently H or C 1-24 Alkyl, R 2a Together with the carbon atom to which it is attached and the adjacent R 2a Together with the carbon atom to which it is connected, it forms a carbon-carbon double bond; R 3a It is H or methyl.
6. The compound according to any one of claims 1 to 5 or its stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate, characterized in that: R1, R2, R3 are each independently selected from: Wherein, p is an integer from 0 to 2, p' is an integer from 1 to 24, and p" is an integer from 0 to 24; b, c, d, and e are each independently an integer from 1 to 22; R 1b and R 2b H or C independently at each occurrence 1-12 Alkyl; or each R 1b Independently H or C 1-12 alkyl, and at least one R 2b Together with the carbon atom to which it is attached and the adjacent R 2b Together with the carbon atom to which it is connected, it forms a carbon-carbon double bond; R 1c and R 2c H or C independently at each occurrence 1-12 Alkyl; or each R 1c Independently H or C 1-12 alkyl, and at least one R 2c Together with the carbon atom to which it is attached and the adjacent R 2c Together with the carbon atom to which it is connected, it forms a carbon-carbon double bond; R 1d and R 2d H or C independently at each occurrence 1-12 Alkyl; or each R 1d Independently H or C 1-12 alkyl, and at least one R 2d Together with the carbon atom to which it is attached and the adjacent R 2d Together with the carbon atom to which it is connected, it forms a carbon-carbon double bond; R 1e and R 2e H or C independently at each occurrence 1-12 Alkyl; or each R 1e Independently H or C 1-12 alkyl, and at least one R 2e Together with the carbon atom to which it is attached and the adjacent R 2e Together with the carbon atom to which it is attached, it forms a carbon-carbon double bond.
7. The compound according to any one of claims 1 to 6 or its stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate, characterized in that: The compound of formula I has a structure shown in the following formula Ia, Ib, Ic or Id: Among them, f, g, h, i, j, k, g1, g2, i1, i2, k1, k2, r, s, t, u, v, w, x, y, and z are each independently an integer from 1 to 24, and q is an integer from 1 to 6.
8. The compound according to claim 7 or its stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate, characterized in that: f, h, and j are each independently an integer of 2 to 24, preferably an integer of 3 to 15, g, g1, g2, i, i1, i2, k, k1, k2 are each independently an integer from 3 to 24, preferably an integer from 3 to 15, r, s, t, u, v, w, x, y, and z are each independently an integer of 1 to 15, preferably an integer of 1 to 10, q is an integer of 2-5, preferably an integer of 2-4; Preferably, in Formula Ia, i and k are each independently an integer of 1-15, preferably each independently an integer of 3-15, preferably, i and k are the same integer; h and j are each independently an integer of 2-11, preferably each independently an integer of 3-7, preferably, h and j are the same integer; m is 3, 4, 5 or 6, preferably 3 or 4; f is an integer of 3-11, preferably an integer of 3-6; g is an integer of 3-15, preferably an integer of 6-12; q is an integer of 2-5; More preferably, in Formula Ia, i, k, g are each independently an integer of 1-15, preferably each independently an integer of 3-15, more preferably each independently an integer of 8-12, preferably, i, k and g are the same integer; f, h and j are each independently an integer of 2-11, preferably each independently an integer of 3-7, preferably, f, h and j are the same integer; m is 3, 4, 5 or 6, preferably 3 or 4; q is an integer of 2-5, preferably 2 or 3; Preferably, in Formula Id, h and j are each independently an integer of 2-11, preferably each independently an integer of 3-8, preferably, h and j are the same integer; m is 3, 4, 5 or 6, preferably 3 or 4; t and v are each independently an integer of 1-10, preferably each independently an integer of 5-10, preferably, t and v are the same integer; y and z are each independently an integer of 1-10, preferably each independently an integer of 3-8, preferably, y and z are the same integer; f is an integer of 3-11, preferably an integer of 3-8; r is an integer of 1-10, preferably an integer of 5-10; x is an integer of 1-10, preferably an integer of 3-8; q is an integer of 2-5; More preferably, in Formula Id, f, h and j are each independently an integer of 2-11, preferably each independently an integer of 3-7, preferably, f, h and j are the same integer; m is 3, 4, 5 or 6, preferably 3 or 4; t, r and v are each independently an integer of 1-10, preferably each independently an integer of 6-10, preferably, t, r and v are the same integer; x, y and z are each independently an integer of 1-10, preferably each independently an integer of 3-7, preferably, x, y and z are the same integer; q is an integer of 2-5.
9. A lipid nanoparticle comprising a compound according to any one of claims 1 to 8 or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate thereof; preferably, the lipid nanoparticle further comprises: one or more auxiliary lipid molecules, one or more cholesterol or cholesterol derivatives and / or one or more polymer-conjugated lipid molecules.
10. The lipid nanoparticle according to claim 9, characterized in that: The auxiliary lipid molecule is a neutral lipid molecule, preferably selected from: DSPC, DPPC, DMPC, DOPC, POPC, DOPE and SM, more preferably DOPE or DSPC; and / or In the polymer-conjugated lipid molecule, the polymer is polyethylene glycol; preferably, the polymer-conjugated lipid molecule is selected from PEG-DMG, PEG-DAG, PEG-PE, PEG-S-DAG, PEG-DSPE, PEG-cer and PEG dialkoxypropylcarbamate, preferably PEG2000-DMG.
11. The lipid nanoparticle according to any one of claims 9 to 10, characterized in that In the lipid nanoparticles, the molar ratio of the compound or its stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate to the auxiliary lipid molecule, cholesterol or cholesterol derivative, polymer-conjugated lipid molecule is 60-5:60-5:50-5:10-1, preferably 60-30:30-10:50-30:5-1.
12. The lipid nanoparticle according to any one of claims 9 to 11, characterized in that The lipid nanoparticles also contain a therapeutic agent or an active agent; preferably, the therapeutic agent or the active agent is a nucleic acid therapeutic agent or the active agent; more preferably, the nucleic acid therapeutic agent or the active agent is selected from: messenger RNA (mRNA), antisense oligonucleotide (ASO), small interfering RNA (siRNA), micro RNA (miRNA), self-replicating RNA (saRNA), small guide RNA (sgRNA), ribozyme and aptamer.
13. A composition comprising the compound of any one of claims 1 to 8 or its stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate; Preferably, the composition is a pharmaceutical composition, which contains a compound according to any one of claims 1 to 8 or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate thereof, a therapeutic agent or an active agent, and one or more auxiliary lipid molecules, one or more cholesterol or cholesterol derivatives and / or one or more polymer-conjugated lipid molecules.
14. The composition according to claim 13, characterized in that The auxiliary lipid molecule is a neutral lipid molecule, preferably selected from: DSPC, DPPC, DMPC, DOPC, POPC, DOPE and SM, more preferably DOPE or DSPC; and / or In the polymer-conjugated lipid molecule, the polymer is polyethylene glycol; preferably, the polymer-conjugated lipid molecule is selected from PEG-DMG, PEG-DAG, PEG-PE, PEG-S-DAG, PEG-DSPE, PEG-cer and PEG dialkoxypropylcarbamate, preferably PEG2000-DMG; and / or The therapeutic agent or active agent is a nucleic acid therapeutic agent or active agent; preferably, the nucleic acid therapeutic agent or active agent is selected from: messenger RNA (mRNA), antisense oligonucleotide (ASO), small interfering RNA (siRNA), micro RNA (miRNA), self-replicating RNA (saRNA), small guide RNA (sgRNA), ribozymes, and aptamers. 15.Selected from the following applications: (1) Use of the compound according to any one of claims 1 to 8 or its stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate in the preparation of lipid nanoparticles or pharmaceutical compositions for treating or preventing a disease or condition in a subject; or (2) Use of the compound according to any one of claims 1 to 8 or its stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug or solvate in the preparation of an agent for delivering a therapeutic agent or an active agent such as a nucleic acid; or (3) Use of the lipid nanoparticles according to any one of claims 9 to 12 in the preparation of a medicament for treating or preventing a disease or condition of a subject; or (4) Use of the composition according to claim 13 or 14 in the preparation of a medicament for treating or preventing a disease or condition of a subject.
Citation Information
Cited By
Ionizable lipid compound, liposome and lipid nanoparticle, and use thereof
WO2025237069A1
